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Abstract 
Viral respiratory infections are associated with substantial mortality, morbidity, 
and a vast economic and healthcare burden. The diagnosis of such infections has 
been revolutionised by the introduction of molecular methods such as RT-PCR. 
This has resulted in high levels of sensitivity and specificity along with a rapid 
turnaround time in comparison to previous methods. As a product of this success, 
the diagnosis of respiratory infections makes up a large proportion of the 
workload in most diagnostic laboratories.  
The development of next generation sequencing (NGS) may be the next 
revolution in the field of virus diagnostics. This allows a metagenomic approach 
to specimen processing whereby target independent sequencing of all genetic 
material is carried out. 
The research presented in this thesis initially sought to examine if NGS would be 
feasible in the field of respiratory virus diagnostics. The aim was to apply NGS to 
clinical specimens in parallel with the current diagnostic RT-PCR assays 
employed by the West of Scotland Specialist Virology Centre (WoSSVC) to 
determine if NGS could give the same level of results as RT-PCR and whether the 
sequence information generated in the process could be used in further 
characterising the detected pathogens. Further to this, the NGS method was 
then applied to the detection of norovirus from faecal specimens to demonstrate 
the utility in other areas of viral diagnostics.    
The results show that multiple viral pathogens can be detected from clinical 
specimens without specific virus targeting. The method was less sensitive than 
RT-PCR but sequence data generated during the process was utilised viral 
detection, subtyping and phylogenetic analysis. We also demonstrated that a 
single workflow could be applied to multiple specimen types in the detection of 
RNA viral pathogens.  
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1 Introduction 
Diagnostic virology and the role of the laboratory has evolved and expanded in 
recent decades with the implementation of genome detection methods being a 
significant driving force behind this (Storch 2000). Perhaps one of the areas 
which have seen the greatest change is that of viral respiratory infections.  
Until recently only a small number of respiratory pathogens were recognised and 
tested for. The methods used in their diagnosis required high levels of expertise, 
lacked sensitivity and resulted in long turnaround times therefore the outcome 
would not impact on patient management. The implementation of molecular 
genome detection methods in a diagnostic setting has brought about a reduction 
in test turnaround times along with an increase in test sensitivity. Generating 
results in a timely fashion impacts on the management of individual patients 
through to population level, through initiation of appropriate therapy, institution 
of infection control measures and accurate epidemiological surveillance. This 
ability to generate rapid and accurate results has driven demand of the service, 
as demonstrated by the progressive increase in the number of sample requests 
received in Greater Glasgow and Clyde. These are now supported by powerful 
molecular epidemiological methods which together have had a significant impact 
on disease surveillance, vaccine development and monitoring.  
The technologies used in viral diagnostics continue to evolve. The advent of 
point-of-care testing may see the next major change in the role of the diagnostic 
service. Such test can be carried out on a ward, general practice or even 
community allowing clinical decisions and diagnoses to be made in real time.   
This chapter outlines the burden of viral respiratory illness in developing and 
developed countries. Following this the viral causes of respiratory illness are 
discussed with reference to their virology epidemiology, clinical presentation, 
treatment and prevention. I will then discuss the diagnostic methods used to 
detect these pathogens and in the process show how technology has evolved. 
The method of next generation sequencing will be outlined and the potential 
application to the diagnosis of viral respiratory illness discussed. Finally the 
chapter will conclude with an overview of the aims of this thesis.    
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At a patient level, the development of antiviral therapeutic agents has increased 
the requirement for laboratory confirmed diagnoses. The substantial cost of 
many of these drugs, the duration of treatment required and potential toxicity 
associated with such compounds necessitates a laboratory confirmed case in 
order to proceed with treatment.  
Diagnosis and the role of patient placement are imperative in the control of 
disease spread. Though the spread of infection from person to person in a 
healthcare setting was recognised since the nineteenth century, it took many 
decades for infection control procedures to be formally introduced in the 
majority of hospitals. Hospitalised patients can be a vulnerable group with co-
morbidities which make them more susceptible to, or more likely to develop 
severe infections. The recognition of infections with the potential to be spread 
among patients allows for heightened procedures to be put in place to prevent 
such spread. Examples include patient cohorting of respiratory syncytial virus 
positive infants or isolation of suspected influenza or norovirus positive patients. 
In these cases rapid diagnoses are critical to prevent avoidable patient exposure 
and unnecessary isolation.  
At a population level virus detection has public health implications, such as the 
identification of notifiable conditions or pathogens that require enhanced 
surveillance, contact tracing or follow up. An example of this would be the 
Scottish Enhanced Respiratory Virus Infection Surveillance (SERVIS) system. As 
part of this surveillance system, primary care practitioners submit samples for 
viral diagnostic testing in patients who present with an influenza-like illness. As 
not all of these will be caused by influenza viruses this information is important 
to gather to determine the start and end of an influenza season. This 
subsequently impacts on vaccination programs and resource planning. The 
diagnostic laboratory can also play a part in epidemiological surveillance 
programmes, such as vaccine effectiveness monitoring.  
The common methods employed in the detection of viral pathogens will be 
discussed in detail later in the chapter, but in brief, the move from classical 
techniques relying on virus culture towards the use of molecular tests in the 
diagnostic service has dramatically reduced the turn-around time to generate 
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results, thus improving the effectiveness of the system and therefore increasing 
reliance and demand of clinicians for rapid and accurate results.  
The greatest burden on a routine viral diagnostic service is that of respiratory 
infections. This will be in part due to the high incidence in a population but also 
the large number of pathogens capable of causing such infections. For this 
reason the main focus of this research will be on the detection of respiratory 
viruses. The common viral pathogens found in respiratory infections will be 
discussed in detail later in the chapter.   
1.1 Importance of Acute Respiratory Tract Infections 
Acute respiratory tract infections (ARTI) represent a significant global health 
issue. The World Health Organization determined that they are the third leading 
cause of death in all age groups and the leading cause of death in children under 
five years old (ARIA 2010). This occurrence is particularly marked in developing 
countries with 70% of all childhood deaths due to ARTI occurring in Africa and 
South East Asia (Williams, Gouws et al. 2002). Pneumonia, the most severe form 
of ARTI, is estimated to affect 35 million children under five years old in Africa 
alone and resulting in over 750,000 deaths annually (Robert F Breiman 2015). It 
should be noted that the true burden of disease in developing areas may be 
underestimated as diagnoses, documentation and information dissemination are 
often impaired. 
The majority of mortality associated with ARTI occurs in developing countries 
but there are multiple points to consider when determining the true burden of 
respiratory infections. The common cold is often thought of as a benign infection 
in the developed world and while it is true that the vast majority of cases are 
mild and self-limiting, there are substantial economic losses associated with the 
illness. In the US alone there are an estimated 214 million lost work days per 
year due to absenteeism and loss of productivity associated with ARTI and a 
further 2 million lost work days when care giving is taken into account (Bramley, 
Lerner et al. 2002). The indirect financial cost associated with such losses in the 
US has been estimated to approach $22.5 billion (Fendrick, Monto et al. 2003).  
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Another aspect to consider when calculating the burden of ARTI is that of 
healthcare attendance and treatment costs. Respiratory diseases are the 
commonest reason for general practice consultations in the UK (Ashworth, 
Charlton et al. 2005); in fact it is estimated that around 20% of the population 
present to their GP with a respiratory infection each year (Fleming, Smith et al. 
2002). Many of these consultations result in a prescription and indeed the vast 
majority of antibiotics prescribed in the UK originate from general practices. 
The most commonly cited reason for antibiotic prescription is that of respiratory 
infection, despite the assumption that many of these cases are of viral aetiology 
(Lindbaek 2006). The efficacy of antibiotics in such cases is overestimated as the 
decrease in the mortality and morbidity associated with respiratory infections is 
multifactorial; general improvements in socioeconomic factors such as housing 
and sanitation have likely improved the general prognosis of illness and the 
introduction of vaccination programs such as those for influenza and 
pneumococcal disease will have an impact on the number of severe cases. 
The individual viral causes of respiratory illness will be discussed in detail later 
in this chapter, but in brief, viruses such as influenza and respiratory syncytial 
virus are well documented to occur in seasonal epidemics in the UK and are 
major contributors to both hospitalisation rates and excess winter mortality. 
There is now increasing evidence that viral respiratory infections themselves 
may be self limiting in childhood but correlates with the development of asthma 
later in life (Kusel, de Klerk et al. 2007). It is not yet clear if these infections are 
causal in the development of asthma or merely highlight already at risk 
individuals. 
1.2 Clinical Presentation 
Acute respiratory tract infection (ARTI) is a broad term which encompasses a 
multitude of clinical syndromes affecting the full length of the respiratory tract. 
These range from the benign common cold to life threatening conditions 
including bronchiolitis and pneumonia. Upper respiratory tract infection (URTI) 
refers to any infection involving the middle ear, nose, paranasal sinuses, pharynx 
and larynx whereas lower respiratory tract infections (LRTI) affect the trachea, 
bronchi, bronchioles and alveoli. The specific symptoms associated with 
infection will depend on the site affected. Involvement of the upper respiratory 
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tract will often produce inflammation, increased secretions, cough, with or 
without systemic signs of fever and loss of appetite. Involvement of the lower 
airways can produce more severe symptoms including wheeze, tachypnoea, 
breathlessness and signs of respiratory distress, along with signs of a systemic 
inflammatory response including fever and haemodynamic compromise 
manifesting as hypotension and tachycardia. Specific respiratory clinical 
syndromes that are frequently attributed to viruses include croup, inflammation 
of the larynx resulting in narrowing of the airway, and bronchiolitis, 
inflammation of the small airways. Many viral pathogens are associated with 
each presentation; an overview is presented in Table 1-1. 
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Virus Colds Pharyngitis Tracheobronchitis Croup Bronchiolitis Pneumonia 
      Children Adults Immunocompromised 
Influenza         
Type A + ++ +++ ++ + ++ ++++ + 
Type B + ++ ++ + + + ++ + 
Parainfluenza         
Type1 + ++ + ++++ +   + 
Type 2 + ++ + ++ +   + 
Type 3 + ++ + ++ ++ +++ + + 
Respiratory syncytial virus ++ + + ++ ++++ ++++ + ++ 
Rhinovirus ++++ ++ + + + +   
Coronavirus ++ +       
Adenovirus  ++ + ++ ++ ++ ++ ++ 
Table 1-1. Frequency of viral respiratory syndromes caused by specific viral pathogens. 
Adapted from Clinical Virology, Douglas D. Richman et al, 3
rd
 Edition.  
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1.3 Aetiology of ARTI 
ARTI are the commonest infections encountered by humans with the average 
adult suffering up to four episodes and children up to 11 episodes per year 
(Gruber, Keil et al. 2008).     
Vast arrays of pathogens are capable of producing ARTIs including bacteria and 
fungi but the majority of episodes are attributed to viruses (Clark, Medina et al. 
2014). The diagnosis of a respiratory tract infection is clinical but establishing 
the precise aetiology can be a challenging task. It is not possible to determine 
the causative agent on clinical symptoms alone due to the vast overlap between 
pathogens. Despite recent advances in diagnostic techniques, which will be 
discussed in more detail later in the chapter, a large proportion of diagnostic 
samples return negative results (Murdoch, Slow et al. 2012)  
Environment factors affecting the aetiology of infection include temperature and 
humidity. Aetiology of infection is also influenced by multiple host factors such 
as age, comorbidities, immune status and possibly sex (Nickbakhsh, Thorburn et 
al. 2016), thus the cause of infection will vary temporally, geographically and 
within a population. It is challenging to determine the relative burden of each 
causative agent as many population based studies which have shaped our 
understanding of the condition were carried out prior to the discovery of a 
number of common pathogens and using less sensitive diagnostic methods than 
those employed today.   
The common viral causes of respiratory illness will vary with age group, season 
and locations. There are some rarer pathogens in the general public that will 
have a higher incidence depending on patient risk factors such as 
immunocompromise.  
The upper respiratory tract is colonised by multiple bacterial species, many of 
which are also potentially pathogenic such as Streptococcus pneumonia, 
Staphyloccoccus aureus and Haemophilus influenzae. Fungal infections are rare 
in immunocompetent individuals but both Pneumocystis and Aspergillus are 
associated with high mortality levels in certain populations. Pneumocystis 
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jirovecii remains one of the commonest opportunistic infections among those 
with HIV and despite the introduction of anti-retroviral drugs this still carries a 
mortality rate of 30 – 60 % (Lee, Park et al. 2015). The incidence of 
Pneumocystis in non-HIV cases is increasing though many are associated with 
immunocompromise relating to haematological malignancies or 
immunosuppressive therapies. Aspergillus sp. are common within the 
environment but also associated with a spectrum of clinical conditions (Kousha, 
Tadi et al. 2011). Infection is frequently associated with chronic lung conditions 
such as cystic fibrosis or asthma or immunocompromise following solid organ 
transplantation (Doligalski, Benedict et al. 2014; Munoz, Ceron et al. 2014). It 
should also be noted that repeated exposure can induce severe asthma and 
eventually result in chronic fibrotic changes in the lungs.  
1.3.1 Viral Causes of ARTI 
Of the viruses known to cause upper respiratory infections rhinoviruses are 
consistently found to be the most common (Makela, Puhakka et al. 1998; 
Ruohola, Waris et al. 2009; Zhang, Hu et al. 2012), followed by respiratory 
syncytial virus and coronaviruses.  In the last 20 years many new pathogens have 
been described, including human metapneumovirus, human bocavirus and novel 
coronaviruses (van den Hoogen, de Jong et al. 2001; Falsey and Walsh 2003; 
Allander, Tammi et al. 2005) along with the pandemic influenza A, emerging in 
2009. It is likely that some of these viruses have circulated for many years where 
as those such as MERS coronavirus occurred as a zoonotic disease, adapting to a 
new host and the novel influenza A resulted from reassortment of other viral 
strains. These are discussed in more detail below. 
There are multiple viruses established as causes of respiratory infections in 
humans with many more capable of producing respiratory symptoms, even if this 
is not the primary infection syndrome. A number of novel viruses and subtypes 
have emerged in recent years with many causing primary respiratory infections 
and others proposed as respiratory pathogens but lacking in definitive evidence. 
The common causes of viral respiratory infections are outlined below.  
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1.3.2 Influenza Viruses 
There are three genera within the Orthomyxoviridae family which are 
recognised as human pathogens, influenza A, B and C. These viruses are 
enveloped with a negative sense single stranded RNA genome comprising of 
seven or eight segments (Figure 1-1). The genera are determined by the 
antigenic structure of the nucleoprotein (NP) and Matrix (M) antigens and in the 
case of influenza A may be further subdivided based on the structure of the 
surface proteins. 
1.3.2.1 Influenza A 
The natural reservoir of influenza A is in wild birds but multiple species are 
known to be susceptible including horses, dogs and poultry. This wide host range 
contributes to the diversity of viruses. There are 18 known HA proteins but only 
1, 2 and 3 are widely associated with human infection, with H5, H7 and H9 
causing human infections in specific circumstances.  
The genus of influenza A is subtyped based on the morphology of the surface 
proteins, haemagglutinin (HA) and neuraminidase (NA). The commonly 
circulating seasonal subtypes in humans are H3N2 and H1N1 with multiple strains 
within theses subtypes. The commonly accepted nomenclature of influenza A 
virus strains is natural host (which is omitted if human), geographical location of 
isolation, strain number and year of isolation, with the addition of HA and NA 
subtypes in parentheses e.g. A/Puerto Rico/8/34 (H1N1) (WHO 1980).  
The virus attaches to the host cell by the HA binding to sialic acid on the cell 
surface. The virus then enters the cell through clathrin-mediated endocytosis. 
Upon cell entry the virus is contained within an acidified endosome. The acidic 
environment leads to a conformational change in the HA structure allowing it to 
associate with the endosomal membrane. The M2 ion channel allows influx of H+ 
into the virus particle and both these processes mediate the release of the virus 
particle contents into the cell cytoplasm. The particle content consists of viral 
RNA bound to the nucleoprotein and the polymerase complex (PB2, PB1 and PA). 
The RNP and polymerase complex are then transported into the nucleus, where 
transcription can take place. Viral transcription is initiated through a process 
known as cap-snatching: following transcription to positive sense RNA the viral 
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NS1 binds to cellular mRNA transcripts, PA then cleaves a short portion from the 
host RNA to be added to the viral positive sense RNA. This process allows the 
viral RNA to be recognised and translated by host ribosomes.  
NEP/NS2 and M1 mediate the export of newly synthesised viral RNP complexes 
from the nucleus to the cytoplasm. The virus particles are assembled and bud 
from the apical surface of the infected cells. The enzymatic activity of NA is 
essential in cleaving the sialic acid from the budding virus to release it from the 
cell surface.  
The genome of influenza A also encodes several non-structural proteins by 
alternative splicing, including NS1, PB1-F2 and PA-X. NS1 inhibits the interferon 
response of the host, PB1-F2 is a pro-apoptotic protein and PA-X contributes to 
the pathogenicity of the virus. 
 
Figure 1-1. Influenza A virus genome.  
Reproduced with permission (Eisfeld, Neumann et al. 2015)  
1.3.2.2 Influenza B 
The structure of Influenza B is essentially synonymous with that of influenza A 
and their appearances are indistinguishable on electron microscopy. The 
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nomenclature also follows similar rules to that of influenza A with the exception 
of host specification and HA/NA subtype.  
Influenza B has a much narrower host range, infecting only humans and seals. 
This is thought to be the reason behind the lack of virus recombination and 
diversity; indeed there are only two influenza B lineages which have been in co-
circulation since the 1980s. 
These lineages, B/Yamagata and B/Victoria contain a number of subgroups. The 
majority of the B/Yamagata in circulation belong to Group 2 B/Brisbane/2/2007 
and group 3 B/Bangladesh/3333/2007 and B/Victoria to B/Brisbane/60/2008.  
1.3.2.3 Influenza C 
The influenza C genome possesses only seven RNA segments, encoding nine 
proteins and differs from other influenza viruses in that it has a single surface 
protein, haemagglutinin-esterase fusion (HEF). Influenza C uses 9-O-acetyl-N-
acetylneuraminic acid as a receptor rather than sialic acid. This is relevant to 
the treatment of influenza which will be discussed below.  
Influenza C tends to result in a mild or asymptomatic infection, with many 
acquiring antibodies in childhood (Dykes, Cherry et al. 1980). It was accepted 
that only one subtype of the virus circulated and there was no animal reservoir, 
however a novel influenza C virus was recently isolated from pigs and cattle, 
showing only a 50% homology with those found in humans (Hause, Collin et al. 
2014).  
1.3.3 Influenza Epidemiology 
Influenza is by far the most frequently studied of the respiratory viruses. This is 
likely a result of the wide host range and devastating pandemics caused by the 
virus. Influenza is present worldwide, occurring sporadically throughout the year 
in tropical regions whereas circulation is more predictable in temperate regions 
with infections peaking in winter months. Influenza is responsible for up to 5 
million cases and 250,000 – 500,000 deaths per annum worldwide and is a major 
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contributor to excess winter mortality rates in the UK (Mann, Mangtani et al. 
2013). 
The host range of the viruses is determined by the affinity of the receptor to 
sialic acids. Most human influenza infections target the 2-6-linked sialic acid 
receptor which is mainly found on the epithelial cells of the upper airway. The 2-
3-linked sialic acids, found in the lower airways of humans, are the preferred 
receptor of avian influenza viruses and proposed to be the reason why human 
infection with avian viruses results in a more severe infection involving the lower 
airways.    
1.3.4 Clinical Presentation 
Influenza viruses are spread by droplet transmission with an incubation period in 
the region of one to four days. Symptoms of an uncomplicated infection usually 
manifest as fever, myalgia, headache and photophobia, with respiratory 
symptoms of dry cough and sore throat. The infection usually resolves after 
seven days but may be associated with feelings of lethargy following the acute 
infection. Influenza C differs in that it associated with a mild upper respiratory 
illness in childhood.   
1.3.4.1 Complicated Infection 
The initial infection may become complicated by either a viral pneumonia or 
secondary bacterial pneumonia. Superimposed infection with other pathogens, 
such as Staphylococcus aureus, Haemophilus influenzae and Aspergillus spp are 
well documented (Adalja, Sappington et al. 2011).  
The RNA dependent RNA polymerase has poor proof reading capabilities and as a 
result mutations occur frequently in virus progeny. These mutations accumulate 
over time, eventually affecting epitopes associated with the host immune 
response. When this occurs to the point where the host immune system can no 
longer recognise the virus then it will be seen as a novel infection. This process 
is referred to as antigenic drift. Alternatively a new infection can arise when a 
human virus undergoes reassortment with a virus associated with infection of 
another species, gaining a new segment of RNA. This is referred to as antigenic 
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shift and results in an abrupt change in the virus and as a result there is little 
residual immunity in the population. This can result in a pandemic outbreak of 
infection as a large number of individuals will be susceptible hosts. 
1.3.5 Paramyxoviridae 
The Paramyxoviridae are enveloped viruses with a single stranded negative 
sense RNA genome which is non-segmented and 13 – 15 kb in length. There are 
three major Paramyxoviridae groups associated with human respiratory tract 
infections, respiratory syncytial virus, the parainfluenzae viruses and human 
metapneumovirus, which are outlined below.  
1.3.5.1 Respiratory Syncytial Virus 
 
Figure 1-2. The respiratory syncytial virus genome. 
1.3.5.1.1 Structural Proteins 
A schematic of the RSV genome is presented in Figure 1-2. The major surface 
proteins on the RSV virion are the fusion (F), attachment glycoprotein (G) and 
small hydrophobic (SH) protein. The G protein mediates attachment of the virus 
to the cell receptor nucleolin (Tayyari, Marchant et al. 2011) whereas the F 
protein is responsible for fusion with the host cell membrane and cell entry. 
Expression of the F protein on the surface of the infected host cell initiates the 
formation of syncytia, fusion of surrounding cells to form giant multinucleated 
cells, from which the name is derived. The majority of paramyxoviruses require 
both F and G proteins to enter a host cell, though the F protein of RSV can do 
this independently of G, suggesting that F is the major contributor to cell entry. 
Both of these surface proteins elicit a neutralising antibody response indicative 
that both have a significant role in the development of infection.  
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The role of the SH protein is unclear. Infection is not attenuated in cell culture 
using recombinant RSV lacking SH but is attenuated in mice and chimpanzees. 
There is evidence that it may act as an ion channel and inhibit the interferon 
alpha signalling (Fuentes, Tran et al. 2007; Gan, Tan et al. 2012). 
The virus core contains ribonucleoprotein complex, consisting of the viral RNA, 
nucleoprotein (N), phosphoprotein (P) and L. Binding of the N protein with RNA is 
essential for replication and transcription as it is required for recognition by the 
viral polymerase. Binding of P to the RNA-bound N protein opens the structure to 
allow the L protein to interact with the RNA template. Together with the P, N 
and M2 protein the L protein forms the viral RNA dependent RNA polymerase 
complex.  
The M protein associates with the RNP complex and lipid envelope during the 
formation of viral particles and also acts as an inhibitor of cellular transcription 
in early infection and viral transcription prior to viral assembly (Ghildyal, 
Baulch-Brown et al. 2003). 
The non-structural proteins NS1 and NS2 counteract the host immune response 
through the inhibition of the type 1 interferon pathway (Bossert and Conzelmann 
2002). This in turn inhibits cell apoptosis, thus increasing the survival time of the 
infected cell and in turn increasing the yield of virus progeny.  
1.3.5.1.2 Classification 
RSV can be subdivided into two types, A and B, based on the serological 
differences. There is cross reactivity between the F antibodies of both subtypes 
A and B and despite the G protein being markedly more variable with only 53% 
homology between the two subgroups (Johnson, Spriggs et al. 1987) there are 
conserved regions between the two subtypes, therefore a degree of antibody 
cross reactivity. There are multiple genotypes described within the two groups, 
determined on the genetic sequence encoding the second hypervariable region 
of the G protein.  
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1.3.5.1.3 Clinical Presentation 
RSV was first isolated in 1957 and has long been recognised as an important 
cause of respiratory illness in infants with nearly all children being infected with 
RSV by age 2. In the UK RSV accounts for around 20,000 hospital admissions per 
year and is the leading cause of hospitalisation in children with respiratory 
infections (Handforth, Friedland et al. 2000). Around 3% of infants under the age 
of 1 will require hospitalisation due to an RSV related illness (Deshpande and 
Northern 2003). 
RSV will elicit both a cell mediated and humoral immune response during a 
primary infection but this is incomplete and can wane with time, leaving 
individuals at risk of future infections, even with the same strain. The exact 
mechanism behind this is uncertain. Although further infections may be less 
severe the elderly, immunocompromised and those with chronic lung conditions 
remain at risk of severe infection. It is now appreciated that RSV is a significant 
cause of mortality and morbidity amongst immunocompromised individuals and 
the elderly (Falsey, Hennessey et al. 2005). 
1.3.5.2 Human Parainfluenza Viruses 
Human parainfluenza viruses are divided into five species which are classified 
into the genera Rubulavirus (HPIV-2, HPIV-4A and HPIV-4B) and Respirovirus 
(HPIV-1 and HPIV-3) based on molecular and serological differences. 
 
Figure 1-3. The Parainfluenza virus genome.  
The genome structure of the parainfluenza viruses are similar however the nucleotide length of the 
protein coding regions varies between the different genera.  
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1.3.5.2.1 Structural Proteins and Non-Structural Proteins 
The haemagglutinin neuraminidase (HN) surface glycoprotein has two major 
functions at the beginning and end of the infection cycle. HN binds to sialic acid 
on the surface of the host cell to initiate cell entry and the neuraminidase 
activity will release newly formed virus particles from the surface of the 
infected cells. Following HN binding with sialic acid the F protein aids fusion of 
between the virus and host cell. The matrix protein M forms a protective layer 
beneath the lipid envelope and is essential in the formation of the virus 
envelope and budding from an infected cell (Lawrence, Borg et al. 2004).  
The nucleocapsid (N), phosphoprotein (P) and large (L) protein form the 
nucleocapsid core along with viral RNA.  
A non-structural protein, V, is detected in the rubulaviruses (HPIV-2 and 4), 
coded by a +1 frameshift in the P reading frame. It has been shown to degrade 
STAT2, thus inhibiting the cellular interferon response (Nishio, Ohtsuka et al. 
2008). 
1.3.5.2.2 Clinical Presentation 
The parainfluenzae viruses, despite their similarities, circulate with distinct 
temporal patterns. HPIV-1 is a common cause of croup and is also the most 
commonly reported of the parainfluenza group. HPIV-2 often affects young 
children, aged one to two years, and again can cause croup. It is noted to occur 
with biennial peaks in odd numbered years. HPIV-3 occurs annually in late spring 
or summer and is the commonest cause of hospitalisation amongst the 
parainfluenzae viruses. HPIV-4 is more commonly seen in autumn and winter but 
is rarely associated with severe disease.  
1.3.5.3 Human Metapneumovirus 
Human Metapneumovirus (hMPV) is classified in the genus Metapneumovirus and 
sub-family Pneumovirinae. The genome is ordered in a similar manner to that of 
the other paramyxoviruses but it lacks any non-structural proteins. The genome 
codes for nine proteins (Figure 1-4).  
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Figure 1-4. The human metapneumovirus genome.  
The F, G and SH proteins are found on the surface. The M protein forms a 
protective layer beneath the lipid envelope and also coordinated virion 
assembly. The virion core contains the ribonucleoprotein complex, containing 
the viral genome and replication proteins N, P and L. M2-1 is a transcription 
factor which interacts with the RNP complex. M2-2 is involved in genome 
replication.  
1.3.5.3.1 Classification 
hMPV comprises of two main subtypes, each with minor subgroups, A1, A2, B1 
and B2 based on serology and the genetic sequence of the surface protein F 
(Huck, Scharf et al. 2006). A further group, A3, has been proposed but further 
study is needed to confirm this (Escobar, Luchsinger et al. 2009).  
1.3.5.3.2 Clinical Presentation 
hMPV was first isolated from children in the Netherlands with upper respiratory 
infections in 2001, but retrospective serological studies suggest it has circulated 
for over 50 years and was probably of zoonotic origin from birds (Njenga, 
Lwamba et al. 2003). There is a worldwide distribution of hMPV and infections 
peak in winter months in temperate regions.  
The incubation period of hMPV is about four to five days. Infection is initiated in 
the nasopharynx and can quickly spread to the lower respiratory tract and 
therefore hMPV is a common cause of lower airway infections such as 
bronchiolitis and pneumonia. Despite there being no described viraemic stage of 
infection there are documented cases of encephalitis attributed to hMPV 
(Schildgen, Glatzel et al. 2005).   
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Most children are infected by age five nevertheless immunity is transient, thus 
reinfections can occur at any age. As is often the case those with underlying lung 
disease, immunocompromised and the elderly are at risk of developing severe 
disease, with mortality rates of up to 50% in outbreaks in elderly care home 
facilities (Liao, Appelgate et al. 2012).    
1.3.6 Picornaviridae 
There are four species within the genus enterovirus, of the Picornaviridae family 
which are known to cause respiratory tract infections in humans, rhinovirus A, B, 
C and enterovirus D. The enteroviruses have a non-segmented single-stranded 
genome of positive sense which is approximately 7.3kb in length (Figure 1-5). 
1.3.6.1 Human Rhinovirus 
 
Figure 1-5. The rhinovirus genome. 
1.3.6.1.1 Structural Proteins 
Three distinct groups of HRV exist, A, B and C which are determined by the 
genetic sequence of the structural proteins VP1-4 which form the capsid of the 
virus particle (Jacobs, Lamson et al. 2013). VP1, 2 and 3 make up the outer 
capsid of the virus and are therefore responsible for the antigenic diversity. VP4 
anchors the viral RNA in the core of the virus to the capsid. Multiple host cell 
receptors have been described for HRV, including ICAM-1, LDLR and heparin 
sulphate. The method of entry to the cell is dependent on the receptor used but 
once inside the cell a drop in the pH of the endosome results in viral uncoating 
and release of the RNA. RNA is then exported across the endosomal membrane 
into the cytosol where host ribosomes translate the positive sense RNA into a 
polyprotein.  
19 
 
The genome codes for two proteases, an RNA-dependent RNA polymerase (RdRp) 
and the VPg protein, all of which are involved in virus replication. The VPg 
protein is flanked to the 5’ UTR and serves as a primer for genome replication 
(Palmenberg, Rathe et al. 2010). The RdRp replicates RNA genome and the 
proteases cleave translated polyproteins. The RdRp lacks any proof reading 
capabilities and therefore mutations occur frequently during HRV replication. 
1.3.6.1.2 Classification 
Multiple serotypes exist within each group and over 100 serotypes of HRV have 
been described. There is extensive genome variability between serotypes and 
this is most marked in the VP1 protein with up to 25% nucleotide variation 
between serotypes. The 5’ UTR is relatively conserved between serotypes and 
groups and is the common target for molecular diagnostic tests, allowing 
detection of the virus but not differentiation between groups.  
1.3.6.1.3 Clinical Presentation 
The human rhinoviruses are often thought of as causing only a mild illness and 
indeed they are amongst the commonest causes of the common cold. They are 
now also acknowledged to be involved in severe infections of the elderly and 
immunocompromised and exacerbation of chronic lung diseases. 
The optimal viral replication of hRV is 33ºC and replication of some serotypes is 
markedly reduced at higher temperatures. For this reason hRVs were thought to 
be a pathogen of the upper respiratory tract only, however further studies of 
various serotypes demonstrated only a minimal difference in replication at 37 
(Papadopoulos, Sanderson et al. 1999) and infection of the lower airways has 
also been demonstrated in healthy volunteers by experimental inoculation 
(Gern, Galagan et al. 1997). 
There are high rates of hRV found in patients with acute exacerbations of 
chronic obstructive pulmonary disease (COPD) in comparison with stable COPD 
patients, and the development of common cold symptoms was associated with a 
prolonged recovery in such patients (Seemungal, Donaldson et al. 2000; 
Seemungal, Harper-Owen et al. 2001). The most recently described group, HRV-
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C, appears to cause more severe illness in comparison to HRV-A and B and is also 
found more frequently in exacerbations of asthma requiring hospitalisation 
(Miller, Edwards et al. 2009).  
1.3.7 Adenoviridae 
Adenoviruses belong to the family Adenoviridae and genus Mastadenovirus. They 
comprise of a double stranded DNA genome of 32kb in length (Figure 1-6). They 
are divided into subgroups A to G and are further classified into at least 52 
serotypes. The first adenovirus was isolated from the adenoid tissue of 
individuals with respiratory infections though they are now known to cause a 
myriad of clinical infections in humans depending on the subgroup. Subgroups C 
and E are commonly associated with infections of the respiratory tract.  
Multiple receptors have been proposed in the initial attachment of the AdV to 
the host cell, including the coxsackie-adenovirus receptor (CAR), sialic acid, 
heparin sulphate and CD46. Following attachment the virus enters the cell 
through endocytosis, mediated by cell surface integrins. Lysis of the endosome 
then releases the virions into the cytoplasm where the capsid is dismantled and 
the DNA is transferred to the nucleus.  
 
Figure 1-6. The adenovirus genome. 
Adapted from Zhao, Wan et al. 2014.  
Adenoviruses code for at least 38 genes from 17 transcriptional units. The 
infection can be divided into early (E) and late (L) phase depending on the genes 
expressed. Following infection the early transcription factors are activated 
which modify the host immune response and cell cycle to maximise viral 
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replication. Following initiation of viral DNA replication, the activation of the 
major late promoter (MLP) results in expression of late phase genes, including 
those coding for the structural proteins. Virions are then assembled in the 
nucleus of the infected cell and released by lysis (Lenaerts, De Clercq et al. 
2008).  
The clinical symptoms of an adenovirus infection of the respiratory tract include 
cough, coryza and nasal congestion along with systemic symptoms but it may 
also manifest as exudative tonsillitis. AdV infection can result in lower 
respiratory tract infections such as pneumonia with certain serotypes being 
associated with severe disease, notably Ad3, Ad4 and Ad7, outbreaks of which 
are associated with high rates of morbidity and rarely death. 
AdV infection has long been noted as a major cause of morbidity amongst 
military personnel with outbreaks in training camps reported worldwide, leading 
to the development of a live vaccine against the commonly detected serotypes 
AdV 4 and 7. This vaccine was mandatory in US military training camps, with 
good effect, between 1971 and 1999 however due to manufacturing issues the 
vaccine was withdrawn. Subsequent surveillance suggested 15,000 cases of 
vaccine preventable cases annually in the US (Hoke and Snyder 2013).  
In an immunocompromised individual the infection can persist, with detectable 
virus shed for months to years following infection. This is a particular problem in 
both bone marrow and solid organ transplant patients, as prior infection can 
reactivate causing clinical disease (Ison 2006).  
1.3.8 Coronaviridae 
Coronaviruses are of the family Coronaviridae and are enveloped viruses with a 
single-strand positive sense RNA genome of 27-33 kb (Figure 1-7), the longest of 
the RNA viruses. The name is derived from the large spike (S) surface proteins 
giving a crown appearance when visualised on EM.  
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Figure 1-7. Coronavirus genomes.  
Adapted, with permission (Stadler, Masignani et al. 2003). 
The virus enters the host cell either by direct fusion with the membrane or 
receptor mediated endocytosis. Multiple receptors have been identified, 
including CD13, ACE-2 and sialic acid (Gierer, Bertram et al. 2013). This process 
is mediated by the spike surface protein (S) and haemagglutinin-esterase (HE). 
The viruses have two additional structural proteins, the membrane protein M 
which associates with the nucleocapsid and is responsible for the virus shape, 
and the envelope protein E which associates with the lipid envelope and 
together with the M protein is essential in the budding and release of virus 
progeny from the infected cell.  
Upon cell entry the viral S protein is cleaved by endosomal acid proteases 
activating fusion with the endosome membrane and release of RNA into the cell 
cytoplasm. The positive sense RNA acts as mRNA to be translated into the 
replicase proteins. The replicase gene comprises of a 22kb portion of the 
genome with two open reading frames, 1a and 1b, coding the transcription-
replication complex. Negative sense RNA is then synthesised as the template for 
progeny virus by RNA dependent RNA polymerase.  
The number of accessory proteins differs between coronavirus species, with the 
greatest number being found in HCoV-SARS. The function of some of these 
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proteins remains unclear and whilst not essential for virus replication, there is 
attenuation of infection up on their deletion.  
1.3.8.1 Classification 
The coronaviruses are divided into four genera containing at least 29 species. 
The genera are based on multiple criteria including genetic sequence, natural 
host and serology. Two genera, alpha and betacoronaviruses, and six species 
cause human infections, namely HCoV 229E, HKU1, OC43, NL63, SARS along with 
the recently described MERS. 
1.3.8.2 Clinical Presentation 
The first human coronaviruses, HCoC-229E and HCoV-OC43, were isolated in the 
1960s and were associated with a common-cold like illness. The coronaviruses 
were thought to only cause either a mild respiratory or gastrointestinal illnesses 
until the emergence of the SARS coronavirus (HCoV-SARS) in 2003 (Fehr and 
Perlman 2015). This completely novel coronavirus was of zoonotic origin from 
bats with the Himalayan palm civet as an intermediate host. HCoV-SARS quickly 
spread worldwide with 8098 cases reported and 774 deaths. The mortality rate 
varied within the population and was as high as 55% in some groups with the 
elderly being at greatest risk of severe disease (Alghamdi, Hussain et al. 2014). 
Interestingly children were not severely affected by the infection which differs 
significantly from the burden associated with many other viral respiratory 
infections though the mechanisms responsible for this pattern are not well 
understood. This virus no longer circulates in humans. 
At least three other coronaviruses have been described since the HCoV-SARS 
outbreak, namely HKU-1, NL63 and MERS. The origin of MERS is again likely 
zoonotic, originating in bats with camels having been proposed as the 
intermediate host (Badawi and Ryoo 2016). In 2012 the Middle East Respiratory 
Syndrome coronavirus (MERS-CoV) was isolated from a patient in Saudi Arabia. 
Within months cases had been reported in multiple countries although all had a 
history of travel to or contact with the region. A significant healthcare 
associated outbreak occurred in South Korea, 2015, resulting in 186 cases (Ki 
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2015). This episode highlights the need for effective detection and isolation of 
cases to reduce spread within healthcare settings and the community. The latest 
WHO update in May 2016 confirmed 1,733 notified cases and at least 628 deaths 
from 27 countries (WHO 2015). This virus continues to circulate in the Middle 
East.  
In comparison with these highly pathogenic viruses, the remaining coronaviruses 
are associated with a range of clinical illnesses including both upper and lower 
respiratory infections but are generally considered non-severe. There are of 
course exceptions and severe infections may occur, generally at the extremes of 
age or in those with underlying immunocompromise. 
The HCoV-HKU1, NL63 and OC43 continue to circulate seasonally in humans, with 
a peak incidence in winter months in temperate regions. HCoV-229E has a less 
distinct seasonal pattern and can be detected sporadically throughout the year 
(Gaunt, Hardie et al. 2010). There is a suggestion of alternating dominance of 
strains each year although a longer duration of study would be required to 
confirm this.   
1.3.9 Human Bocavirus 
The human bocavirus is a member of the Parvoviridae. It is non-enveloped and 
has a single stranded DNA genome of 5.3kb in length. HBoV was first identified in 
2005 (Allander, Tammi et al. 2005) but the role in clinical disease has since been 
debated. Seroepidemiological studies suggest up to 20% of the population have 
been exposed (Li, He et al. 2015). And while bocavirus is frequently identified 
alongside a further respiratory pathogen (Sloots, McErlean et al. 2006) the virus 
has been detected as a single agent from symptomatic children (Kahn 2008).  
1.3.10 Polyomaviruses 
The WUV and KIPyV are both newly discovered polyomaviruses identified from 
human respiratory samples using high throughput screening methods. Their 
pathogenicity is also still debated. Their presence has been confirmed in many 
countries, with both serological and DNA evidence. However, the carriage in 
asymptomatic individuals has not been fully explored. In the United Kingdom a 
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small study reported the carriage rates of WUV and KIPyV to be similar in a 
symptomatic and asymptomatic control group (Norja, Ubillos et al. 2007). It 
should also be noted that in a large proportion of symptomatic individuals a 
further virus was detected, most commonly rhinovirus (Gaynor, Nissen et al. 
2007).  
1.4 Management of Viral Acute Respiratory Infections 
A small number of anti-viral drugs are currently available for use in respiratory 
infections but, in general, specific drugs are limited to influenza infections. The 
treatment of any other virus has little in the way of clinical evidence to support 
the use. This small number of drugs is dwarfed by the relative abundance of 
antibacterial agents licensed for use in bacterial respiratory infections.  
There are many challenges which have hampered the development of specific 
treatment and prevention strategies for viral infections. Vaccine development 
has thus far proved unsuccessful, likely due to the vast number of aetiological 
viruses compounded by their extensive antigenic variability (Simancas-Racines, 
Guerra et al. 2013).  
Trials in the prevention of the common cold using compounds such as Vitamin D, 
Vitamin C or Zinc have also yielded little success (Murdoch, Slow et al. 2012; 
Hemila and Chalker 2013; Singh and Das 2013).  
Presently management options of these infections are limited to symptomatic 
relief. Antibiotics are not recommended in the treatment as there has been no 
clinical benefit demonstrated, nevertheless over 30% of all antibiotics prescribed 
by ambulatory care physicians in the United States are associated with common 
colds, upper respiratory tract infections and bronchitis and similar findings have 
been documented worldwide (Gonzales, Steiner et al. 1997; Higashi and 
Fukuhara 2009).  
This is a major contributor to the global issue of inappropriate antibiotic use. 
This is a cause of great concern, both due to the economic costs – antibiotics 
prescribed in the US for upper respiratory tract infections cost $227 million each 
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year (Bertino 2002) – and the association with the rise in antibiotic resistant 
bacteria (Gonzales, Bartlett et al. 2001). For example, Streptococcus 
pneumoniae is a member of the commensal flora but is also a leading cause of 
bacterial meningitis, community acquired pneumonia and otitis media. Prior to 
1967 all strains of the bacteria were fully sensitive to penicillin but penicillin-
resistant as well as multidrug-resistant strains have emerged which is thought to 
be linked to antibiotic exposure. Many studies have demonstrated that 
resistance patterns vary geographically and positively correlate with the level of 
antibiotic consumption; conversely, rationalising antibiotic prescribing is 
associated with a reduction in drug-resistant strains (Linares, Ardanuy et al. 
2010).  
This pattern has heightened the realisation that we have two options, develop 
new methods of combating infections (Riley, Robinson et al. 2012) or rationalise 
antibiotic prescribing. An essential component of rationalising antibiotic 
prescribing is to improve diagnostic testing of respiratory tract infections in 
order to target the use of therapies currently available (Pavia 2011). 
Characterising the viruses which are present during these episodes will be an 
important step in this process. Epidemiological studies to determine the major 
viruses contributing to the burden of respiratory infection will aid in focusing 
vaccine development as well as specific drug therapies. 
Current management strategies, treatments and proposed treatments are 
discussed below. 
1.4.1 Anti-viral Drugs 
1.4.1.1 Adamantane derivatives 
Some of the first commonly used anti-viral drugs for respiratory infections were 
the adamantane derivatives amantadine and rimantidine. Their mechanism of 
action is to block the influenza M2 ion channel, inhibiting viral uncoating and 
release of RNA into the cell. The M2 proteins of influenza A and B show very little 
homology and as a result influenza B is inherently resistant to adamantanes. 
These drugs were used for many years in both the prevention and treatment of 
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influenza infections with very few cases of resistance noted. There was however 
a spike in 2000 in the circulation of resistant strains, both seasonal H3N2 and 
avian influenza A H5N1 in Asia and later in North America. Resistance was 
conferred by a single amino acid substitution in the M2 protein, S31N however a 
further five mutations that confer resistance have been described. High rates of 
resistance are now documented in H1N1 and H3N2 isolates worldwide (Dong, 
Peng et al. 2015). For this reason these drugs are no longer recommended in 
treatment or prophylaxis.   
1.4.1.2 Neuraminidase Inhibitors 
Drugs of the class neuraminidase inhibitors act on influenza A and B by blocking 
the function of the viral neuraminidase thus inhibiting viral budding and release 
from an infected cell. Resistance has also been noted to this class of drugs; the 
H275Y mutation in the NA segment is widely associated with oseltamivir 
resistance. Initially this was not concerning as the mutation also negatively 
affected virulence and infectivity of the virus (Carr, Ives et al. 2002) but a 
resistant strain has emerged, A/Brisbane/59/07(H1N1), which retained virulence 
and the ability to transmit from person to person.  
The benefit of these therapies has been a subject of debate in recent years as a 
Cochrane review found that the duration of symptoms is reduced by less than 
half a day and there was no evidence to support reduction in complications or 
hospitalisation associated with influenza (Jefferson, Jones et al. 2014).  
1.4.1.3 Nucleoside/nucleotide analogues 
Ribavarin is a nucleoside analogue which has a mutagenic effect when 
incorporated into the viral genome. It is licensed for use in humans and has been 
shown to inhibit viral replication of coronaviruses, influenza, RSV and 
adenoviruses. Ribavirin has not been used routinely in the treatment of 
coronaviruses however with the emergence of highly pathogenic viruses such as 
SARS and MERS there are ongoing trials into the use of interferon-α2b in 
combination with ribavirin (Falzarano, de Wit et al. 2013). The results in animal 
studies are promising but there are only a small number of case reports in 
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humans (Khalid, Al Rabiah et al. 2015). Toxicity is limiting factor as the drug can 
cause both leukocytopenia and haemolysis.  
Cidofovir is a monophosphate nucleotide analogue which has a broad spectrum 
of activity against DNA viruses. The diphosphate metabolite of cidfovir is 
competitively incorporated into DNA in place of the nucleotide cytosine resulting 
in chain termination. Cidofovir is recommended as a first line therapy in the 
treatment of adenovirus infections in immunocompromised individuals such as 
those undergoing stem cell or solid organ transplantations and a recent study 
suggests clinical benefit in immunocompetent individuals with pneumonia (Kim, 
Kim et al. 2015). The drug is only available as an intravenous preparation and it 
is associated with potentially significant side effects including nephrotoxicity. 
Brincidofovir, a prodrug of cidofovir, is conjugated to a lipid and therefore 
associated with higher intracellular levels of drug. This results in lower plasma 
levels of the drug which in turn reduces nephrotoxicity.    
1.4.2 Symptomatic Management 
Where no specific prevention measure or drug treatments are available 
individuals and clinicians are limited to recommending symptomatic 
management. There are many options available as part of this multi-billion 
pound economy. Pharmacological agents such as anti-inflammatories, mucolytics 
and decongestants are readily available over the counter but the small number 
of varied studies carried out on such measures makes it difficult to corroborate 
any beneficial role. In the vast majority of cases it is unlikely that these 
measures are associated with harm (Smith, Schroeder et al. 2014). The 
exception to this is centrally acting antitussives where the active ingredient is 
derived from opiates, associated with addiction and respiratory suppression.  
Additional simple measures such as vapour and maintaining hydration are seen as 
helpful but again there is little evidence available to corroborate any positive 
role in disease outcome (Singh 2013).  
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1.4.3 Vaccines and Immunisations 
An important strategy in the management of viral respiratory infections is that 
of prevention. There is a great need for vaccines against viral respiratory 
pathogens particularly in groups at risk of severe disease. However there are 
multiple barriers to the development of effective viral vaccinations. As discussed 
previously there are multiple virus groups which cause acute respiratory 
infections and within each group there are several, up to hundreds of serotypes. 
For a vaccine to be effective it must target a conserved yet neutralising epitope 
of the pathogen.  
Some viruses, for example RSV, present the greatest risk to young infants who 
still possess maternal antibodies, interfering with infants’ own ability to mount a 
vaccine response. Antibodies generated at this age can be transient with a lower 
affinity compared with those generated in later life (Siegrist 2000). At the other 
extreme of age, the elderly have a marked reduction in the immune response to 
infection and altered reaction to vaccination. Aside from these host factors, the 
number of viruses and array of serotypes within each group of viruses 
responsible for respiratory illnesses makes it difficult to develop an effective 
vaccination. The large number of serotypes is often a representation of the viral 
mutations which occur over time as an effective escape mechanism from the 
host immune system.  
As a result of these barriers, few viral vaccines exist with the exception of an 
influenza vaccine. Multiple vaccine preparations are available with the most 
commonly used vaccine in the United Kingdom being the trivalent injection. The 
2015 season vaccine contained two IFA strains (A/Switzerland/9715293/2013 
(H3N2) and A/California/7/2009 (H1N1)pdm09) and one IFB strain 
(B/Phuket/3073/2013). The trivalent injection preparations contain inactivated 
viruses but a newer intranasal Quardravalent preparation with live attenuated 
viruses is licensed and contained the same strains as the trivalent vaccine along 
with an additional IFB strain (B/Brisbane/60/2008) (WHO 2016). In the United 
Kingdom the influenza vaccine is recommended to all people over the age of 65 
years and under 5 years, pregnant females and those with chronic medical 
conditions such as diabetes, cardiovascular disease or chronic lung disease, as 
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these individuals may be more severely affected by the infection. The vaccine 
contains two strains of influenza A and one strain of influenza B (influenza C 
rarely circulates and is associated with mild illness and is therefore not 
included). The vaccine is modified regularly to contain the strains most likely to 
circulate during the standard influenza epidemic. This choice is based on 
surveillance information from previous seasons along with modelling data and 
must be modified frequently as the viruses are prone to antigenic shift and drift 
which will impact on vaccine effectiveness. No vaccine is associated with 100% 
efficacy and therefore not all cases will be prevented but on average around 50% 
of cases are prevented through vaccination programs.  
The group at greatest risk from severe RSV infections is infants, due to their 
degree of immunosuppression related to circulating maternal antibodies and 
immature immune systems. A passive immunisation against RSV is licensed for 
use, the humanised monoclonal antibody palivizumab. Its use remains limited to 
a small and specific population of at risk individuals, in part due to the cost of 
the preparation and the short half-life, requiring frequent dosing during an RSV 
outbreak. It is administered to premature infants but is neither practical nor 
cost effective to be used in the general population.  
A live vaccine is available against adenovirus types 4 and 7 which have been 
responsible for outbreaks associated with high levels of morbidity in specific 
areas, particularly those with close living quarters such as military recruits, 
holiday camps and healthcare settings. The vaccine was routinely administered 
to military recruits during basic training in the United States which was 
associated with a reduction in the number of cases. It has been hypothesised 
that the reduction may in part be due to falling numbers of recruits as similar 
patterns had been noted in countries not administering the vaccine. Due to 
manufacturing issues and a lack of supplies the vaccination programme ceased in 
1999. Surveillance of US military training camps suggested there were around 
15,000 vaccine preventable cases of AdV infection per year, therefore the 
program was reinstated in 2011 with a novel vaccine (Hoke and Snyder 2013). 
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1.5 Diagnosis of Infection 
The idea of an external cause of illness dates back many centuries, however our 
understanding of infectious disease has evolved with the ability to magnify and 
visualise the minute. Hippocrates documented outbreaks of disease in great 
detail in the fifth century BC but he was limited to describing what could be 
observed with the naked eye such as location, habit and appearance of 
individuals.  
 
“Whoever wishes to investigate medicine properly, should proceed thus: 
in the first place to consider the seasons of the year, and what effects 
each of them produces for they are not at all alike, but differ much 
from themselves in regard to their changes. Then the winds, the hot 
and the cold, especially such as are common to all countries, and 
then such as are peculiar to each locality. We must also consider 
the qualities of the waters, for as they differ from one another in 
taste and weight, so also do they differ much in their qualities.” 
    
 On Airs, Waters And Places 
 Hippocrates (translated by Francis Adams) 
 
While Hippocrates is undoubtedly the father of epidemiology it is only with the 
technological advances of recent centuries that the aetiology of many diseases 
could be explored. 
1.5.1 Historical aspect of viral diagnostics 
The methods used to diagnose infections have run in parallel with the ability to 
visualise microorganisms and their effects. Robert Hooke was the first to publish 
a description of microorganisms in his 1665 seminal work Micrographia where he 
used light microscopy to give a detailed account of microfungi. Within a few 
years Antonie van Leeuwenhoek had used similar methods to describe the 
appearance of bacteria and protozoa. It would be many years later, in 1876, that 
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Robert Koch would demonstrate the link between such organisms and disease 
through his work with Bacillus anthracis as the cause of anthrax. Following on 
from this initial discovery many bacteria were identified and characterised as 
pathogens but it was acknowledged that there was a yet unidentified entity 
capable of causing disease. The work of Adolf Mayer and Dmitri Ivanovsky 
demonstrated a non-bacterial pathogen which was able to replicate and transmit 
disease between tobacco plants. The experiment was reproduce by Martinus 
Beijerinck, who coined the term “virus”, derived from the Latin meaning “slimy, 
poisonous liquid” in reference to the filtered plant sap which transmitted 
disease. Due to the small size of virus particles they remained invisible until the 
1930s when they were unveiled by electron microscopy; however the effects of 
viral infections could be demonstrated much earlier than this using experimental 
animals and later cultured cells. As this can be used as a diagnostic tool, the 
method will be discussed in more detail in the following section.  
1.5.2 Diagnosis of Viral Infections 
1.5.2.1 Case definitions 
Perhaps the most basic way of diagnosing an infection is based on the clinical 
syndrome with which the patient presents. This is a particularly useful tool in 
resource poor settings where laboratory tests may not be accessible or 
affordable. A standardised definition of symptoms used across many countries 
will also allow a comprehensive geographical and chronological comparison. This 
method is often employed in surveillance programmes where the goal is not to 
diagnose an individual, rather to look for trends in illness presentation on a 
larger scale. The commonest utilisation of case definitions is in the context of 
influenza-like illness (ILI) and severe acute respiratory infection (SARI) 
surveillance. There are no pathognomonic features of infection which distinguish 
influenza from other respiratory pathogens therefore often a subset of patients 
will also have diagnostic tests carried out to confirm aetiology of infection. Case 
definitions can also be used to triage those at greatest risk of having a disease. 
This method was used during the recent outbreak of the ebola virus in West 
Africa. Using the clinical symptoms and the history of presentation, patients can 
be identified and, where appropriate, isolated while awaiting laboratory 
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confirmation. This use of triage and patient cohorting aims to reduce the spread 
of infection (WHO 2010).  
1.5.2.2 Culture and Virus Isolation  
It has been possible to maintain living tissues and cells in a laboratory setting for 
many decades but advances made in the 1940s and 50s brought the ability to 
grow viruses in cultured cells. Henry Eagle described the nutrients required to 
maintain living cells for an extended period (Eagle 1955) thus allowing the 
propagation of virus. One of the first uses for this technique was growing 
purified polio virus to be used in the mass production of vaccines.  
For many years this technique was the workhorse of virus diagnostic 
laboratories. The presence of a viral pathogen can be confirmed by directly 
inoculating a healthy monolayer of cells with a clinical sample from a 
symptomatic individual. If the virus is present in the sample and an appropriate 
susceptible and permissive cell line is used, the virus will replicate. The cells can 
then be observed for signs of damage due to infection – cytopathic effect (CPE). 
This process may take days to weeks depending on the virus in question, if 
indeed it develops at all. Although it can inform an experienced individual of the 
presence of an infectious agent, one must rely on previously documented 
patterns of cell damage. This is of course not possible when dealing with novel 
pathogens, though in such cases the presence of CPE in the absence of known 
pathogens can indicate a yet unidentified pathogen. Today this technique is used 
infrequently in routine diagnostics but its value must not be forgotten; it was 
the process used to initially identify the novel SARS corona virus during the 
outbreak in 2003.  
1.5.2.3 Direct Detection Assays 
1.5.2.3.1 Direct and Indirect Immunofluorescence 
Using direct immunofluorescence (DIF), also known as direct fluorescence 
antibody testing (DFA), antigens can be detected in clinical samples by using 
antisera to a specific protein or epitope. Using the direct method, antisera 
containing antibodies coupled with a fluorescent dye which will bind to the 
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antigen if present, are combined with a clinical sample. The reaction is 
thoroughly washed to remove any unbound antibody and mounted on a slide. If 
antigen bound antibody remains it will fluoresce when viewed with a fluorescent 
microscope (Figure 1-8). 
 
Figure 1-8. Direct and indirect immunofluorescence. 
This shows a schematic representation of the direct and indirect immunofluorescence methods. 
The arrows represent a fluorescent indicator which can be detected using microscopy. 
 
The indirect method is very similar to that outlined above, with the exception of 
the virus specific antibody is not coupled with the fluorescent dye, rather a 
secondary antibody directed at the virus specific primary antibody is labelled. 
This method is more time consuming as two incubation periods are required but 
only a single labelled antiserum is required to detect multiple antigens, in 
comparison to the direct method where a labelled antiserum is required for each 
antigen.  
Regardless of which method is used, the reactions must first be optimised to find 
the antibody concentration which results in a sensitive test whilst reducing the 
background fluorescence to an acceptable level (Odell and Cook 2013).  
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1.5.3 Serological Assays 
In these methods the study of patient serum can detect current infection 
(antigen) or inform of an immune response mounted to recent or previous 
infection (antibody).  
1.5.3.1 Complement Fixation and Haemagglutination 
In this process the naturally occurring complement proteins are removed from 
the patient serum, usually through heat treatment which will degrade the 
complement proteins but preserve antibodies. The serum is then supplemented 
with a standardised quantity of complement proteins, red blood cells and the 
antigen under study. If antibodies to the antigen are present the antibody-
antigen complexes will consume the complement proteins but if no antibodies 
are present the complement will be free to lyse the red blood cells, turning the 
reaction pink. If antibodies are detected the levels can be quantified through 
serial dilutions of patient serum, to determine an antibody titre. This can be 
used to determine if an immune response has been mounted, in that the 
antibody titre will increase over the time of the infection. 
Agglutination of red blood cells can be exploited in a similar fashion if the virus 
is capable of producing haemagglutination to determine virus and antibody 
quantity. If a sample contains virus, when it is added to red blood cells (typically 
chicken or turkey) the virus and red blood cells will agglutinate and form a 
diffuse lattice structure. If the virus is not present the red blood cells will settle 
in a dot or clump at the bottom of the reaction well. Dilutions of the initial 
sample are used to determine a quantity. Inhibition of red blood cell 
agglutination in the presence of virus (influenza) and patient serum confirms the 
presence of neutralising antibodies in the serum. Again serial dilutions of this 
process can be used to quantify antibody levels. 
1.5.3.2 Enzyme-linked Immunosorbent Assay 
The Enzyme-Linked Immunosorbent Assay (ELISA) has similar applications to 
indirect immunofluorescence. Antibody is bound and immobilised on a surface. 
The clinical specimen is then added and if antigen is present within the 
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specimen it will bind to the antibodies. A second antibody is then added to the 
reaction. This may be labelled with an enzyme (direct), typically horseradish 
peroxidise (HRP) or alkaline phosphatise (AP), or not labelled (indirect). Any 
unbound antibody is washed from the reaction and in the direct reaction a 
substrate is then washed over the reaction. In the presence of labelled antibody 
the substrate reacts with the enzyme resulting in a colour change which can be 
read by photometry. As with indirect immunofluorescence, in the indirect 
reaction an unlabelled antibody is washed over the reaction followed by a 
labelled antibody directed against the previous. Again a substrate is added and 
colour change detected (Figure 1-9).    
 
Figure 1-9. Enzyme-linked Immunosorbent assay. 
A graphical representation of an enzyme-link immunosorbent assay. The presence of antibody to 
the target under study results in a reaction colour change.  
The detection of antibodies against a pathogen in the serum of a symptomatic 
individual can inform if they have mounted an immune response to a pathogen. A 
rise in antibody titres in paired serum samples taken three to four weeks apart 
(as this process takes time to develop) indicates recent infection. The 
production of antibodies is not only a process which takes times but also one 
which can be affected by many inherited and acquired conditions such as 
primary immune deficiencies, haematological malignancies or infections e.g. HIV 
(Lazzarotto, Dal Monte et al. 1992). In people affected by these conditions 
serology results may be unreliable or difficult to interpret. Autoimmune 
conditions such as rheumatoid arthritis or systemic lupus erythematosus have 
been associated with false positive results due to non-specific antibody cross-
reactivity (Salonen, Vaheri et al. 1980).  
Many of the viral pathogens involved in respiratory tract infections are not 
commonly associated with a viraemic stage therefore serological testing is 
limited to providing a retrospective diagnosis as antigen is unlikely to be 
present. In general serological assays inform of past URTIs and would not guide 
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treatment options as infections will have resolved by the time the second 
convalescent sample is collected. Serology does provide important 
epidemiological data which can influence patient management, a good example 
being strain selection for influenza vaccines. 
1.5.4 Molecular Diagnostic Methods 
1.5.4.1 Nucleic Acid Amplification Testing 
The first account of deoxyribonucleic acid, DNA, was in the 1860s, when 
Friedrich Miescher identified a new substance which behaved like no known 
protein or carbohydrate. He called this “nuclein” which Oskar Hertwig 
determined was responsible for hereditary characteristics and would later be 
known as DNA. Many decades later Phoebus Levene went on to describe the 
structure of individual bases which make up DNA with the overall double helix 
structure being resolved in 1953 by Watson and Crick, the names most frequently 
associated with DNA and the recipients of the Nobel prize for their work (Watson 
and Crick 1953).  
The recognition that DNA, the building blocks of life, is present in all living 
organisms revealed a further target in the detection of pathogens. 
The introduction of culture-independent molecular methods to the diagnostic 
laboratory revolutionised routine diagnostics. Not only has the turn-around time 
been reduced dramatically but as the viral genome is the target the tests are 
both sensitive and specific. For these reasons molecular testing constitutes the 
majority of work in many diagnostic laboratories. There is however a need for a 
priori knowledge of the pathogen genome. Diagnosing a viral infection with 
these methods requires the pathogen to be present in the clinical specimen, so 
appropriate and effective sampling must be carried out within the period of 
detectable viral shedding.  
1.5.4.1.1 Polymerase Chain Reaction 
Nucleic acids must be extracted from the cells or particles within a given 
sample. Oligonucleotide primers which complement the target genome, one 
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against each strand, are added to the extracted nucleic acids along with a 
thermostable DNA polymerase. Heating of the mix melts any secondary 
structures of the DNA to expose the area complementary to the oligonucleotide 
primer. Primer binding acts as a starting point for the DNA polymerase enzyme 
which can then extend a complementary sequence in the 5’ and 3’ direction. 
Multiple cycles of this process are carried out, resulting in an exponential 
increase in target genome copies. These can then be visualised by gel 
electrophoresis. An additional reverse transcription step to generate cDNA from 
RNA allows amplification of RNA genomes. 
1.5.4.1.2 Nested Polymerase Chain Reaction 
Nested PCR is essentially the same process as two standard PCRs. The primers 
used in the first reaction are designed against a target and the product of this is 
used as the template in a subsequent reaction. The primers used in the second 
reaction are designed against a target within the first target. The specificity of 
PCR amplification is dependent on primer binding and it is possible for a primer 
set to bind at more than one locus on a template genome. To increase the assay 
specificity this second set of primers which target the product of the first 
reaction are added, thus if the wrong locus is amplified during the first reaction 
it is extremely unlikely that this unwanted product will be further amplified in 
the second reaction. 
1.5.4.1.3 Real-Time Polymerase Chain Reaction 
The PCR process can be modified to allow real-time detection and quantification 
of the target. The addition of a fluorescent dye which only binds to double 
stranded DNA, i.e. the target, means as the target increases the fluorescence 
intensity will in turn increase. Alternatively a third oligonucleotide probe can be 
added to the reaction. This probe is specific to the target and labelled with a 
fluorophore and quencher. When the fluorophore and quencher are in close 
proximity the fluorescence cannot be detected. However when the probe binds 
to the target the exonuclease activity of the polymerase degrades the probe, 
releasing the quencher and thus exposing the fluorescence which can be 
detected following excitation by laser.  
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Using both PCR and real-time PCR it is possible to detect several targets in a 
single reaction by adding multiple primer sets. This is referred to as a multiplex 
PCR. It must be considered that there is a limit to the number of primer sets 
which can be added, usually up to four, before the sensitivity of the assay is 
affected in comparison with the individual assay.  
Testing samples with standardised quantities of DNA in parallel with the unknown 
samples can be used to determine the quantity of the unknown samples. A 
standard curve can be generated from results of samples with known DNA 
quantities; this is used as a reference by which the DNA quantity in unknown 
samples can be extrapolated. 
1.5.4.2 Microarrays 
Microarrays (also known as DNA chips or biochips) utilise a collection of 
oligonucleotide probes about 70 bases in length, immobilised on a solid surface. 
The probes are complementary portions of DNA or RNA, designed against 
conserved regions of a genome or gene and thus if the target is present within a 
given sample it will bind to the corresponding probe. Probe binding is then 
quantified using a fluorophore or chemilluminescent reaction. Multiple probes 
can be attached to a single surface, allowing for screening of a large number of 
pathogens in a single reaction. As probes are targeted against conserved regions 
of the pathogen genome they may also detect related but novel pathogens.   
1.5.5 Point-of-Care Testing 
All of the above methods will be carried out in a specialist laboratory but point-
of-care tests (POCT) are being introduced, so called as they can be performed in 
an area of patient care such as an emergency department or intensive care unit, 
in community or even in the home. The introduction of the Cepheid GeneXpert® 
has brought PCR into the clinical area. This portable, self-contained device 
utilises pre-packed cartridges of reagents therefore does not require extensive 
training or additional equipment. As a result, tests can be offered in the clinical 
areas, community or even in the field (Jenson, Dize et al. 2013).   
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Many POCT are available using the methods described above e.g. ELISA and 
haemagglutination however the majority of the POCT currently available are 
based on lateral flow immunochromatography (LFI) (Gubbins, Klepser et al. 
2014). Using this method, a conjugate e.g. antibody, is bound to a porous 
surface.  The liquid sample migrates across the porous surface and releases the 
conjugate. This mix migrates further to a capture molecule which will bind the 
analyte-conjugate complex, often resulting in a colour change to indicate a 
positive result. A second non-specific capture molecule is often included as a 
positive control to indicate sample migration was adequate (Figure 1-10). 
 
  
Figure 1-10. Lateral flow immunochromatography.  
(Adapted from http://www.cytodiagnostics.com/store/pc/Lateral-Flow-Immunoassays-d6.htm) 
 
A positive result with be indicated by a colour change which can be visualised by 
the user, although this can vary depending on the user. These rapid diagnostic 
assays will often provide results that will facilitate patient management, be that 
initiation of appropriate treatment or cohort care based on positive results i.e. 
41 
 
those with the same condition are treated in the same space to limit further 
spread of infection. Such tests could also help avoid unnecessary hospital 
admission and treatment. In the case of febrile illness in malaria endemic 
regions, such tests result in more accurate diagnosis, therefore a reduction in 
inappropriate anti-malarial treatment use (Ameyaw, Nguah et al. 2014). 
Access to such tests could aid in detection of diseases in populations where it 
can be difficult to engage with medical services such as developing countries or 
rural areas far from a central diagnostic laboratory. Results are available rapidly 
and do not necessarily require healthcare trained staff providing training and on-
going performance evaluation is carried out (Drancourt, Michel-Lepage et al. 
2016).  
1.5.6 DNA Sequencing 
Following the discovery of DNA and its gross structure it then seems a natural 
progression to determine the finer details and patterns of the structure. This 
information can provide great insight into the pathogens responsible for 
infection. This was successfully achieved independently by two groups using very 
different methods as outlined below.  
DNA sequencing is not routinely used as a first line diagnostic test but is used to 
further characterise a pathogen or determine virulence/resistance patterns. The 
commonly used sequencing methods are discussed below followed by an 
overview of the Next Generation Sequencing techniques which are currently 
available.  
1.5.6.1 Maxam-Gilbert Sequencing 
This method uses four chemical cleavage reactions to split DNA at specific bases 
or pairs of bases (Maxam and Gilbert 1977) (Figure 1-11). The DNA under study is 
cleaved using a restriction enzyme and a radioactive label is placed at the 5’ end 
of the fragment. The labelled DNA fragment is separated using gel 
electrophoresis and divided into four separate chemical reactions. Each reaction 
cleaves DNA at a specific base or pair of bases (e.g. G, G+A, C and C+T). The 
fragments produced are electrophoresed in parallel and the DNA sequence can 
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be inferred from the pattern and placement of the resulting bands as the rate of 
travel trough the gel will be related to the size of fragment (Figure 1-11). This 
method is rarely used due to the complexity of the process and exposure to 
hazardous and radioactive materials. 
 
Figure 1-11. Maxam-Gilbert sequencing. 
An example of gel electrophoresis output and interpretation following the Maxam-Gilbert 
sequencing process.  
1.5.6.2 Sanger Sequencing 
The names most frequently associated with genetic sequencing are Sanger and 
Coulson who successfully determined the sequence of an E. Coli bacteriophage 
(Sanger and Coulson 1975) using chain-termination. This method involves 
purification and denaturation of DNA followed by amplification through cloning 
or polymerase chain reaction (PCR). The resulting DNA is then divided into four 
tubes. In each tube one of the four dideoxynucleotides ddATP, ddCTP, ddGTP or 
ddTTP is added in the presence of DNA polymerase along with the four normal 
nucleotides. The ddNTP act as chain terminators, therefore if they are 
incorporated into a DNA strand extension will terminate at that point. The 
ddNTPs will be incorporated over the normal nucleotide by chance, resulting in 
fragments of varying lengths. As only one ddNTP is added to each tube the final 
nucleotide of each chain is known. The resulting double stranded DNA is 
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denatured and gel electrophoresis performed with one lane used for each ddNTP 
and from this the DNA sequence can be inferred. The use of fluorescent labels 
for each individual nucleotide allowed this four tube reaction to be combined in 
one reaction and the individual ddNTPs can be read by a laser as each emits a 
different signal.  
This new found ability to determine the genetic make-up of living organisms led 
to the establishment of Human Genome Project in 1986, aiming to map the 
human genome within 15 years. The Sanger method was used in this project and 
whilst it took slightly longer than anticipated, the 3 billion base pair sequence of 
the human genome was completed in 2003 at a cost of $2.7 billion.  
The cost of Sanger sequencing on such a massive scale remains prohibitive to 
most laboratories but is perhaps one of the driving forces behind the search for 
alternative sequencing methods. 
1.5.6.3 Next Generation Sequencing 
Next generation sequencing (NGS), also referred to as massively parallel, high 
throughput or deep sequencing, has vastly increased the throughput of genetic 
sequencing in comparison with previous methods. There are multiple platforms 
available, utilising different methods, which are continually evolving and 
improving. Below is an overview of the currently available platforms but we are 
in a period of exponential change therefore it is likely that this will soon be out 
of date.  
1.5.6.3.1 Illumina 
Illumina (previously known as Solexa) utilise a sequencing-by-synthesis (SBS) 
method, where DNA fragments are immobilised onto a flow cell with primers 
where PCR is carried out to produce multiple copies of the target in clusters. 
The clusters are washed with four types of fluorescently labelled reversible 
terminating bases in the presence of DNA polymerase. The bases compete for 
binding sites and if incorporated a laser is used to excite the labelled dyes and 
photograph the location on the flow cell. The terminating dye is removed and 
the process is then repeated. All resulting sequenced fragments will be the same 
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length as length is determined by the number of cycles carried out. With the 
reagents currently available 600 cycles can be carried out to generate pair-end 
fragments of 300 bases each. In the paired-end process the DNA target fragment 
is sequenced in the forward direction and then folded over and sequenced in the 
reverse direction. This generates two high quality reads from a single target 
fragment (Illumina 2016).  
1.5.6.3.2 Ion PGM Sequencing 
In this method nucleotides are sequentially washed over microwells containing 
target DNA. As a nucleotide is incorporated into the sequence by the DNA 
polymerase a hydrogen ion is released, resulting in a change in pH in the 
microwell. It is this change in pH which is detected and used for base calling 
(Bragg, Stone et al. 2013). As with 454 pyrosequencing it is possible that more 
than one nucleotide will be incorporated when homopolymers are encountered 
but the hydrogen ions released and thus the change in pH is proportional to the 
number of bases added.  
1.5.6.3.3 454 Pyrosequencing 
Pyrosequencing also uses a SBS approach and relies upon detection of phosphate 
release as a nucleotide is incorporated. Fragmented DNA is attached to a bead 
and enclosed within a water droplet where PCR amplification coats the bead 
with multiple copies of the fragment. Beads are then immobilised on a plate and 
bases washed over the plate sequentially. Pyrophosphate is released as a base is 
incorporated, providing the substrate in a luciferase reaction. Visible light is 
emitted by this reaction which is then detected by a camera. The quantity of 
light emitted is proportional to the quantity of pyrophosphate released and 
therefore if multiple bases are incorporated in a reaction this can be detected. 
The immobilisation of the beads allows the camera to maintain the position of 
each bead and thus multiple sequences are simultaneously created.  
1.5.6.3.4 SOLiD Sequencing 
Sequencing by Oligonucleotide Ligation and Detection (SOLiD) employs 
sequencing by ligation. The template is hybridised to a bead where clonal 
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populations of the template are prepared with emulsion PCR. All the components 
of this PCR microreaction are contained in a droplet, suspended in oil. The beads 
are then immobilised on a glass slide where fluorescently labelled probes ligate 
to the target releasing a fluorescent signal. The ligation process is repeated up 
to five times, starting in the n-1 position on subsequent cycles. As a result nearly 
every base is covered by ligation probes multiple times, hence increasing 
accuracy.   
1.5.6.4 Third Generation Sequencing 
1.5.6.4.1 Pacific Biosciences 
Pacific Biosciences utilise a Single Molecule Real-Time (SMRT) sequencing 
method. Essentially this is a sequence-by-synthesis method where a single DNA 
polymerase compound is immobilised at the bottom of a pore in a solid surface, 
a zero-mode waveguide (ZMW). A single-stranded DNA molecule attaches and 
runs through the polymerase compound. Each of the four bases is labelled with a 
different fluorescent dye at the terminal phosphate and can therefore be added 
simultaneously. When the polymerase incorporates a nucleotide into the DNA 
sequence fluorescent dye is clipped off and, upon excitation by a laser, a light 
signal is emitted which can be detected in real-time. In this method all reagents 
are incorporated at the beginning of the process with no wash steps required 
during the process therefore it is rapid in comparison to the alternative 
(Roberts, Carneiro et al. 2013).  
1.6 Importance of diagnostics 
The specific therapeutic options for viral respiratory infections may be limited 
but this does not take away from the importance of accurate diagnosis. 
Correctly identifying a virus as the cause of illness can still impact on the clinical 
management of patients through the prevention of inappropriate therapies. 
Antibacterial resistance poses a real threat to human health and should be 
considered a major public health issue. No new classes of antibiotics have been 
developed in over 20 years and the circulation of multidrug resistant organisms 
is increasing at an alarming rate. The vast majority of antibiotics are prescribed 
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in primary care and most of these are for respiratory infections. Antibiotic 
prescribing rates vary throughout Europe with the UK being amongst the highest 
(Butler, Hood et al. 2009). This is despite the knowledge that a large proportion 
of infections, particularly respiratory infections are viral in origin. This approach 
stems from the historical observations that a simple upper respiratory infection 
could quickly progress and become complicated by pneumonia (NICE 2008). As a 
result of the general improvements in healthcare, sanitation and the 
introduction of vaccinations this is now a much rarer occurrence. There is also a 
perceived expectation that patients feel antibiotics should be used but these 
ideas are being challenged.  
The use of antibiotics in simple respiratory infections results in no clinical 
benefit to patients and exposes them to potential drug reactions and side effects 
(Butler, Hood et al. 2009) as well as being at great expense to healthcare 
systems. The increasing use of antibiotics correlates with a rise in the rates of 
antibiotic resistant organisms and rationalising prescribing has been shown to 
reduce the circulation of resistant bacteria. One of the commonest reasons for 
antibiotic prescribing is that of viral respiratory infections (van Buul, Veenhuizen 
et al. 2014). It is now well documented that the presence of a viral infection 
does not preclude a bacterial infection, in fact co-infections and secondary 
bacterial infections are seen in up to 15% of childhood pneumonia cases (Jain, 
Williams et al. 2015). But this same study demonstrated the evidence of a 
pathogen in 81% of childhood pneumonia cases, 66% of which were viral alone 
and only 7% were bacteria-viral co-infections. Investigations into the aetiology of 
acute respiratory infections frequently find viruses as the most common cause of 
illness.  
Penicillin was first introduced to clinical practice in 1940 and within months 
resistant organisms were detected (Abraham and Chain 1940). Of course at this 
time the methods of resistance development were not known and it is now 
understood that multiple mechanisms are responsible. There was an early 
realisation that antibiotic use could be associated with drug resistance, indeed 
erythromycin was removed from clinical practice for S. aureus treatment as over 
25% of cases were found to be erythromycin resistant (Dagan and Bar-David 
1992).  
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Perhaps one of the first cases to highlight this issue as a major public health 
concern was the emergence of methicillin-resistant Staphylococcus aureus 
(MRSA). MRSA is frequently associated with colonisation; however it poses a 
great risk to hospitalised individuals as it can result in severe pneumonia, 
infections of surgical wounds and prosthetic equipment e.g. venous or urinary 
catheters.  
1.7 Potential gains from the utilisation of NGS in a diagnostic setting  
As discussed above, the diagnosis of respiratory infection aetiology is an 
important aspect of clinical management, despite the lack of specific treatment 
measures. The process of NGS generates vast quantities of data which could be 
of important use to a health service. The target independent nature of the 
process could allow for the detection of multiple pathogens using a single 
sample processing method.  
The sequence information generated could be used in molecular epidemiological 
studies into the presence, spread and evolution of viral diseases. Projects aiming 
to develop such a system have highlighted issues with regard to incomplete 
clinical data accompanying sequence data though developing a database in 
conjunction with clinical testing could improve this situation (Araujo, Souza-
Brito et al. 2012).  
The long term benefit of such information could be a greater understanding of 
the viruses which cause disease in humans. This could be used to support vaccine 
development and clinical research into treatment options through long-term 
study of viral pathogens and therefore allow the targeting of viral weaknesses 
which could be exploited to generate further treatment or prevention options.  
In a shorter term period such information could allow the real-time study of 
outbreaks of viral disease. Again, the knowledge of such cases could be essential 
in development of mechanisms to prevent such instances in the future.  
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1.8 Research Aims 
The aims of the research presented in this thesis were to use next generation 
sequencing methods and bioinformatic analyses to detect viral pathogens in 
clinical respiratory samples and compare the outcomes with the current 
molecular diagnostic assays. 
Specific aims: 
1) Develop a reliable and reproducible protocol for the processing of clinical 
samples for next generation sequencing. 
2) Develop a data analysis pipeline for the detection of viral genetic 
sequences from the resulting data sets. 
3) Use sequenced information to characterise the viral respiratory pathogens 
detected in clinical samples. 
4) Compare the sequencing outcomes with the current standard respiratory 
diagnostic molecular assays. 
5)  Test the developed protocol with further specimen types to determine if 
the methods are transferable to other clinical areas of viral diagnostics. 
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2 Materials and Methods 
2.1 Materials 
2.1.1 Kits 
Kit Source 
NEBNext mRNA Second Strand Synthesis Module New England BioLabs Inc. 
Advantage 2 PCR Kit Clontech 
Nextera XT DNA Sample Preparation Kit Illumina 
KAPA SYBR FAST qPCR Complete kit Kapa Biosystemes 
MagJET Viral DNA and RNA Purification Kit Thermo Fisher Scientific 
Tapestation D1000 ScreenTape System Agilent 
Bioanalyzer DNA 7500 Kit Agilent 
Table 2-1. Kits used in sample processing. 
2.1.2 Enzymes 
Enzyme Name Supplier 
TURBO DNase Life Technologies 
DNA Polymerase I, Large (Klenow) Fragment New England BioLabs Inc. 
RNase A Life Technologies 
Table 2-2. Enzymes used in sample processing 
2.1.3 Primers 
Primer Name Sequence 
FR26RV-N 5' GCC GGA GCT CTG CAG ATA TCN NNN NN 3' 
FR20RV 5' GCC GGA GCT CTG CAG ATA TC 3’ 
Table 2-3 Primers used in PCR 
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2.1.4 Chemicals 
Chemical Abbreviation Supplier 
Agarose - Sigma-Aldrich 
Ethanol EtOH Sigma-Aldrich 
Nuclease free water NFH2O Thermo Fisher Scientific 
Sodium hydroxide NaOH Sigma-Aldrich 
Ethidium Bromide EtBr Sigma-Aldrich 
Isopropanol IPA Sigma-Aldrich 
Tris-acetate-EDTA TAE In-house 
Polyethylene Glycol PEG Sigma-Aldrich 
Phosphate buffered saline PBS Sigma-Aldrich 
Table 2-4. List of chemicals 
2.1.5 Illumina reagents and abbreviations 
Reagent Abbreviation 
Tagment DNA Buffer TD 
Amplicon Tagment Mix ATM 
Neutralize Tagment Buffer NT 
Nextera PCR Master Mix NPM 
Hybridization buffer HT1 
Table 2-5. Illumina sequencing reagents 
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2.2 Methods 
2.2.1 Nasopharyngeal swab sample preparation 
After obtaining a diagnostic swab from a patient, it was placed in viral transport 
media (VTM) and submitted to the diagnostic laboratory. Upon arrival in the 
laboratory the VTM tube was opened, the swab pressed against the wall of the 
tube to remove any cells or fluid and from this point the VTM was treated as the 
specimen. When samples were not in use they were stored at -20ºC or -80ºC for 
long term storage. 
The NPS used in the main body of the project were obtained from the University 
of Otago, New Zealand. These samples were collected as part of a large cohort 
study (Murdoch, Slow et al. 2012). Following completion of this project the 
residual samples were obtained. Frozen samples were thawed in a water bath at 
37ºC then transferred to a sterile 1.5 ml tube and centrifuged at 1500 x g to 
remove any debris which may hinder nucleic acid extraction. The supernatant 
was retained and transferred to a fresh tube.  
2.2.2 Nucleic acid extraction 
Initially DNA and RNA were extracted from clinical samples manually. This 
method was not thought to be appropriate for high throughput of samples and 
the number of steps requiring hands-on time and transferring samples between 
tubes was a risk for potential contamination. Nucleic acids for next generation 
sequencing were therefore extracted from samples using the MagJET Viral DNA 
and RNA Kit on the KingFisher™ Flex Purification System (ThermoFisher 
Scientific). This process utilises guanidium thiocyanate to lyse the cells and 
particles within samples releasing nucleic acids which bind to beads in the 
presence of a chaotropic agent before washing and elution from the beads.   
A sample volume of 200 μl was transferred to a fresh 1.5 ml tube. To this 200 μl 
of lysis buffer and 50 μl of proteinase K was added and mixed well. This mixture 
was transferred to a microtitre deep well 96 plate (plate 1). Plates 2 - 4 were 
loaded with wash buffers as per manufacturer’s instructions and plate 5 loaded 
with 100 μl of nuclease free water for elution. The Viral_NA_Flex protocol was 
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initiated on the machine, which pauses following the lysis step to add 25 μl 
MagJET Magnetic beads and 450 μl 100% isopropanol to each sample well. The 
protocol was the recommenced and upon completion the eluted nucleic acids 
were removed from the 96-well plate, transferred to individual 0.2 ml tubes, to 
be stored at -80oC until processed.  
2.2.3 DNase Treatment 
DNA was removed by DNase treatment. Reactions comprised of 10 μl of 10x Turbo 
DNase buffer, 2 μl of 2U/μl DNase (Turbo DNase, Ambion Life Technologies), 10 μl 
of nucleic acids and 78 μl of nuclease-free water. Reactions were incubated for 
30 min at 37oC and mixed every 10 min during this time. 
2.2.4 Reverse Transcription 
Reverse transcription of purified RNA was carried out using Maxima H Minus (Life 
Technologies). Reactions comprised of 13 μl purified RNA, 1 μl 10mM dNTPs and 1 
μl FR26RV-N primer which was heated to 65oC for 5 min. Then, on ice, 4 μl of 5x 
Maxima H Minus buffer and 1 μl Maxima H Minus enzyme mix was added. This 
was incubated at 25oC for 10 min, 55oC for 60 min and finally 85oC for 5 min to 
terminate the reaction.  
2.2.5 RNA Purification 
RNA was purified from the DNase reaction using RNAClean XP beads (Agencourt). 
The beads were vortexed to resuspend and added to the DNase treated solution 
at a ratio of 1:1.8 and mixed well. The mixture was incubated at room 
temperature for 5 min then placed on a magnetic rack until the beads were 
pelleted on the tube wall and the supernatant clear. The supernatant was 
removed and the bead pellet washed carefully with 200 μl of 70% ethanol. The 
wash step was repeated and all ethanol removed. The pellet was left to air dry 
for 15 min and then resuspended in 15 μl of nuclease free water. (This procedure 
has been shown to effectively purify miRNA with average lengths of 22 nts 
therefore larger RNA fragments should also be retained (Beckman Coulter Life 
Sciences)).  
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2.2.6 Second Strand Synthesis 
Second strand DNA was synthesised using NEBNext mRNA Second Strand Synthesis 
Module (New England BioLabs). DNA was heated to 95oC for 3 min, then on ice 36 
μl of nuclease-free water, 6 μl of 10x NEBNext mRNA Second Strand Synthesis 
Module buffer and 3 μl of NEBNext mRNA Second Strand Module enzyme mix was 
added. This was mixed gently and incubated at 16oC for 2 hours and 30 min on a 
heat block.  
2.2.7 DNA Purification 
DNA was purified using AMPure XP beads (Agencourt, Beckman Coulter). The 
beads were vortexed to resuspend and allowed to equilibrate to room 
temperature and then added to the second strand cDNA mix at a ratio of 1:1.8 
and incubated at room temperature for 5 min. The solution was then placed on a 
magnetic rack until the beads pelleted on the wall of the tube and the 
supernatant was clear. The supernatant was removed and the pellet washed with 
200 μl of 70% ethanol. The ethanol was removed and the wash step repeated. All 
ethanol was then removed and the pellet allowed to air dry for 15 min at room 
temperature. The dried pellet was resuspended in 20 μl of nuclease-free water.  
2.2.8 Sequence Independent Single Primer Amplification (SISPA) 
Polymerase Chain Reaction 
PCR reactions were set up in a total volume of 50 µl. A template volume of 10 µl 
was added to a master mix containing 1µl Advantage 2 Polymerase, 5 µl 10x 
buffer, 1 µl 10nM dNTPs, 0.2 µl primer FR26RV (10mM), 1 µl primer FR20RV 
(10mM) (Froussard 1992) and nuclease-free water 31.8 µl. The PCR was carried 
out on an ABI 2720 (Applied Biosystems) with the following cycling parameters: 2 
min 95ºC, followed by 35 cycles of 95ºC for 30 seconds, 63.5ºC for 1 minute and 
72ºC for 3 min, then a final extension time of 72ºC for 10 min. 
2.2.9 Agarose Gel Electrophoresis 
The presence of PCR products were confirmed using 1% agarose gels, prepared 
using 1x TAE buffer and a final ethidium bromide concentration of 0.4 μg/ml. 
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The gels were immersed in 1xTAE and samples loaded with a 3:1 volumes loading 
dye in parallel with a 1kbp ladder to determine fragment size. The gels were 
loaded and run at 100V until separation was achieved then fragments were 
visualised and imaged using a UV transilluminator (GeneFlash, Syngene). 
 
Figure 2-1. An example of the gel electrophoresis output following a SISPA reaction. 
The lanes containing samples show a smear rather than distinct band as the PCR does not have a 
specific target, rather aims to non-specifically bind to and amplify all DNA within the sample.   
2.2.10 DNA Quantification 
DNA was quantified prior to library preparation using the Qubit dsDNA HS Assay 
Kit for the Qubit Fluorometric Quantification system (Life Technologies). The 
Qubit working solution was prepared by diluting the Qubit dsDNA HS reagent 
1:200 in Qubit dsDNA HS buffer in a nuclease free tube, with 200 μl in total being 
prepared for each sample and standard. Prior to each set of samples the 
fluorometer was calibrated using the supplied standards. 190 μl of working 
solution was added to 10 μl of standard 1 and 2 and 198 μl of working solution 
was added to 2 μl of each cDNA sample in a fresh thin-wall, clear 0.5mL PCR 
tube. All mixes were allowed to incubate for 2 min at room temperature prior to 
reading. Standards 1 and 2 were read by the fluorometer followed by the 
samples. The stock concentration was calculated as Qubit value x (200/X) where 
X is the initial volume of sample used and converted to ng/ul.  
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2.2.11 Nextera XT Library Preparation 
Following Qubit quantification 1ng of DNA was diluted to a total volume of 5 μl 
with nuclease-free water. Sequencing libraries were prepared using the Nextera 
XT DNA Library Preparation Kit (Illumina). The kit was removed from -20oC and 
allowed to thaw on ice. Before use each reagent tube was inverted 5 times to 
mix thoroughly. Reactions were set up in nuclease-free 0.2 ml PCR tubes.  
2.2.11.1 Tagmentation 
To each reaction 10 μl of TD, 1 ng of DNA and 5 μl ATM was added, gently 
pipetted up and down 5 times to mix and spun down briefly before incubating at 
55oC for 5 min. NT 5 μl was added to the mixture, mixed and spun down briefly 
to halt the reaction.  
2.2.11.2 Library Indexing 
Barcode tags were added to each sample through PCR amplification. 15 μl of 
NPM was added to each tube containing a library then 5 μl of the corresponding 
index 1 and 2 primers. The original caps of each primer were discarded and 
replaced with new caps to prevent cross-contamination. The mix was gently 
pipetted and briefly spun down before placing on a thermocycler (ABI 2720, 
Applied Biosystems) using the following programme; 72oC for 3 min, 95oC for 30 
seconds, 12 cycles of 95oC for 10 seconds, 55 oC for 30 seconds, 72oC for 30 
seconds, then a final extension step of 72oC for 5 min. The reactions were 
purified using AMPure XP beads as described for cDNA purification.  
2.2.11.3 Library Quantification 
Libraries were quantified using the KAPA SYBR FAST qPCR Complete kit. Each 
library was diluted to 1:1000, 1:2000 and 1:10000 with nuclease-free water and 
4 μl of each dilution was transferred to a 96-well plate along with duplicate 
wells for each of the 6 supplied standards. To each well containing a library or 
standard 4 μl of PCR grade water and 12 μl of KAPA SYBR FAST qPCR Master Mix 
was added. The KAPA SYBR FAST qPCR Master contained primers Primer P1 (5’-
AAT GAT ACG GCG ACC ACC GA-3’) and Primer P2 (5’-CAA GCA GAA GAC GGC ATA 
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CGA-3’) targeting the Illumina adapters used in barcoding during library 
preparation. The following cycling parameters were used; 95oC for 5 min then 35 
cycles of 95oC for 30 seconds and 60oC for 45 seconds (ABI 7500, Applied 
Biosystems). The concentration was corrected for the dilution and the mean of 
the three measurements taken as the final concentration. 
2.2.11.4 Library Insert Size Calculation 
The average library insert size was calculated using the High Sensitivity D1000 
ScreenTape System (Agilent). A 2 μl aliquot of the prepared library was 
transferred to a fresh 0.2 ml tube, to which 2 μl of High Sensitivity D1000 Sample 
Buffer was added. For each set of samples 1 lane contained High Sensitivity 
D1000 Ladder in place of a library to allow fragment size quantification. The 
tubes were loaded into the 2200 Tapestation and sample names entered into the 
controller software before commencing the run.  
The corrected library concentration was calculated by: 
 
Figure 2-2. Formula used to determine library concentration. 
2.2.11.5 Library Pooling and Denaturing 
A reagent cartridge was removed from storage at -20 °C and placed in a water 
bath at room temperature for 60 min. The cartridge was inverted several times 
to ensure adequate mixing of reagents and to check for any precipitation which 
would indicate that the cartridge was not usable. 
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Figure 2-3. This single use reagent cartridge is pre-filled with sequencing reagents.  
The prepared sample libraries are added to the highlighted aperture while the other apertures allow 
access to the separate regents during the process. The cartridge is then loaded onto the MiSeq, 
shown on the right. Image obtained from Illumina Inc.  
 The addition of barcode indexes during the library preparation process allowed 
multiple samples to be sequenced during a single run of the sequencer. In order 
to ensure equal coverage between samples the concentration of each individual 
library was diluted to 4nM with nuclease-free water and a 5 µl aliquot of each 
diluted library was pooled in a single tube. The concentration of the pooled 
library was calculated by a combination of the concentration measured by Qubit 
and the average insert size by Tapestation using the formula below. 
 
Figure 2-4. Calculation of library molar concentration. 
The pooled library was denatured into single stranded DNA using freshly 
prepared sodium hydroxide 0.2 M and left to stand at room temperature for five 
min. The denatured library was then diluted to 12.5 pM using HT1 buffer 
(Illumina). An internal control, Phi X (Illumina), was added to concentration of 
1%. This not only acts as an internal control but also helps to increase sample 
diversity which improves base-calling. The final concentration of the libraries is 
important as it determines the density of clustering on the sequencing flow cell 
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and can vary between machines. This concentration was optimised for the in-
house machine following installation. The diluted library was loaded on to the 
thawed MiSeq reagent cartridge which was placed on the MiSeq. The time taken 
to complete the run will depend on the number of cycles being carried out i.e. 
the length of reads generated. At the time of optimisation the longest available 
length of reads was 2 x 150 bases.  
2.3 Data Analysis 
The steps taken and tools used during data analysis are outlined below (Figure 
2-5). 
 
Figure 2-5. Graphical overview of steps taken and tools used during analysis of sequenced reads.  
2.3.1 Quality Trimming of Sequenced Reads 
During cDNA and library preparation primers and adapters were introduced into 
the DNA fragments to be sequenced. These artificial sequences have the 
potential to interfere with subsequent analyses and were therefore removed 
from the dataset. This was carried out using a combination of the command line 
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tools Trim Galore! (Lindgreen 2012) and PrinSeq (Schmieder and Edwards 2011). 
The read quality was visualised with FastQC (Andrews) before and after trimming 
and any dataset with an average quality score persistently below Q30 was 
deemed to have failed quality control and was not used in downstream analyses. 
Example outputs are shown in Figure 2-6. 
 
Figure 2-6. FastQC visualisation of Phred quality scores. 
The quality scores of sequenced reads visualised with FastQC before and after quality trimming. 
The red line is the median value and blue line the mean, the yellow boxes show the interquartile 
range (25-75%) and the whiskers represent the 10 and 90% points. 
2.3.2 De Novo Assembly 
Sequenced reads were assembled into longer contiguous sequences i.e. contigs 
as part of the MetAmos pipeline (Treangen, Koren et al. 2013). Multiple 
assemblers were used during this step, Velvet, IDBA-ud and SparseAssembler, 
with the default parameters. The contigs from the most effective assembly, as 
determined by the LAP score (log average probability), were used for 
downstream analysis. As part of this pipeline the assembled contigs were 
assigned taxonomy using a BLASTp search. The output of this process was saved 
to a text file as well a visual representation in a Krona chart, an example of 
which is shown below in Figure 2-7. 
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Figure 2-7. An example of a Krona output chart. 
Panel A shows an output chart where viral reads were detected within the sample and panel B 
shows an output with no viral reads. 
2.3.3 BLAST 
The Basic Local Alignment Search Tool (BLAST) algorithm was run on a local 
server against the NCBI nucleotide (nt) or non-redundant protein (nr) database 
which is updated on a monthly basis. For all searches the Expect value (E) was 
set at 0.001. The output was saved in a text file and inspected manually.  
2.3.4 Alignment of reads to reference database 
Both BWA and Bowtie2 v 2.2.5 (Li and Durbin 2010; Langmead and Salzberg 2012) 
aligners were used to map sequenced reads to reference genomes, generating 
sequence alignment / map (SAM) files. The commands and settings used for 
these programs are documented in Appendix 1.  
2.3.5 Manipulation of alignment files 
Mapped reads were removed or extracted from SAM files using commands within 
SamTools. SAM files were also transformed to their binary counterparts, BAM, to 
reduce the computational memory required in analysis. This was also carried out 
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using SamTools. The commands and settings used for these processes are 
documented in Appendix 1.   
2.3.6 Generating an alignment consensus 
A consensus sequence was generated from the alignment file using a custom Perl 
script (J. Hughes, unpublished). A subset of these consensus sequences were 
manually compared with a visual output of the SAM file using Tablet, to ensure 
accuracy.  
2.3.7 Phylogenetic analysis 
Sequences used in phylogenetic analyses were initially aligned in MEGA6 
(Tamura, Stecher et al. 2013) using Muscle. Neighbour-joining or maximum-
likelihood trees were inferred using MEGA6 with a model determined by the 
Bayesian Information Criterion (BIC) score. Where possible, a similar viral 
sequence was included as an outgroup though in some cases this was not possible 
as the most closely related virus introduced too many gaps to the alignment. The 
bootstrapping method was used with 100 replicates for maximum-likelihood and 
1000 for the neighbour joining method unless stated otherwise.  
2.3.8 Statistical Analyses 
All statistical analyses, unless stated, were carried out using GraphPad Prism 
Version 5.01 (GraphPad Software, Inc., California, USA) 
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3 Utilising Next Generation Sequencing as a diagnostic tool for 
viral respiratory tract infections 
3.1 Introduction 
Acute respiratory infections represent a significant cause of mortality and 
morbidity worldwide and are the commonest reason for primary care 
consultation in developed countries (Stanton, Francis et al. 2010). Viruses are 
the major contributing pathogens to infections of the human respiratory tract.  
The common pathogens associated with respiratory infections are outlined in 
chapter 1. In brief, rhinoviruses, coronaviruses and influenza are the main 
contributing viruses to human respiratory infections but it is worth noting that 
contributing viruses will vary with population demographics and time of year as 
many circulate with distinctive seasonal patterns (Nickbakhsh, Thorburn et al. 
2016). Please note that many other viruses can also cause respiratory symptoms 
as part of a further disease syndrome such as Epstein-Barr, measles and mumps 
viruses but these are not included in further discussion here as respiratory illness 
is not the main characteristic of infection. 
As outlined previously the diagnostic tests for viral respiratory illness have 
changed significantly over the last 20 years. Until relatively recently, diagnostic 
testing in this field relied on immunofluorescence studies or culture and 
isolation of virus. Such methods are technically challenging and in the case of 
culture, result in a long turn-around time of up to 30 days for some pathogens. 
This is of little benefit in the management of respiratory tract infections as the 
individual will either recover or succumb prior to test results being issued. There 
is also difficulty in detecting some viruses through isolation, for example, 
rhinoviruses will not grow easily in cell lines. Many diagnostic virology 
laboratories now employ molecular based assays such as PCR or RT-PCR, which 
are now considered the gold standard in this field. Molecular assays have 
increased test sensitivity and specificity over previous methods (Aguilar, Perez-
Brena et al. 2000; Ingram, Fenwick et al. 2006). Such tests can be developed 
quickly in reaction to the emergence of novel pathogens or strains. These tests 
can also be combined to test for multiple pathogens from a single specimen.    
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Respiratory virus testing is now a major part of most diagnostic virology 
laboratories’ workload. The current method used to detect respiratory 
pathogens at the WoSSVC, Glasgow is a multiplex real time PCR test. This panel 
of five assays contains multiple specific primer and probe sets and is designed to 
detect 15 common pathogens associated with respiratory infections. The use of 
multiplex assays reduces overall workload and cost by reducing the number of 
tests carried out and volume of consumables required (Edwards and Gibbs 1994). 
The use of a single workflow also reduces the hands-on time required and 
generates results from a single workflow rather than the staggered results which 
would have been seen using a combination of methods. The syndromic approach 
of testing is particularly useful in respiratory infections; although many 
pathogens circulate with a seasonal pattern there may also be outbreaks, 
epidemics and even pandemics outwith the expected season. This blanket 
approach to testing will ensure that unexpected pathogens are detected in a 
timely manner.   
Assay number 
1 2 3 4 5 
Influenza A 
Parainfluenza 1 
Human 
Metapneumovirus 
Parainfluenza 
2 
Parainfluenza 
3 
Parainfluenza 
4 
Adenovirus 
Respiratory 
Syncytial 
Virus-A 
Respiratory 
Syncytial 
Virus-B 
Influenza B 
Coronavirus 229E 
Coronavirus OC43 
Coronavirus NL63 
Rhino/Enterovirus 
Mycoplasma 
pneumoniae 
Bordetella 
pertussis 
Bordetella 
pertussis toxin 
Table 3-1. Pathogens detected by multiplex assays used in respiratory testing. 
As discussed in chapter 1 there are pitfalls of using such tests. Two important 
examples would be firstly, established viral pathogens can undergo genetic 
mutations by various mechanisms, be that genetic drift, shift or recombination. 
It is important to consider that this evolution may affect PCR primer and probe 
target regions resulting in reduced efficacy of an assay or even false negative 
results. Also, in order to detect a pathogen it must be actively sought. As a 
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result, new or unknown viral infections will not be detected unless a specific 
assay has been designed.  
The introduction of NGS in a research setting has been used in the discovery and 
characterisation of viral pathogens (Svraka, Rosario et al. 2010). We propose 
that this metagenomic approach (metagenomic referring to the study all genetic 
material within a specimen) could be used in the routine laboratory setting to 
detect respiratory pathogens in a single test/assay. The use of this technique 
would in theory, obviate the need for pre-test selection of a target pathogen. As 
all genetic material can be sequenced from a specimen in a single assay, this 
also raises the possibility of pan-microbial diagnostic test with the ability to 
detect viruses, bacteria and fungi from a single sample. The sequenced data 
generated could then be used for pathogen typing and subsequent 
epidemiological analyses. As a result these tasks could be carried out within the 
same test, something not currently achievable with the current real time PCR 
method.  
3.2 Aim 
The aim of this chapter was to compare the performance of NGS with that of 
real-time PCR using a panel of clinical respiratory samples. The performance 
points to be analysed included viral detection, quantitation and subsequent viral 
typing using sequence data generated by NGS. We compared the ability of the 
NGS pipeline to detect viral pathogens to RT-PCR. We also compared the number 
of sequenced viral reads with the RT-PCR Ct to determine if pathogen 
quantification would be possible. We then used the sequence information 
generated by NGS in the typing of detected viral pathogens.  
3.3 Methods 
3.3.1 Samples 
Nasopharyngeal swabs (NPS) were collected as part of a cohort study into the 
use of vitamin D supplementation as a prophylactic treatment of upper 
respiratory tract infections (Murdoch, Slow et al. 2012). Healthy adults, working 
in a university hospital were recruited and asked to report any episodes of upper 
respiratory tract illness. Upon reporting symptoms swabs were collected for 
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diagnosis. When nasopharyngeal swabs were obtained from symptomatic 
individuals they were placed in a liquid viral transport media (VTM) and any cells 
or material obtained by swabbing a patient was then transferred from the swab 
to the VTM. From this point on the media was treated as the sample and stored 
at -80ºC until testing. Eighty-nine samples from 686 episodes were randomly 
selected to be included in this study.  
3.3.2 Sample Preparation for Next Generation Sequencing 
The sample preparation process is described in detail in chapter 2. In brief, VTM 
(sample) was thawed in a water bath at 37ºC and centrifuged at 500 g for 10 min 
to pellet any mucous or debris. A 200 µl aliquot of the supernatant was retained 
and nucleic acids extracted using the MagJET Viral DNA and RNA Purification Kit 
for the Kingfisher™ Flex platform (Thermofisher). Reverse transcription was 
carried out with the enzyme Maxima H Minus (Life Technologies) in the presence 
of primer FR26-RV. Second strand cDNA synthesis was carried out using NEBNext 
mRNA Second Strand Synthesis Module (New England BioLabs) and amplified with 
Advantage® 2 PCR Kit (Clontech) and primer FR20RV. The double stranded cDNA 
was purified with Agencourt Ampure XP beads (Beckman Coulter) and quantified 
with the Qubit® dsDNA HS Assay (ThermoFisher Scientific).  
The cDNA was diluted to a concentration of 0.2 ng/µl and a 5 µl aliquot was used 
for sequencing library construction using the Nextera XT DNA Library Prep Kit 
(Illumina) as per the manufacturers’ instructions. The resulting sequencing 
libraries were quantified using real-time PCR (Kappa Library Quantification Kit) 
and the concentration corrected for size using the average fragment size as 
determine by capillary electrophoresis (High Sensitivity D1K Reagents, Tape 
station, Agilent). 
Multiple libraries were processed in each sequencing run therefore to ensure 
equal coverage of each the libraries were diluted to 4 nM and 5 µl of each 
diluted library pooled in a fresh tube. The pooled library was diluted and the 
internal control, PhiX, added at 1% before commencing the sequencing run. 
Sequencing was carried out on the MiSeq (Illumina) platform generating 150 bp 
paired-end reads.  
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3.3.3 Data Analysis 
Multiple steps were taken in the analysis of the generated sequences, which are 
described in detail in chapter 2. An overview of these steps and the tools used 
for each are presented in Figure 2-5. 
3.3.3.1 Quality Control Steps 
Primers, sequencing adapters and low quality reads were removed from the 
dataset using Trim Galore! and Prinseq (Schmieder and Edwards 2011). The 
quality trimmed reads were mapped against a database of human reference 
sequences containing the human genome, human cDNA and endogenous 
retroviruses using the alignment tool Bowtie2 (Langmead and Salzberg 2012) and 
mapped reads removed from the dataset. The aim of this step was to reduce the 
computational power required for subsequent analysis. These steps were carried 
out using a Perl script, thus reducing the amount of input required by the user.  
There is a possibility of cross-talk between adapters during the sequencing 
process. While the introduction of dual indexing has been shown to reduce the 
level of sample-to-sample contamination (Kircher, Sawyer et al. 2012) this can 
still occur in areas of high clustering on a flow cell. As it would not be possible 
to determine which sample these arose from any identical reads found in two or 
more samples were removed from the datasets.  
To identify identical viral reads within samples the sequenced reads were 
aligned a database of viral reference sequences using bowtie2. The resulting SAM 
alignment files were then converted to BED files using BEDTools (Quinlan and 
Hall 2010). The BED file was compared to all samples on the same sequencing 
run, also using BEDTools, to retain reads mapping to unique portions of the 
reference. 
3.3.3.2 Virus detection pipeline 
The remaining unique non-human reads were entered into the MetAmos pipeline 
(Treangen, Koren et al. 2013), using the Bowtie2 alignment tool, multiple de 
novo assembly programs and annotation carried out using BLAST against a 
protein database. The presence of viral contigs was determined through manual 
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inspection of the Krona output chart (see Figure 2-7 for an example chart). These 
contigs were then used in a BLAST search against a viral nucleotide database. 
The top hit from this search as defined by E value and percentage identity was 
then used as a reference against which to align non-human reads, in order to 
generate an alignment and consensus sequence.  
3.3.3.3 Real Time PCR Method and quantitation 
In order to compare the efficacy of an NGS approach to diagnostics with that of 
current practices a 40 µl of the same nucleic acid extract was screened for 
human rhinovirus (HRV), influenza A/B (IFA/IFB), respiratory syncytial virus 
(RSV), adenovirus (ADV), human metapneumovirus (hMPV), parainfluenzavirus 1-
4 (PIV 1-4), coronaviruses (HCoV) NL63, OC43 and 229E and Mycoplasma 
pneumonia using the routine diagnostic qRT-PCR at the West of Scotland 
Specialist Virology Centre (WoSSVC) as previously described (Gunson and Carman 
2011). 
The PCR results were compared with those of NGS, initially for virus 
identification.  To assess quantitation the PCR Ct values were compared with the 
proportion of sequenced reads generated which were of viral origin to determine 
if there is a relationship between virus quantity and sequenced reads. Statistical 
analyses were carried out using GraphPad Prism 5 software.  
3.4 Results 
3.4.1 Virus detection by RT-PCR 
To determine the efficacy of an NGS approach as a diagnostic tool, the same 
nucleic acid extract was subjected to both the current diagnostic RT-PCR test 
and the NGS method of viral detection. The results of this diagnostic screen 
could then be used as a standard from which the performance of a sequence 
independent NGS approach could be calculated.  
Within the cohort, 48/89 samples tested positive for a virus by RT-PCR. One 
sample (1G1) was positive for two viruses, adenovirus and rhino/enterovirus 
therefore there were 49 viral detections in total. The viruses detected by RT-
PCR were as follows: HRV 24/49, RSV 5/49, HCoV 229E 9/49, HCoV NL63 3/49, 
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HCoV OC43 3/49, hMPV 3/49, PIV-3 2/49, PIV-2 1/49, IFA 1/49 and AdV 1/49. The 
Ct of the detected viruses ranged from 14.63 to 36.07. 
3.4.2 Virus detection by NGS 
During optimisation of the protocol the nucleic acid concentration following 
extraction was found to be too low to quantify in most samples therefore the 
concentration was not routinely measured after extraction. cDNA was quantified 
after SISPA PCR and bead purification of the PCR product. The cDNA 
concentrations of the prepared samples are listed in Table 3-2. The 
concentration was then corrected to 0.2 ng/µl for subsequent library 
preparation.   
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Run 1 Run 2 Run 3 Run 4 
Sample Conc. 
ng/µl 
Sample Conc. 
ng/µl 
Sample Conc. 
ng/µl 
Sample Conc. 
ng/µl 
2A1 20.7 1E6 0.530 1C1 3.64 1B1 36.5 
2A2 26.9 1E7 2.23 1C2 10.6 1B2 28.8 
2A3 36.0 1E8 8.05 1C3 13.7 1B3 23.5 
2A4 28.8 1E9 0.985 1C4 29.2 1B4 31.2 
2A5 28.6 1F1 1.29 1C6 20.7 1B5 35.0 
2A6 38.8 1F2 0.802 1C7 16.7 1B6 36.8 
2A7 29.5 1F3 1.18 1C8 25.8 1B7 29.0 
2A8 28.2 1F5 1.41 1C9 11.8 1B8 28.0 
2A9 26.9 1F7 1.25 1D1 24.1 1B9 34.6 
2B1 37.0 1F8 3.13 1D2 11.1 1D7 28.0 
2B2 28.4 1G1 0.858 1D3 33.6 1D8 32.9 
2B3 25.1 1G2 1.14 1D4 37.5 1D9 45.5 
2B4 28.9 1G3 1.88 1D5 15.5 1E1 31.6 
2B5 32.1 1G5 6.84 1D6 9.21 1E2 25.7 
2B6 31.7 1G6 1.02 1I2 25.7 1E3 47.2 
2B7 24.88 1G7 2.47 1I3 13.0 1E4 37.5 
2B8 27.4 1H1 19.6 1I4 20.4 1E5 36.4 
2B9 24.9 1H3 1.50 1I5 20.5 2D1 38.9 
2C1 26.4 1H4 1.53 1I6 24.1 2D2 27.2 
2C2 29.1 1H5 4.14 1I7 22.7 2D3 47.0 
2C3 22.7 1H6 1.35 1I8 17.9 2D4 40.4 
2C4 27.5 1H7 4.98 1I9 1.16 2D5 30.9 
2C6 23.3   1H8 1.55 2D6 39.3 
Table 3-2. Concentration of sample cDNA after RT, second strand synthesis and PCR clean up. 
3.4.2.1 Sequenced Reads 
Samples were processed in four runs of the Illumina MiSeq. The number of raw 
sequenced reads generated from each sample ranged from 206,898 – 2,235,798 
(mean = 1,116,238) and after quality trimming 46,072 – 1278122 (mean = 
661,799). Following mapping against the set of human reference sequences 5004 
– 836868 (mean = 125,316) reads remained unmapped. The proportion of reads 
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removed by quality trimming and filtering per sample are detailed in Figure 3-1 
with 15-60% of the total reads mapping to human reference sequences and over 
90% of the raw reads being removed in the majority of samples.  
One sample, 1E6, was removed from further analysis as the average read quality 
remained below Phred 20 following the quality control steps. As this correlates 
with an error rate of between 1 in 10 and 1 in 100 these reads could not be 
reliably assessed.  
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Figure 3-1. The distribution of sequenced reads.  
The top panel shows the number of reads removed by quality trimming (blue), mapping to a human reference (red) and the remaining unmapped reads (green) which were 
entered into the MetAmos data analysis pipeline. The bottom panel shows the read distribution as a proportion of the total.  
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3.4.2.2 Multiple common respiratory viruses were detected by 
NGS 
Using the virus detection pipeline, viral pathogens were detected in 38 of 89 
clinical specimens. Picornaviruses were detected at the highest frequency and 
throughout the study period, with 21 detections. The next most frequently 
detected viral group was the coronaviridae. Nine samples were found to contain 
coronaviruses of the following types: HCoV 229E (4/9), HCoV NL63 (3/9) and 
HCoV OC43 (2/9). Paramyxoviruses were detected in seven samples, RSV (3/7), 
hMPV (2/7) and HPIV3 (2/7). One orthomyxovirus was detected and the 
consensus sequence identified as influenza A H3N2. All detections by NGS were 
also detected by RT-PCR. There were 49 viral detections by RT-PCR, 11 of these 
were not identified by NGS.   
Using the quality trimmed and filtered reads it was possible to reconstitute 
partial or full genome consensus sequences from reference based alignments. 
The alignments showed between 1 and 10.8% nucleotide difference from the 
closest available reference sequences and in all but one case included a protein 
coding region. From this level of similarity the viral species could be inferred. 
The BLAST results with the accession number for the relevant BLAST hits and 
summary of subsequent reference alignments are shown in Appendix 2. 
Respiratory Specimens: Summary of Results. This information will be referred to 
throughout this section. Each virus group will be discussed individually below.     
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3.4.2.3 Rhinovirus 
Multiple different rhinovirus species were detected: A (11/21), B (4/21) and C 
(5/21) as well as enterovirus D (1/21). The Ct of the viruses detected by RT-PCR 
ranged from 17.24 to 33.66. 
 
Figure 3-2. Sequencing coverage of the rhinovirus genome.  
Alignments were visualised using Tablet.  
A representation of the rhinovirus genome with the sequencing coverage of each clinical sample 
shown below, demonstrating the breadth and depth of coverage generated by NGS.  
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In general the coverage obtained of rhinoviruses was broad, with an average 
68.3% reference genome coverage (range of 2.6 – 100%). The aligned reads 
showed a low level of nucleotide mismatch, an average of 4.3%, to the closest 
reference sequence as determined by BLAST (range of 1.2 – 10.8%). Sequence 
information was obtained from protein coding regions of the genome in all cases 
with the exception of 1I6 where only UTR sequence was generated. From this 
coverage of protein coding regions and the high level of nucleotide similarity to 
the reference in the remaining 20 cases, this information was then used to infer 
viral species. From this we identified the serotypes found in Table 3-3.  
HRV A - 
Serotype 
Number HRV B - 
Serotype 
Number HRV C - 
Serotype 
Number Enterovirus Number 
A1 4 B27 1 C11 1 D68 1 
A21 1 B3 1 C15 2   
A49 1 B4 1 C17 1   
A60 1 B92 1 Untyped 1   
A8 1       
A90 1       
A97 1       
 Table 3-3. Rhinovirus and Enterovirus serotypes identified in clinical specimens.  
 NGS failed to detect virus in three samples which were RT-PCR positive, 1F7, 1B7 and 2B9. The 
Ct in these samples was 28.03, 28.94 and 33.31 respectively.  
3.4.2.4 Respiratory Syncytial Virus 
hRSV was detected in three clinical samples, 1E3, 1F1 and 2B4. These samples 
had a RT-PCR Ct of 20.84, 25.08 and 19.32 respectively. 
 
Figure 3-3. Sequencing coverage of the respiratory syncytial virus genome.  
Alignments were visualised using Tablet. 
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Following assembly to the top BLAST hit, coverage was obtained for between 
54.6 and 99.3% of a reference genome with a low level of nucleotide mismatch 
to the reference, 0.5 to 2%. The genome coverage is shown in Figure 3-3, shows 
at least partial G protein coverage in all cases and low level coverage of the F 
protein coding region. As both these regions have been used in the molecular 
typing of hRSV the top BLAST was used to infer type. Samples 1E3 and 1F1 were 
typed as hRSV-A and 2B4 was hRSV-B.  
NGS failed to detect hRV in two cases which were RT-PCR positive, 1E5 and 2B6 
with Cts of 30.01 and 33.96 respectively.  
3.4.2.5 Human Metapneumovirus 
Two cases of hMPV were identified with NGS in sample 1G6 and 2A9. These 
samples had Cts of 26.84 and 25.68 respectively. Genome coverage was 
generated against 18.5 and 48.4% of the reference with a low level of nucleotide 
mismatch, 2.0 and 3.1%. As shown in Figure 3-4, the reference coverage in these 
cases was not complete but partial coverage of the G protein coding region was 
obtained from both specimens. As this protein has been used in the molecular 
typing of hMPV the types for both specimens were inferred from the BLAST hit as 
type B.    
 
Figure 3-4. Sequencing coverage of the human metapneumovirus genome.  
Alignments were visualised using Tablet. 
3.4.2.6 Parainfluenza Viruses 
Parainfluenza viruses were detected in two clinical cases, 1B5 and 1G2. The 
alignments generated reference coverage of 5.0 and 2.8% only. The Cts of these 
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specimens were 25.57 and 28.09 respectively. The top BLAST for these specimens 
were both PIV-3 which were consistent with the RT-PCR results. 
NGS failed to detect one specimen which was RT-PCR positive for PIV-2, 
specimen 2D4, with a Ct of 36.07. 
 
Figure 3-5. Sequencing coverage of the parainfluenza 3 genome.  
Alignments were visualised using Tablet. 
3.4.2.7 Coronaviruses 
Using an NGS approach, three different species of coronaviruses were detected 
in this cohort, OC43, 229E and NL63. 
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Figure 3-6. Sequencing coverage of the coronavirus genomes.  
Alignments were visualised using Tablet. 
3.4.2.7.1 Coronavirus OC43 
Two cases of HCoV-OC43 were identified in this cohort by NGS, in sample 1H1 
and 2D5, generating near full reference genome coverage at 99.9 and 97.6% 
respectively. The RT-PCR Ct for these samples was 14.63 and 17.21. The 
consensus sequences generated showed low levels of nucleotide mismatch at 0.7 
and 1.6% respectively (accessions KF530099 and JN129835). 
One RT-PCR positive case of HCoV OC43 was not detected by NGS. The Ct for this 
specimen was 24.05. 
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3.4.2.7.2 Coronavirus 229E 
Four cases of HCoV-229E were identified in this cohort by NGS, in sample 2A3, 
2A4, 2C3 and 2D2, generating reference genome coverage of 99.8, 55.3, 20.0 
and 73.9% respectively. The RT-PCR Cts for these specimens were 18.14, 20.00, 
25.83 and 19.74. The lowest genome coverage was in sample 2C3, the sample 
with the highest Ct value by PCR, implying a lower viral load in the initial 
clinical sample. Even though there was a low breadth of reference coverage in 
some cases there remained a high level of similarity to the closest reference 
sequence with nucleotide mismatch at 0.6 – 0.7% (accession JX503060).  
3.4.2.7.3 Coronavirus NL63 
Three cases of HCoV-NL63 were detected by NGS in this cohort, in sample 1D3, 
1E7 and 1F8, generating reference genome coverage of 11.7, 23.3 and 3.7% 
respectively. The RT-PCR Cts for these specimens were 27.17, 24.36 and 25.22. 
In these cases the genome coverage was sporadic but the areas with coverage 
showed a high level of nucleotide similarity to the closest reference, with 
nucleotide mismatch rates of 0.4 – 0.5% (accessions KF530112 and JQ765569).  
3.4.3 Orthomyxoviridae 
 
Figure 3-7. Sequencing coverage of the detected segments of the influenza genome.  
Alignments were visualised using Tablet. 
Influenza A was detected in a single specimen. The RT-PCR Ct of this specimen 
was 22.34. Assembled contigs returned BLAST hits to five of the eight viral RNA 
segments (PB2, PB1, HA, NP and NA) arising from H3N2 subtype references. 
Following reference assembly only partial reference coverage was obtained at 
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low coverage, therefore the amino acid mutations associated with drug 
resistance or high pathogenicity could not analysed.  
3.5  NGS reads detected in PCR negative specimens 
As a further quality control step, where specimens were found to have NGS reads 
mapping to viral sequence but were negative by RT-PCR, the reads were 
compared to all other PCR positive samples on the same sequencing run. When 
reads mapped to identical sequence positions in a RT-PCR positive sample these 
reads were then removed as probable contaminants. The table below shows the 
number of remaining mapping reads following this step.  
 
Sample Total reads 
(after quality trimming) 
HRV RSV PF 
1B3 41390 0   
1B4 32376 0  0 
1B5 343780 0   
1B6 68520 3   
1C1 341430 1   
1C8 128244 0   
1C9 441800 0   
1D3 26720 0   
1D6 265146 3   
1E1 289930  0  
1E3 43508 1   
1E4 13896 2   
1E5 22364 1   
1E9 15958 10   
1F8 43578 1   
1G7 27822 0   
2A1 26476 3 3  
2A3 130726 3   
2B5 232046  0  
2B9 135998  0  
2D1 25336 1   
Table 3-4. The number of unique mapping reads in PCR negative samples following duplicate 
removal.  
In these cases the proportion of viral reads in RT-PCR negative specimens 
following duplicate removal ranged from less than 0.01 to 0.06%. These 
specimens were deemed negative by NGS. 
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3.6 Comparison of NGS with RT-PCR 
3.6.1 Diagnostic Test Evaluation – sensitivity and specificity 
A total of 13 viral pathogens were tested by RT-PCR in 89 samples, equating to 
1157 tests in total. To compare the efficacy of NGS as a diagnostic test with that 
of PCR sensitivity and specificity were evaluated. A true positive was defined as 
corresponding virus detection by NGS and PCR. A true negative was defined as no 
virus detection by NGS or PCR. A false negative was defined as lack of virus 
detection by NGS where the sample was found to be PCR positive and a false 
positive was taken as detection of viral reads by NGS where the sample was PCR 
negative.   
True positive (a) 38 False positive (c) 12 
False negative (b) 11 True negative (d) 1098 
 
The sensitivity of a test can be defined as the probability that a test will be 
positive when the disease is present i.e. the true positive rate: 
True positives  =     a     =    38  =           77.6% 
True positives + False negatives      a + b    38 + 11    (95% CI 63.4 to 
88.2) 
The specificity of a test can be defined as the probability that the test will be 
negative in the absence if disease i.e. the true negative rate: 
True negatives  =     d     =    1098  =   98.9% 
True negatives + False positives     d + c     1098 + 12    (95% CI 98.1 – 
99.4) 
Statistical analyses were performed using MedCalc for Windows, version 12 
(MedCalc Software, Ostend, Belgium). 
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The number of tests carried out here would be too small to prove the efficacy of 
NGS as a diagnostic test but these calculations, even with the small numbers 
suggest that there is potential that the efficacy of NGS could be competitive 
with PCR.  
3.6.2 Quantitation of Target with NGS 
The number of PCR cycles required to enable target detection above a threshold 
relates to the initial target quantity within the sample. This allows an estimate 
of quantitation however without standardised samples run in parallel 
quantitation cannot be absolute. The threshold cycle value (Ct) of respiratory 
samples positive by RT-PCR which were either concordant or discordant with the 
NGS assay results are shown in Figure 3-8. The bars indicate the mean and one 
standard deviation. An unpaired t-test demonstrates a significant difference 
between the two groups (p<0.0001) suggesting a relationship between viral 
quantity and likelihood of detection with NGS. 
The mean Ct of the discordant specimens was ~ 32, suggesting this could be a 
test sensitivity cut off.  
  
 
Figure 3-8. Ct value of PCR positive samples that were concordant or discordant with NGS 
diagnosis. 
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As the absolute number of sequenced reads varied between samples the overall 
proportion of reads mapping to a viral reference sequence was compared with 
the Ct value to determine if a similar semi-quantitative approach could be used 
in NGS (Figure 3-9).   
 
Figure 3-9. The proportion of sequenced reads mapping to viral reference. 
The percentage of sequenced reads, after quality trimming, mapping to the taxonomic reference 
genome determined by BLAST. Linear regression of complete dataset, R
2
 value = 0.21 (p = 
0.0009). Linear regression of virus groups, Picornaviruses: R
2
 = 0.37 (p = 0.0015), Coronaviruses: 
R
2
 = 0.34 (p = 0.0471), Paramyxoviruses: R
2
 = 0.40 (p = 0.0359).  
 
The number of detections for each virus group was too small to prove any 
definitive correlation but the R2 value following linear regression suggests there 
is a relationship between the proportion of reads mapping and the Ct value but 
this relationship varies between virus groups. As a consequence the lower limit 
of detection is also likely to vary between virus groups.  
3.6.3 Detection of viral co-infection  
The detection of viral co-infection using NGS could not be assessed in this 
cohort. A viral co-infection was identified by RT-PCR in a single sample (1G1). 
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HRV and AdV were detected in this sample with Ct values of 28.5 and 35.1 
respectively. The AdV was not detected by NGS in this case however it could not 
be determined if this was due to sample processing methods or due to the low 
viral load as previous analysis suggested detection cut off in the region of Ct 32. 
The DNAse step early in sample preparation may preclude detection of viral 
genomic DNA; however the detection of mRNA using RT-PCR has been 
demonstrated previously (Ko, Cromeans et al. 2003) therefore it was hoped that 
the presence of a DNA virus could still be detected with this method.      
3.7 Discussion 
In this research sequence independent PCR with NGS was carried out with the 
aim being to determine if this method could be used to detect viral pathogens in 
clinical samples. The results from this method were compared with the current 
diagnostic method of RT-PCR to establish if it would be possible to use this as an 
alternative diagnostic test.  
Viruses were detected with a high rate of concordance between the two 
methods (77.6%). Multiple different viruses were detected using a single NGS 
workflow with a sequence independent approach, in contrast with PCR which 
relies on targeting specific nucleotide sequences, and therefore requires 
numerous primer/probe sets to detect a panel of pathogens predetermined by 
the user.  
The virus quantity within clinical samples, as determined by using the PCR Ct 
value as a proxy, correlated with both the likelihood of detection and the 
proportion of NGS sequenced reads mapping to the virus. A linear regression 
model of the small number of viral detections in this study shows there is a 
relationship between the proportion of sequenced reads of viral origin and the 
RT-PCR Ct. These data would suggest a lower level of detection with a cut off 
equivalent to a Ct of 32. This suggests the possibility of using NGS for 
quantitation as well as detection. In general quantitation of respiratory 
pathogens is not required in diagnostics yet in certain cases this can be valuable, 
such as monitoring response to therapy in adenovirus or influenza infections, 
particularly in those who are immunocompromised. Quantitation may also be 
important when considering the use of NGS in detecting bacterial pathogens 
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which are known to be part of the commensal microbiotia but presence at a high 
level may indicate pathogenic overgrowth. 
The detection of viral pathogens by PCR relies on targeting conserved portions of 
the viral genome and as a result, in most cases, can only identify the virus to 
species level. Using a NGS approach, in some instances full genome sequences 
were obtained and in many cases protein coding regions were sequenced, aiding 
in molecular genotyping of the viral pathogen where appropriate. The value of 
this information in a diagnostic laboratory is not clear as the clinical impact of 
specific subtypes has not been proven.  
In comparison with RT-PCR the sensitivity of NGS was lower, detecting fewer 
positive results from clinical samples. The detection of co-infections could not 
be analysed in this cohort of samples as only one sample contained greater than 
one virus by PCR.  
The method used here enriched for RNA and would likely preclude the detection 
of DNA viruses. While the majority of known viral respiratory pathogens are RNA 
viruses there are DNA viruses which are established or proposed pathogens of the 
human respiratory tract such as adenoviruses and human bocaviruses. This has 
further implications when proposing to use this technique as a pan-microbial 
diagnostic test as bacterial and fungal pathogens possess a DNA genome. It is 
possible that RNA transcripts could be detected but adapting the methodology 
for the detection of DNA as well as RNA would be essential.  
3.7.1 Future work 
A major barrier to using this technique with the method outlined above is the 
sensitivity in comparison to RT-PCR. Many approaches could be applied to 
increase sensitivity and these require being trialled to determine what would be 
effective with clinical samples in a diagnostic setting. The introduction of 
further processing steps will increase both time and cost associated with sample 
processing but if this allows higher sample throughput it could offset the 
increased cost.   
Alterations or additional steps would also be required to permit detection of DNA 
and RNA, ensuring a true representation of the known respiratory viral 
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pathogens. The ability to sequence both RNA and DNA in a single workflow would 
then make the prospect of pan-microbial diagnostic test a real possibility. 
Analysis of samples containing more than one pathogen would be required to 
determine if there are further factors which may affect the likelihood of 
pathogen detection. It is probable that the presence of one pathogen at high 
levels may affect the lower limit of detection of further pathogens.   
The established method of RT-PCR can generate results in a matter of hours. The 
speed of the NGS process would need to be improved before being implemented 
as a diagnostic test. When undertaken manually many of the steps, in particular 
clean-up processes are time-consuming. If undertaken in a diagnostic laboratory 
it is likely that automation could be applied, reducing manual intervention and 
streamlining the process.  
The initial data analysis steps in this research were undertaken as part of a 
pipeline but the more in-depth analysis required user input. Much of this work 
could be implemented into a complete purpose-built diagnostic pipeline. A lot of 
information can be generated in this process, not all of which is useful to a 
diagnostician or clinician; in fact the output of processes such as BLAST could 
potentially be confusing for those without prior training in the area. Generation 
of an analysis pipeline which takes into account the salient information required 
for diagnostic purposes would ultimately be needed for the end users. In-depth 
analysis of viral subtypes could then be undertaken at a later stage as this is 
unlikely to have an impact on the patient in real time but is useful for 
epidemiological purposes.   
The cost of NGS is decreasing but remains considerably higher than that of PCR. 
Increasing throughput, optimising protocols and reagents will contribute to 
reducing the cost of the process. The potential for pan-microbial detection from 
a single sample would greatly increase the cost effectiveness of NGS in a 
diagnostic setting and a single workflow could potentially combine the multiple 
processes which are currently required to detect viruses, bacteria and where 
appropriate, fungi, from clinical specimens.  
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4 The Use of an NGS pipeline for the Epidemiological Study of a 
Respiratory Pathogen 
4.1 Introduction 
The research presented in chapter 3 demonstrates that an NGS approach can be 
used to detect multiple viral pathogens from clinical respiratory samples using a 
single sample workflow without a priori selection of a target. The detection rate 
using this method was found to be similar to RT-PCR, the current gold standard 
diagnostic test. There was also evidence that the proportion of sequenced reads 
mapping to viral reference correlated with the RT-PCR Ct value. Although the 
number of specimens in the panel was too small to prove a definitive link this 
suggests that the NGS method may also be able provide semi quantitative data. 
The results outlined in chapter 3 also showed that the sequence data provided 
by the NGS method could be used for typing the detected virus and therefore 
may also be useful for epidemiological analysis. Unfortunately the panel tested 
in Chapter 3 was not large enough to determine the utility of the NGS method in 
this context. 
This chapter describes the results of using the NGS method to study the 
epidemiology of Enterovirus 68 – a re-emerging pathogen – in the West of 
Scotland.  Human enterovirus 68 (EV-D68) belongs to the genus Enterovirus and 
family Picornaviridae and possesses a positive sense single-stranded RNA genome 
approximately 7500 bases in length (Jacobs, Lamson et al. 2013). There are 
seven species of enterovirus known to cause infections in humans, enterovirus A, 
B, C and D and rhinovirus A, B and C. Within the group D enteroviruses there are 
four recognised serotypes, D68, D70, D94 and D111 which infect humans and a 
fifth, D120, associated with infection of gorillas (Holm-Hansen, Midgley et al. 
2016). EV-D68 was first isolated in the 1960s in the United States from children 
with acute respiratory tract illness (Schieble, Fox et al. 1967). From then on only 
a small number of cases were reported annually. From 2000 onwards there has 
been a marked increase in the number of reported cases, now documented in 
several countries such as Germany, Japan and Mexico (Kaida, Kubo et al. 2011; 
Ly, Tokarz et al. 2014; Bottcher, Prifert et al. 2016; Vazquez-Perez, Ramirez-
Gonzalez et al. 2016).  
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The clinical symptoms associated with EV-D68 were thought to range from 
asymptomatic to a mild respiratory illness. However, the recent outbreaks have 
highlighted a potential to cause more severe infections (Messacar, Schreiner et 
al. 2015). For example, during 2014 a large multistate EV-D68 outbreak occurred 
in the US, which resulted in a large number of severe lower respiratory 
infections in children and a possible association with acute flaccid paralysis.  
During 2015 a pan-European study was carried out to examine the prevalence, 
clinical presentation and epidemiology of EV-D68 in European countries. The 
WoSSVC in Glasgow took part in this study. Between 1st July 2014 and 1st 
December 2014 all respiratory samples from children under 16 years of age 
found to be rhino/enterovirus positive by RT-PCR were screened for EV-D68 with 
a type specific PCR (Poelman, Scholvinck et al. 2015). During this time all 
enterovirus positive (by PCR) CSF samples were also screened for EV-D68. Sanger 
sequencing of the enterovirus VP1 segment was then carried out by the WoSSVC 
to subtype any positive samples.  
In total EV-D68 was detected in 22 of the 488 respiratory samples (4.51%) 
screened. Interestingly nine samples also contained other viral respiratory 
pathogens. This level of EV-D68 prevalence is in line with those reported in other 
European studies (Poelman, Schuffenecker et al. 2015). The clinical details 
associated with these samples are outlined in appendix 3. EV-D68 was not 
detected in any CSF samples. This is in keeping with results from previous 
studies which did not demonstrate the presence of the virus in CSF, even in those 
with neurological symptoms (Greninger, Naccache et al. 2015).  
The positive samples from the aforementioned work were then sequenced by the 
NGS method in order to provide a direct comparison. 
4.2 Aim 
The aim of this chapter was to examine the utility of the NGS pipeline (chapter 
3) within an epidemiological context. EV-D68 positive samples from the work 
described above were then sequenced by the NGS method. We evaluated 
whether the NGS pipeline could correctly detect and type enterovirus positive 
samples. This panel also provided a further opportunity to assess whether the 
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NGS pipeline could detect additional respiratory pathogens from a clinical 
specimen. Finally we compared the sequence data generated by the NGS 
pipeline to that provided by the Sanger method. The results are presented and 
discussed below. 
4.3 Methods 
4.3.1 Samples 
The clinical details associated with the samples are presented in Appendix 3. 
Nucleic acids were extracted from clinical samples using the EasyMag platform 
(BioMeriaeux) at WoSSVC and stored at -20°C until tested.  
4.3.2 Real Time PCR 
An EV-D68 specific RT-PCR was carried out using the primers, probes and 
parameters as described previously (Poelman, Scholvinck et al. 2015). This 
reaction utilises highly specific primers targeting the 5’-NTR of the EV-D68. This 
was carried out at WoSSVC.  
4.3.3 Sanger Sequencing 
A nested PCR approach was used to amplify and sequence a 316 bp segment of 
the VP1 coding region as described by Nix et al (Nix, Oberste et al. 2006). In 
samples where an appropriately sized amplicon was identified, Sanger 
sequencing was then carried out at WoSSVC. 
4.3.4 Sample Preparation for Next Generation Sequencing 
The methods used are described in detail in chapter 2. Briefly, the frozen 
extract was thawed in a water bath at 37°C and 10 µl was used as the template 
in a reverse transcription reaction. Second strand synthesis was carried out, 
followed by a SISPA step. The resulting DNA was clarified using AMPure XP and 1 
ng of DNA used to prepare sequencing libraries (Nextera XT DNA Sample Prep kit, 
Illumina). Sample libraries were indexed and multiplexed using the Illumina 
Nextera indices and sequenced using an Illumina MiSeq to generate 150 base 
paired-end reads. 
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4.3.5 Data Analysis 
4.3.5.1 Quality Trimming 
Indices and primers were removed from sequenced reads using Trim Galore!. 
Reads with an average Phred quality score greater than 30 and length greater 
than 30 bp were retained and aligned to a database of human reference 
sequences (Bowtie2 (Langmead and Salzberg 2012)). The reads which did not 
map to the human references were extracted from the dataset using SamTools 
and used for further analysis.  
4.3.5.2 Reference Based Detection and Consensus Generation 
 All EV-D68 full genome sequences freely available at the time of research 
(16/6/2015) were obtained and used as a database for a reference based 
assembly. The accession numbers of sequences used can be found in appendix 4. 
Sequenced reads remaining following quality trimming and alignment to human 
reference sequences were mapped to this database. The reference sequence 
with the greatest number of reads mapping was then used as a template for a 
reference based assembly against that sequence only. Multiple alignment tools 
were used for each sample to generate alignments (SAM files) and the alignment 
with the greatest reference coverage was used to generate a consensus 
sequence using a PERL script developed at the CVR (J. Hughes, unpublished). 
After choosing a virus reference sequence, all reads were then realigned to this 
single reference increasing both the number of reads mapping and the breadth 
of reference coverage. 
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Figure 4-1. Workflow of reference based virus detection and consensus sequence generation. 
4.3.5.3 Virus Detection Pipeline 
Sequenced reads which did not map to a human reference were entered into the 
virus detection pipeline MetAmos (Treangen, Koren et al. 2013), using the 
Bowtie2 alignment tool, multiple de novo assembly programs (IDBA-UD, 
SparseAssembler and Velvet) and annotation carried out using BLAST. The 
presence of viral contigs was determined through visual inspection of the Krona 
output chart (see appendix 6 for charts). 
4.3.6 Phylogenetic Analysis 
Nucleotide sequences were aligned using MUSCLE as part of MEGA6 (Tamura, 
Stecher et al. 2013). Phylogenetic analyses were also carried out using MEGA6. 
Neighbour-joining and maximum likelihood trees were generated using the 
bootstrap test of reliability with 1000 bootstrap replicates. Trees were inferred 
using the best fit model as determined by the Bayesian Information Criterion 
score. 
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4.3.7 Recombination Detection 
An alignment of all available complete genome sequences and the consensus 
sequences with greater than 80% coverage was generated in MEGA6. This 
alignment was then used in recombination detection using RDP4 (Darren P. 
Martin 2015).  
4.3.8 Comparison of Sanger Sequencing and NGS 
For specimens with both Sanger and NGS sequences available, these were 
aligned with each other using MEGA6. A pairwise comparison of nucleotides was 
calculated using CLC Genomics Workbench 6. The nucleotide alignments were 
then translated to amino acid sequences to assess for non-synonymous amino 
acids differences between the two methods. Phylogenetic trees were then 
inferred using the sequences from each method to determine if these 
differences resulted in a change of topology (MEGA6).  
4.4 Results 
4.4.1 Virus Detection and Identification 
The metagenomics pipeline identified enterovirus contigs from the majority of 
clinical specimens tested, 19 of 22. The Cts from the clinical specimens where 
enterovirus contigs were not detected were 29.75, 32.76 and 32.82. A 
comparison of the Cts between specimens with concordant and discordant 
results by RT-PCR and NGS are shown in Figure 4-2. The number of reads mapped 
and breadth of reference coverage for each sample is detailed in Appendix 5. 
The top hit reference sequences determined by a BLAST search against a 
nucleotide database were the same in numerous cases, which would suggest 
similar viruses in these individuals. The reference with accession KP745768 was 
identified in 11 cases and KP745769 in eight cases. Of interest, from the 
remaining three where enterovirus contigs were not detected by the pipeline, 
enterovirus reads were identified by direct alignment to reference sequences.  
However the numbers were too small (e.g. 5. 35 and 51) to be considered 
relevant and were not studied further. 
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Figure 4-2. Ct value of EV-D68 RT-PCR positive specimens that were concordant or discordant 
with NGS diagnosis. 
The EV-D68 RT-PCR positive specimens where viral contigs were not detected by NGS have a 
higher Ct with a significant difference between the two groups (P = 0.027). These data would 
suggest a sensitivity cut-off of Ct = 32. 
 
The RT-PCR Ct related to the likelihood of detection of viral contigs by NGS. The 
specimens with concordant results by both methods had lower Cts, therefore a 
higher viral load. In specimens with discordant results i.e. no viral contigs 
detected by NGS the mean Ct was 31.78 which could be considered the lower 
limit of detection.  
As mentioned above, the samples used in this study had initially been subjected 
to the full diagnostic panel for respiratory viruses. In 9 of the 22 an additional 
viral pathogen was detected by RT-PCR. The additional viruses detected are 
shown in Table 4-1 and include adenovirus, HHV-6, hMPV, PIV-4 and RSV. The NGS 
method failed to detect the DNA viruses AdV and HHV-6 with Cts of 22.34, 35.51 
and 35.89. NGS also failed to detect some RNA viruses including one hMPV (Ct 
37.73) and three HPIV4 detections (Cts of 26.08 – 34.53). In specimen 429519, 
EV-D68 was not detected by NGS though RSV-A was detected with greater than 
97% reference genome coverage. EV-D68 and RSV-A were both detected in two 
cases, 430139 and 429319. 
Interestingly, additional non EV-68D enterovirus reads were detected in a further 
four samples. In three of these, reads mapping to coding regions which are 
unique to the serotype were obtained. This suggested concurrent infection with 
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multiple enterovirus species, HRV-A80, HRV-C40 and HRV-C species. In one 
sample reads mapping to multiple 5’ UTR sequence of HRV-B were detected but 
as this region of the viral genome is conserved between serotypes it does not 
confirm the presence of an additional virus. 
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Sample EV-D68 
Ct 
Additional  
Virus by RT-
PCR 
Ct NGS EV-D68 
detected 
Virus 
detection 
pipeline 
Accession Coverage 
428891 21.92 Adenovirus 22.34 +    
429110 32.76 HHV-6 35.89 -    
430146 21.26 hMPV 37.73 +    
430741 20.24 HPIV4 26.08 +    
430038 24.96 HPIV4 33.54 +    
428005 20.94 HPIV4 
Adenovirus 
31.38 
35.51 
+    
429159 32.82 RSV 18.27 - RSV-A 
Parecho-3 
JF920053 97.85% 
430139 30.58 RSV 18.36 + RSV-A JF920053 99.98% 
429319 25.50 RSV 
HPIV4 
26.41 
34.53 
+ RSV-A JF920052 16.93% 
429323 16.25   + HRV-B Multiple 5’ 
UTR 
 
429660 28.1   + HRV-C JN815251 100% 
430038 24.96   + HRV-A FJ445156 4.62% 
429915 28.07   + HRV-C HM236934 Partial 
(VP1) 
Table 4-1. Detection of additional viruses in EV-D68 positive samples.  
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Figure 4-3. The correlation of Ct value with sequenced reads and reference genome coverage. 
The top panel shows the correlation of Ct value and the proportion of sequenced reads mapping to 
a viral reference. Linear regression, R
2 
= 0.60 (p <0.0001). The bottom panel shows the correlation 
of Ct value and the percentage of reference genome coverage obtained. Linear regression R
2 
= 
0.45 (p = 0.0006).   
 
The relationships of the EV-D68 RT-PCR Ct with the proportion of mapped reads 
to EV-68D and reference coverage are shown in Figure 4-3. This demonstrates 
that in clinical samples with a low Ct i.e. a high viral load, a large proportion 
reads are of viral origin however this proportion decreases with a rise in Ct. 
Linear regression of this relationship shows an R2 of 0.60 suggesting a 
relationship between these values.  A similar trend is seen with the breadth of 
reference coverage.  For example, in sample 429323 with a Ct of 16.25 100% 
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coverage of the reference genome was obtained, however in sample 428008 with 
a Ct of 28.79 this was 68.99%. This distribution of genome coverage is detailed in 
Figure 4-4. Again this shows that in specimens with a low Ct, for example 429323 
and 430741 (Ct 16.25 and 20.24) there is broad coverage of the reference 
sequence with especially deep coverage of the VP1 region. In specimens with a 
higher Ct, for example 428129 and 428008 (Ct 25.39 and 28.79) the reference 
coverage is incomplete and sporadic.  
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Figure 4-4. Coverage of enterovirus reference genome by sequenced reads. 
This image shows a visual output of the alignment of sequenced reads against an annotated 
schematic of the reference genome for scale. 
 
This was consistent with previous findings that the viral quantity in the sample 
correlates with likelihood of detection and proportion of viral reads sequenced. 
Greater than 80% reference genome coverage was obtained in cases with a Ct 
value lower than 25 (Figure 4-3). In samples with a higher Ct value, the breadth 
of coverage was sporadic and was not guaranteed to generate information from 
protein coding regions (Figure 4-4).  
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4.4.2 Phylogenetic Analysis 
Assembled sequences with greater than 90% reference genome coverage were 
generated from eight of 22 clinical samples. These were added to an alignment 
of reference genomes and used for subsequent phylogenetic analysis. Figure 4-5 
shows that all eight isolates belong to clade B and share a common origin. 
Full VP1 coverage was available in 13 of the 22 samples. This included the 8 
samples with >90% genome coverage (see above) and a further 5 samples. In a 
further four specimens a partial VP1 coverage was generated. Additionally, VP3 
coverage was generated in a further case, 428192; therefore capsid protein 
coding information was generated in 18 of 19 cases detected by NGS. No capsid 
protein coding regions were sequenced from specimen 429319.  
The VP1 sequences generated here were then aligned with reference VP1 
sequences, including those available from the flaccid paralysis cases during the 
aforementioned US outbreak. This again confirmed that the majority of cases 
clustered in clade B. One case, 428194, was shown in clade B1 and was closely 
related to the sequences obtained from cases with acute flaccid paralysis in the 
recent US outbreak (Figure 4-6).  
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Figure 4-5. Enterovirus D68 complete genome phylogenetic analysis. 
This neighbour joining tree was inferred using the Tamura-3 parameter model with 1000 bootstrap 
replicates. Bootstrap values greater than 90 are shown next to the nodes on the tree. The analysis 
involved 46 nucleotide sequences. There were a total of 7382 positions in the final dataset. 
Evolutionary analyses were conducted in MEGA6. The samples from this study are highlighted with 
teal triangles. 
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Figure 4-6. Enterovirus D68 VP1 phylogenetic analysis. 
This Maximum Likelihood tree was inferred using the Tamura 3-parameter model with 1000 
bootstrap replicates. Bootstrap values are shown next to the nodes of the tree. The analysis 
involved 65 nucleotide sequences. There were a total of 922 positions in the final dataset. 
Evolutionary analyses were conducted in MEGA6. The isolates from this study are highlighted with 
blue triangles. The isolates highlighted with red markers were from patients with neurological 
symptoms and those with blue or grey markers had respiratory symptoms only.  
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4.4.3 Recombinant Detection 
The results obtained using RDP4 analysis indicated that no recombination events 
were detected among the EV-D68 virus sequences obtained from these clinical 
samples.   
4.4.4 Comparison with Sanger sequencing 
The Sanger sequencing method was applied to the same cohort of clinical 
samples as part of a separate study (Poelman, Schuffenecker et al. 2015). This 
method required nested PCR (two reactions) followed by a sequencing reaction, 
commonplace methods in large diagnostic centres.  This targeted a 316 bp portion 
of the hypervariable region of VP1, commonly used in typing of enteroviruses (Nix, 
Oberste et al. 2006).  
Sequence information was successfully obtained from 17 of 22 clinical samples. 
Phylogenetic analysis of this short fragment shows clinical samples within multiple 
clades (Figure 4-9). One lies within clade A and of the remaining 16, 14 cluster 
together in clade B and two cases fall within clade B1.   
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Figure 4-7. Phylogenetic analysis of EV-D68 VP1 sequences generated by Sanger sequencing.  
This Maximum Likelihood tree was inferred using the Tamura 3-parameter model with 1000 
bootstrap replicates. Bootstrap values are shown next to the nodes of the tree. The analysis 
involved 65 nucleotide sequences. There were a total of 316 positions in the final dataset. 
Evolutionary analyses were conducted in MEGA6. The isolates from this study are highlighted with 
circles. Clade A sequences are in red, clade C in blue and clade B is shown in green with B1 in 
light green.    
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As discussed earlier, NGS identified full VP1 coverage from 13 specimens. The 
Sanger method used here targets a 316 bp hypervariable region of the protein. 
This region was identified from 17 specimens using NGS. Both methods identified 
the region from 14 specimens. Three were identified by Sanger alone (429395, 
428192 and 429319) and three were identified by NGS alone (430139, 427086 and 
428008). A direct comparison of the VP1 sequences generated by each method, 
where available, showed multiple differences at a nucleotide level (Table 4-2). 
Up to 6 nucleotide differences were identified in six of 14 cases.  
Specimen 
Nucleotide 
differences 
Ambiguous base 
calls by Sanger 
NGS gaps 
427334    
427759    
428005    
428287 6  18 
428891 2 17  
429031 2   
429323    
429660  1  
429915 2  18 
430038 4 14  
430146    
430741    
431467  1  
428134 1   
Table 4-2. Nucleotide differences between NGS and Sanger sequences. 
Analysis of the translated sequences shows non-synonymous differences in six of 
the 14 specimens with sequence coverage by both methods. Many amino acid 
changes could not be analysed due to lack of NGS coverage or ambiguous 
nucleotides generated by the Sanger method (Figure 4-8).  
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Figure 4-8. A comparison of non-synonymous nucleotide substitutions between Sanger and NGS 
methods.  
The sequences with a prefix of S were generated with Sanger and those without a prefix were 
generated with NGS. Non-synonymous nucleotide substitutions are highlighted in green. Amino 
acids which could not be analysed due to ambiguous base calling are highlighted in blue and those 
due to lack of NGS coverage in yellow.  
 
The NGS alignments were visually inspected using to tablet to determine if 
mixed bases were present at the same positions with ambiguous bases calls by 
Sanger sequencing. There were a number of bases with mixed populations at low 
levels, although not at these positions. Interestingly, as described above, in 
specimens 430038 and 429660 an additional enterovirus was detected which 
would be a possible explanation for ambiguous base calls. Unfortunately in the 
remaining two specimens with additional enteroviruses the VP1 sequences were 
not available from both methods to directly compare.  
The phylogenetic relationship among the sequences generated from each 
method shows partners that fall within the same branch, therefore the small 
number of differences is not sufficient to alter the topology of the tree (Figure 
4-9).  
In comparison to analyses carried out using NGS sequences alone, the Sanger 
method provides a similar level of resolution into the relationship of the viruses 
in this cohort with those previously described. 
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Figure 4-9. Comparison of phylogenetic relationship of Sanger and NGS sequences. 
A Maximum Likelihood tree was inferred using the Tamura-3 model. A total of 316 bp from 84 
sequences were included. Panel A shows the relationship of NGS sequences with VP1 references. 
The clinical isolates are highlighted with triangle markers. Panel B reiterates the tree inferred using 
Sanger sequences for comparison.  
4.5 Discussion 
In this research, diagnostic specimens which were screened for EV-D68 as part of 
an epidemiological study subsequently underwent NGS using the methods 
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optimised in the previous chapter. The aim of this being to determine if NGS 
could simultaneously detect pathogens and provide the sequence information 
required for additional typing and epidemiological analyses. The research 
presented here demonstrates that using an NGS approach in a diagnostic virology 
setting would allow simultaneous detection and in-depth sequence analysis 
utilising a single workflow and without specific pathogen targeting. Further to 
the work presented in the previous chapter, the NGS method used here was also 
capable of detecting more than one viral pathogen from a single clinical 
specimen.  
Here we assessed the use of the NGS method for the detection and typing of EV-
D68. We used a panel of 22 specimens found to be EV-D68 positive by the type 
specific real time PCR method used in the WoSSVC. The NGS method correctly 
identified EV-D68 in 19 of these specimens. A small number of EV-D68 sequenced 
reads were detected in the remaining three specimens by direct alignment to 
reference sequences however this would be equivalent to predefining a target 
and as the numbers were small there is less confidence in this result. As 
documented in chapter 3, detecting a small number of reads may not indicate a 
positive result.   
As discussed in chapter 1, the NGS method can be carried out without a 
predefined target. Using this method it was possible to identify the virus under 
study including subtype using a single workflow, in comparison to the RT-PCR 
method where a genus specific RT-PCR followed by a type specific reaction was 
required. Whilst it would be technically possible to identify positive specimens 
using the type specific PCR alone this would not be an appropriate use of 
resources in a diagnostic laboratory since the prevalence of the virus is low. 
Instead pre-test probability is increased with the use of a genus specific RT-PCR 
as a screening tool.  
The virus under study in this example, EV-D68, is highly variable and prone to 
both mutations and recombination events as are many viral pathogens. These 
mutations may result in a loss of primer binding efficiency over time and as a 
result reduce test performance of a type specific PCR. 
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The panel tested included nine specimens that were positive for an additional 11 
RNA or DNA pathogens by real time PCR. This allowed us to assess the ability of 
the NGS pipeline to detect multiple infections – something that we couldn’t 
ascertain in Chapter 3. Three of the 11 co-infections were detected by NGS. 
These were all RSV-A with Cts ranging from 18.27 to 26.41.  Of the eight that 
were not confirmed, three cases were attributed to DNA viruses (two AdV and 
one HHV-6 with Cts of 22.34 – 35.89). It is unclear why these were missed and is 
in line with the limited data provided in Chapter 3 where an AdV (Ct = 35.1) was 
also missed by the NGS pipeline. As has been discussed previously, the method 
used in this research targets RNA and therefore may preclude the detection of 
DNA genomes. In three of the remaining five missed positives the Ct of the 
missed pathogen was greater than 32, which based on data from the previous 
chapter and supported by analysis of the smaller number of viral detections in 
this study, maybe the lower limit of detection for NGS. Interestingly, HPIV4 was 
detected as a co-infection in four cases by RT-PCR, however despite a Ct range 
of 26.08 to 34.53 no cases were identified by NGS. The reason for this is unclear. 
One explanation may be a variation in the reverse transcription and sequencing 
performance between virus groups (Prachayangprecha, Schapendonk et al. 
2014).  
In summary, the detection of co-infections using NGS was not comparable with 
RT-PCR, however of the 11 detections by RT-PCR only six had a Ct less than 32 
which we found to be the lower limit of detection by NGS. Of these six, three 
were detected by NGS.  
When considering the introduction of this method to a diagnostic laboratory the 
limit of detection for each pathogen would need to be assessed. This would 
require sequencing a panel containing serial dilutions with known viral 
quantities. To assess the ability of co-infection detection, a mix of viral 
pathogens at differing quantities should be sequenced. It may be that the 
presence of a pathogen in high concentration would inhibit the detection of 
subsequent pathogens. It was not possible to assess that relationship with the 
panel tested here.  
As discussed in the previous chapter, the methodology used here would need to 
be assessed for the detection of DNA pathogens using more examples than were 
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available here. If the sensitivity for DNA pathogens is lacking then additional 
processing steps would be required.  
The NGS method did detect co-infections that that were missed by the routine 
real time PCR method used at the WoSSVC. For example, in three cases the NGS 
method co-detection of other Enteroviridae pathogens, rhinovirus A and C, 
which would not be identified using current diagnostic practice. These would not 
be identified by the real time PCR in place at WoSSVC since the assay targets an 
area of the genome which is conserved between species. This is necessary as the 
number of distinct subtypes precludes targeting each individually. The EV-D68 
RT-PCR and Sanger sequencing method would also fail to detect such mixtures. 
For example, the EV-D68 assay would only detect the presence or absence of 
this pathogen whereas the Sanger sequencing will only highlight a mixture if it is 
present in ~50:50 ratio. As most recent studies of viral respiratory infections 
have used a PCR based approach in the detection of pathogens there is little 
information on the clinical significance of infection with more than one of the 
Enteroviridae.  
In this research, more than one virus and indeed more than one enterovirus was 
detected from a single clinical specimen. While multiple viruses can be detected 
by RT-PCR, this requires numerous primer sets and assays. It is not feasible to 
differentiate viral subtypes, this was not detected by either PCR or Sanger 
sequencing. The clinical significance of viral co-infection is not proven however 
this is clearly an opportunity for recombination events between serotypes and 
could shed light on the evolutionary dynamics of enteroviruses by linking events 
that take place within single patients with those observed at the population 
level.  As discussed previously there are multiple clades of EV-D68 in circulation 
worldwide. The characterisation of a partial or single protein coding region is 
unlikely to highlight recombination events. Recombination is an important viral 
mechanism of evolution. These events can result in novel virus strains which are 
antigenically distinct and therefore not recognised by the host immune system. 
As has been discussed previously the Enteroviridae are responsible for multiple 
clinical syndromes and as a result of recombination involving neurotropic 
viruses, the potential exists for novel neurotropic strains or established strains 
to gain the ability to infect the CNS (Tapparel, Junier et al. 2009). 
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As in chapter 3 we found that the breadth of genome coverage and the number 
of reads with viral origin were again related to the RT-PCR Ct value, further 
evidence to suggest both that sequencing efficacy is linked to viral quantity and 
that NGS could be used in virus quantification. The detection cut-off was again 
in the region of Ct = 32, as the mean Ct of RT-PCR positive specimens which 
were not detected by NGS was 31.78. This correlates with findings from chapter 
3, although a smaller number of specimens were included in this analysis. Near 
full genome coverage was generated in strongly positive cases by PCR (e.g. Cts < 
25) but at lower viral quantities genome coverage was sporadic and 
unpredictable with no guaranteed coverage of the area of interest for 
comparison with Sanger or epidemiological analysis. As shown in chapter 3, the 
relationship between virus quantity and NGS sequencing varied between virus 
groups, for example, the breadth of sequencing coverage for the 
Paramyxoviridae was poor in comparison to the Enteroviridae, despite similar 
Cts. This would suggest that the test performance would require to be analysed 
for a full panel of pathogens to determine what initial viral load is likely to 
result in full genome coverage with NGS.   
In comparison with Sanger sequencing which generated the targeted sequence in 
17 of 22 cases, the same target area was also sequenced in 17 of the 22 clinical 
specimens. Both methods generated sequence information from 14 specimens. 
Each method generated sequence from three specimens which was not identified 
by the other. It is important to point out that following the highly specific 
amplification process utilised for Sanger sequencing no VP1 sequence was 
obtained in four cases and in the remaining case a sequence identified as 
parechovirus-3 was obtained. The perfect test would be 100% sensitive and 
specific however this is rarely the case. With regard to the VP1 coding region, 
NGS identified the same number as Sanger. Though, as this approach was target 
independent and other coding regions of interest, VP2 and VP3, were identified 
in a further two cases. These areas encode for the remaining capsid proteins and 
have been used in the molecular typing of Enteroviridae. VP2 and VP3 have been 
shown to give typing results comparable with those of VP1. This would indicate 
that the use of NGS in the detection, typing and epidemiological analysis of an 
enterovirus is comparable with that of nested PCR and Sanger sequencing. It is 
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difficult to extrapolate this information for other pathogens as molecular typing 
targets and methods vary between virus groups.   
Additionally NGS sequencing provided near full genome information in eight of 
22 cases. Is it possible to infer viral subtype from a single protein coding region 
however to study the evolution of the pathogen and detect possible 
recombination events would require greater genome coverage. To generate full 
genome coverage of the enterovirus genome would necessitate multiple PCR and 
sequencing reactions. There is a limit to the size of amplicon that can be reliably 
produced with RT-PCR and while it would be possible to generate an amplicon of 
7.3kb there is a high likelihood of introducing errors, therefore it would not be 
appropriate to use this as a template for a sequencing reactions.  
Comparable sequence regions between NGS and Sanger were identified in 14 
cases. Nucleotide mismatches were found between these despite arising from 
the same clinical specimen. Where nucleotide differences occurred, many of 
these were as a result of Sanger sequencing allowing a mixed ambiguous 
nucleotide to be called. The generation of a consensus sequence by NGS with the 
programs used in this research will only allow an A, C, T or G base to be called. 
In a small number of cases the nucleotide differences were not to ambiguous 
bases, rather a different base. Phylogenetic analysis comparing the sequences 
generated in both methods showed that this small number of differences was not 
enough to alter the topology of the tree generated.  
An interesting point to note is that of the four specimens noted to have 
ambiguous bases called by Sanger two had additional Enteroviridae detected by 
NGS. In a third case (428891) a co-infection with AdV was detected by PCR with 
a strong Ct, 22.34. It may be possible that this could affect NGS identification of 
a further enterovirus in this case as there may be a limit to the number of 
viruses detectable in a clinical specimen or this may preclude detection of low 
levels of other viruses. This would imply that despite species specific 
amplification reactions, the presence of a related virus in the clinical specimen 
is affecting the output of the Sanger sequencing.   
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5 The Application of an NGS Pipeline to the Detection and 
Epidemiological Investigation of Norovirus 
5.1 Infectious Intestinal Disease 
The research demonstrated in the previous chapters demonstrated that the 
implementation of an NGS method into a diagnostic setting can be used to 
identify respiratory viral pathogens from clinical specimens. The correlation 
between viral sequenced reads, proportion of reference coverage and the RT-
PCR Ct suggests that this method could also be semi-quantitative. As 
demonstrated in chapter 4, multiple pathogens can be detected from a single 
specimen; however the sensitivity of this requires improvement to be used as a 
diagnostic tool.  
The research presented in chapter 4 also demonstrates that the sequence 
information generated as part of this process can be used in for typing and 
epidemiologic analyses, which may not currently be carried out or, if studied, 
would necessitate further processing steps such as nested PCR and Sanger 
sequencing in order to generate similar levels of data.  
The aim of this chapter was to apply the methods used in previous chapters to 
an alternative disease syndrome and specimen type to describe the efficacy of 
applying a single workflow to different specimen types for the identification of 
pathogens. The identification of gastrointestinal infections is a commonly 
requested test for most virology diagnostic services and was thus identified as an 
area which may benefit from such technology.  
Multiple pathogens are associated with infectious intestinal diseases (IID) 
including bacteria and parasites but the majority are thought to be caused by 
viruses (Wikswo, Kambhampati et al. 2015). Within these cases noroviruses are a 
major contributor alongside sapovirus and rotavirus. Overall, such episodes of IID 
are responsible for over 1 million GP consultations and up to 17 million cases 
annually in the UK (Tam, Rodrigues et al. 2012). The introduction of the rotavirus 
vaccine to the routine schedule for children has seen norovirus become the 
leading reason for medical attendance related to IID (Payne, Vinje et al. 2013). 
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The research presented in this chapter will focus on norovirus, as this is an RNA 
pathogen associated with closed outbreaks and whose typing is important for 
both epidemiological and infection control purposes.     
5.2 Norovirus 
The Caliciviridae contains four genera; norovirus, sapovirus, vesivirus and 
lagovirus, of which only norovirus and sapovirus are human pathogens. They are 
non-enveloped viruses with a single-stranded positive sense RNA genome 
approximately 7.5 kb in length. The norovirus genome possesses three open 
reading frames. The first, ORF-1 is found at the 5’ and codes for at least six non-
structural proteins (p48, NTPase, p22, VPg, 3C like protease and the RdRp). This 
is followed by ORF-2 which codes for the major structural protein VP1 and ORF-3 
coding for the minor structural protein VP2.  
 
Figure 5-1. The norovirus genome. 
VP1 can be divided into the shell (S) and the protruding (P) domain. The P 
domain is further subdivided into the P1 and P2 domain. P2 contains the 
hypervariable region of the capsid, responsible for antigenic and histo-blood 
group antigen binding sites. This variable region can be used to group and sub-
type viral strains.   
Norovirus was first described as the cause of a gastroenteritis outbreak in 
Norwalk, Ohio, US which had occurred in 1968 (Kapikian, Wyatt et al. 1972). The 
pathogenicity of the virus was confirmed using healthy human volunteers. In 
vitro study of pathogenicity is limited as to date there remains no permissive cell 
line in which to culture the virus in a laboratory setting. Studies carried out in 
Japan many years earlier had proven that bacteria-free stool filtrates could 
transmit gastrointestinal infections from one person to another, suggesting a 
virus as a likely causative agent. In 1972 Kapikian used bacteria-free samples 
derived from rectal samples obtained during the illness outbreak in 1968 which 
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were then serially passaged in adult volunteers. The stool from these volunteers 
was examined with immune electron microscopy (IEM). During this process a 
stool sample is incubated with serum obtained from a convalescing individual. 
The antibodies present in the convalescent serum resulted in aggregation of viral 
particles which could then be visualised with EM. This revealed the gross 
structure of the virus, with distinctive cup like structures on the capsid layer of 
the particle, from which the name is derived (Latin “kulix” meaning cup or 
goblet).  
The genetic structure of the virus was determined in the 1980s at which point 
two distinct genogroups (I and II) were described. This has since been revised to 
include genogroup III, IV and V (and possibly VI) with over 30 genotypes within 
these. Only genogroups I, II and IV are associated with human infections. The 
lack of a cell culture model means typing of the noroviruses with neutralisation 
assays is not possible. There is no agreed standard method for the genotyping of 
norovirus although it is commonly based on the amino acid sequence of the VP1 
protein (Kroneman, Vega et al. 2013). Accurate genotype identification can be 
problematic in the context of recombinant viruses possessing an established 
ORF-2 sequence with a novel polymerase, which has also been used in 
genotyping. The large number of variants likely arises from both genetic drift 
and recombination events, common methods used by viruses in escaping the host 
immune response.  
The virus is spread by the faecal-oral route and can be transmitted through 
aerosols, environmental contamination and direct contact. A dose of only 18-
1000 particles is enough to establish infection. Very high viral loads are found in 
vomitus and faeces of symptomatic individuals, who are the drivers of 
outbreaks, however asymptomatic infection also occurs in up to 7% of healthy 
individuals (Ahmed, Hall et al. 2014; Iturriza-Gomara and Lopman 2014). The 
immune response to norovirus is incomplete and is not life-long, leaving 
individuals vulnerable to repeated infections. The exact duration of immune 
protection is not clear as previous figures of six months to two years were based 
upon challenge studies using large doses of virus, far greater than those which 
result in natural infection thus it is unclear if the natural antibody response is 
protective against a smaller virus challenge (Simmons, Gambhir et al. 2013).  
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Host genetic factors play an important role in the development of illness. 
Investigations using virus like particles (VLP) demonstrated that the particles will 
only bind to host cells in the presence of genetically determined carbohydrates, 
the histo-blood group antigens (HBGA). This relationship is complex and the 
binding of noroviruses are strain and HBGA specific. Those who do not produce 
antigen H are immune to infection and those with histo-blood group B antigen 
are resistant to infection with norovirus GI strains (Nordgren, Nitiema et al. 
2013).   
5.3 Epidemiology of Norovirus Infections 
Norovirus is estimated to be responsible for up to 18% of all cases of acute 
gastroenteritis and was the cause of 82% of the 137 reported outbreaks of 
infectious intestinal disease in Scotland in 2014 (HPS 2015). Infections occur 
both as sporadic events and outbreaks, occurring all year round but 
predominating in winter months. It is estimated that there are in the region of 3 
million episodes of norovirus in the UK each year, resulting in up to 130,000 GP 
consultations (Tam, Rodrigues et al. 2012). 
The most frequently detected genotype in outbreaks is GII.4 and this has 
remained the case for many years. This genotype contains multiple strains and 
the emergence of novel strains, occurring every few years, is often associated 
with increased virus activity and prolonged norovirus seasons (Bennett, MacLean 
et al. 2013). As is seen with influenza, this increase of viral activity is related to 
a lack of residual immunity within a population. Recombination events are also 
proposed to play an important role in the development of new variants (Bull, 
Eden et al. 2012) and a further reason for the genetic diversity of the virus.  
5.4 Outbreaks and outbreak control 
Norovirus outbreaks predominate in areas with high levels of contact, such as 
hospitals and care facilities. Such outbreaks result in a substantial amount of 
disruption to service at a great financial cost to health services (Lopman, 
Reacher et al. 2004).  
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Multiple factors contribute to risk of norovirus hospital outbreaks. The infectious 
dose required to result in infection is in the range of 10 to 1000 viral particles 
and there are multiple routes of infection, including direct contact with infected 
faeces or vomitus, but also aerosolised particles and fomite transfer (Robilotti, 
Deresinski et al. 2015). Infected individuals also continue to shed virus after 
resolution of symptoms. Contaminated hands can spread particles to up to seven 
subsequent surfaces (Barker, Vipond et al. 2004); therefore special attention 
must be pain to both hand washing and environmental decontamination. Viral 
particles can survive on surfaces for up to 12 days (Dalling 2004) therefore 
hygiene is essential in halting the spread of infections and outbreaks. The high 
predominance of the virus in the general population is a further risk for the 
introduction into a healthcare setting from the community.  
The illness is usually short in duration with low mortality rates in the general 
population but the elderly and those with co-morbidities are at risk of becoming 
compromised by the infection. Individuals who are immunosupressed are also 
likely to shed the virus for a prolonged time. This has implications for the spread 
of disease. Variation of the virus within host in those with immunosupression 
may also play a role in emergence of viral strains (Vega, Donaldson et al. 2014).  
The main strategy in the prevention of spread is to prevent direct contact 
between infected and susceptible individuals. In a hospital setting this is usually 
achieved through ward closures, patient isolation or cohorting and restriction of 
visitors. Additional measures include the use of personal protective equipment 
(PPE) such as gloves and aprons, effective hand hygiene and the control of staff 
movement i.e. preventing staff from affected areas entering non-affected areas 
and hand hygiene (Lopman, Reacher et al. 2004). The rapid identification and 
isolation of potentially infected individuals is imperative in the control of 
outbreaks. 
5.5 Norovirus Treatment and Prevention 
A greater understanding of viral spread and diversity is required to overcome 
some of the barriers which have thus far prevented the development of effective 
vaccines or therapies in the management of noroviruses (Bull, Eden et al. 2012).  
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No current therapies are available for the treatment of norovirus infections; 
however a proposed drug target is that of the VPg protein which is tethered to 
the 5’ end of viral genome. This protein is also relatively conserved between 
variants. The exact purpose of the protein is unclear but it is likely involved in 
the replication process. In murine models of infection the removal of this protein 
results in an attenuation of infection.  
As with many viral pathogens the variability and large number of genotypes with 
lack of cross-protective antibody responses has made this a difficult process. 
Within the highly variable P2 domain of the VP1 protein there are relatively 
conserved regions associated with the histo-blood group antigen binding site 
which is proposed as a potential vaccination target. There are promising studies 
on the development of effective norovirus vaccines (Lindesmith, Ferris et al. 
2015). 
5.6 Diagnosis of Infection 
The diagnosis of norovirus infection relies on the detection of the virus in stool 
samples. Norovirus cannot be grown in cell culture; requiring diagnosis to be 
confirmed using other methods. Transmission electron microscopy (TEM) has 
previously been the accepted method of viral identification however this method 
is both labour intensive and insensitive. Access to such a technique is now not 
available in most settings. Enzyme immunoassays (EIA) are commercially 
available and demonstrate ease of use with high throughput but many report 
sensitivity in the region of 50%. For this reason they are not recommended as a 
single diagnostic test and samples testing negative should be confirmed with an 
alternative method (Rabenau, Sturmer et al. 2003). As for respiratory viruses, in 
the diagnosis of norovirus, PCR has become the gold standard. High levels of 
both sensitivity and specificity have been demonstrated with the use of 
molecular methods. While gel based and nested PCR methods are available, a 
real-time assay used in the WoSSVC as it requires a single reaction therefore 
offers increased speed and ease of use. This assay is capable of detecting and 
differentiating genogroup I and II (Gunson and Carman 2005) but cannot 
distinguish between the genotypes within these. This results in a low resolution 
understanding of cases and outbreaks in real time. Genotyping can be carried 
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out but again this relies on the additional nested PCR reactions and Sanger 
sequencing. 
5.6.1 The Role of NGS in Norovirus Diagnosis 
The ability of NGS to detect norovirus from clinical specimens has been 
demonstrated, although to date there are no centres using NGS as a primary 
diagnostic method. There are many potential benefits from its implementation. 
The study of chronically infected individuals has revealed that nucleotide 
substitutions occur even within the P2 domain thus may affect the structure of 
the HBGA binding site (Carlsson, Lindberg et al. 2009). Such chronically infected 
individuals may be a source of new variants. Even minor variants at low 
frequencies can be transmitted and therefore play an important role in the 
increasing virus diversity (Bull, Eden et al. 2012).  
Genotyping of norovirus strains is important in monitoring the epidemiology. A 
greater understanding of virus evolution and transmission events will be 
essential in the development of vaccinations.   
5.7 Aim of Research 
The aim of this chapter was initially to determine the efficacy of NGS as a 
method for the identification of noroviruses associated with IID from a panel RT-
PCR positive clinical specimens. We wanted to evaluate whether this system 
could detect, type and provide data which could be used in potential 
epidemiological analyses such as detection of recombination events which may 
give rise to novel strains. As the RT-PCR Ct in norovirus positive specimens is 
generally low, it was hoped that the depth of sequencing coverage would be 
great enough to analyse single nucleotide polymorphisms and determine intra-
host variability. It was acknowledged that the number of specimens and 
timeframe included would preclude analysis of within host evolution but as a 
proof of concept study, given norovirus is frequently associated with closed 
setting outbreaks, could such analyses which would be applied to determine the 
direction of spread between hosts be applied to these data.  
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5.8 Methods 
5.8.1 Samples 
Residual nucleic acids extracted from stool specimens submitted to the WoSSVC 
for IID diagnostics were used in this study. Two outbreaks were picked at random 
and all associated specimens from each outbreak were used. In total, 11 stool 
specimens which had tested positive for norovirus by RT-PCR (WoSSVC) were 
used in this study, five from outbreak 1 and six from outbreak 2. The RT-PCR Cts 
ranged from 9.06 to 24.54.  
RT-PCR results 
Lab No Real-Time Ct Date Collected Time 
Outbreak 1 
500860 15.78 18/2/15 07:45 
500863 12.51 17/2/15 15:45 
500868 17.89 17/2/15 10:33 
500920 12.22 19/2/15 N/A 
500922 24.54 20/2/15 04:45 
Outbreak 2 
500967 15.04 23/2/15 N/A 
500968 10.05 23/2/15 N/A 
500969 21.33 23/2/15 N/A 
500970 9.06 22/2/15 N/A 
500971 23.14 23/2/15 N/A 
500973 9.93 23/2/15 N/A 
Table 5-1. Date and time of collection of norovirus positive specimens. 
5.8.2 Sample Preparation 
The methods used are described in detail in chapter 2. In brief, the extracted 
nucleic acids from clinical specimens were treated with DNase, reverse 
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transcribed and second strand cDNA synthesised. Random whole genome 
amplification was carried out using the SISPA method.  
The resulting PCR product was clarified using Ampure XP beads and sequencing 
libraries prepared using the Nextera XT DNA Sample Prep kit (Illumina). 
Sequencing libraries were quantified using the Qubit HS DNA assay and the DNA 
fragment size measured with the Tape Station HS DNA kit.  
Libraries were then sequenced using the Illumina MiSeq V2 300 cycle reagents to 
generate 150 bp paired-end reads. 
5.8.3 Data Analysis 
Sequenced reads were quality trimmed and mapped to a database containing 
human reference sequences. The remaining sequences following this process 
were entered into the MetAmos pipeline where de novo assembly of contigs was 
carried and subsequent identification of contigs using a BLAST search against a 
protein database.  
When norovirus contigs were identified in specimens, the assembled contigs 
were then used in a BLASTn search against a database of all norovirus full 
genome sequences available from NCBI. The top BLAST hit, based on coverage 
and identity scores, was the used as a template for a reference based assembly 
(Bowtie2).  
Consensus sequences were generated from the alignment files using an in house 
tool (J. Hughes, unpublished). The consensus sequence was visually inspected 
and compared with the alignment file using Tablet to ensure correct consensus 
calling. The sequenced reads were then mapped to this consensus to increase 
coverage. 
5.8.4 Phylogenetic Analysis 
Consensus sequences were aligned with reference genome sequences in MEGA6. 
Phylogenetic analysis was carried out using MEGA6. Maximum likelihood trees 
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were inferred with 1000 bootstrap replicates. The model used for tree 
generation was chosen based on the BIC score.  
5.8.5 Viral strain identification 
The viral strain of each isolate was identified using the Norovirus Automated 
Genotyping Tool (Kroneman, Vennema et al. 2011). The consensus sequence was 
entered into this web based tool which determines viral strain based on a BLAST 
analysis of the ORF1 and/or ORF2 sequence. 
5.8.6 Intrahost Virus Diversity 
As single nucleotide polymorphisms can be used as markers to determine 
direction of viral spread within an outbreak, in order to assess if variable 
nucleotides could be detected within the consensus sequences reads were 
mapped back to the generated consensus. A pileup file was generated with 
DiversiTools. The SNP variants in the alignment were called using LoFreq where 
the depth of coverage was greater than 100 reads. Variants are assigned a p-
value based on coverage and frequency. Those with a p-value greater than 0.05 
were considered non-significant and excluded from analysis.  
5.8.7 Recombination Analysis 
Recombination analysis was carried out using RDP4 with sequence alignments 
generated using Muscle as part of MEGA6. A database of complete norovirus 
genome sequences was compiled from sequences available in PubMed (search 
term “norovirus”, sequence length 7300 – 8000 bp). The sequences were 
clustered at 99% homology (using cd-hit-est) to remove similar sequences and 
therefore reduce the overall size of database. This in turn reduces computation 
power required for analyses.  The remaining nucleotide sequences were aligned 
with the consensus sequences using Muscle in MEGA6. The alignment file was 
entered into RDP4 to determine if the clinical isolates from these outbreaks 
were involved in recombination events.   
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5.9 Results 
5.9.1 Virus identification 
The distribution of reads generated by sequencing is shown in Figure 5-2. On 
average 1,000,000 reads were generated per specimen (range 808198 – 
1615450). An average of 18% of reads was removed following quality trimming. 
Of the remaining reads 4% (range 0.03 – 32.36%) mapped to a human reference 
and 45% mapped to a viral reference (range 0.11 – 92.87%). Using the MetAmos 
pipeline norovirus contigs were detected in all specimens.  
 
Figure 5-2. Distribution of sequenced reads from norovirus RT-PCR positive specimens. 
The panel on the left shows the number of reads removed by quality trimming, mapping to a human 
reference, mapping to a viral reference and those remaining unmapped. The panel on the right 
expresses each of these as a proportion of the total number of sequenced reads.   
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RT-PCR results NGS results 
Lab No 
Real-
Time Ct 
Human 
reads 
Accession 
(genotype) 
Reads mapping to 
viral reference 
Reads mapping to 
NGS consensus 
% mapped 
reads viral 
% 
coverage 
Average 
depth 
Nucleotide 
mismatch 
500860 15.78 42138 
KJ196292 
(GI.3) 
290300 323571 47.55 99.91 4766 7 
500863 12.51 10827 
KJ196292 
(GI.3) 
467031 518968 76.72 99.91 7658 6.8 
500868 17.89 23677 
KJ196292 
(GI.3) 
96486 108759 13.70 96.372 1595 6.9 
500920 12.22 2463 
KJ196292 
(GI.3) 
304077 343826 31.67 99.742 4979 7 
500922 24.54 187303 
KJ196292 
(GI.3) 
49655 56378 14.40 93.906 833 6.2 
500967 15.04 7114 
KC631827 
(GII.4) 
585627 590245 69.92 97.91 8903 2.9 
500968 10.05 362 
KC631827 
(GII.4) 
579716 585677 83.02 99.511 8657 3.1 
500969 21.33 1021 
KJ685412 
(GII) 
1859 1907 0.14 95.379 28 3.2 
500970 9.06 228 
KC631827 
(GII.4) 
754763 763037 93.88 98.836 11429 3.3 
500971 23.14 592 
KJ685412 
(GII) 
744 761 0.11 91.051 11 3.7 
500973 9.93 4251 
KC631827 
(GII.4) 
679042 686646 91.83 97.447 10015 3.1 
Table 5-2. Sequenced reads mapping to norovirus reference genome.
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Near full length genomes (>90% coverage) were generated in all cases (Table 
5-2). The mean sequencing depth was 5352 and ranged from 11 to 11429 reads 
per base. 
Viral contigs were detected in all clinical specimens. Following the nucleotide 
BLAST search five of 11 samples returned a norovirus of genogroup I, genotype 3, 
four of 11 returned genogroup II, genotype 4 and two of 11 returned genogroup II 
but no genotype documented. The specimens which failed to return a genotype 
had Cts of 21.33 and 23.14. 
Assessment of both the proportion and number of sequenced reads mapping to 
the viral reference shows there is a relationship between these and the RT-PCR 
Ct (Figure 5-3). For example, in 500973 with a Ct of 9.93, 91.83% of non-human 
reads were viral and covered 97.45% of the reference genome. In contrast, in 
500971 with a Ct of 23.14, 0.11% of the non-human reads were viral and covered 
91.05% of the reference genome. The depth and breadth of reference coverage 
also correlated with the Ct. Linear regression of each of these parameters 
returned a high R2 value, 0.68 or greater, suggesting a linear relationship. 
Following assembly to the top nucleotide BLAST hit the depth of coverage 
ranged from 11 to 11429 reads. The level of nucleotide mismatch in the GII 
specimens was lower, 2.9 to 3.7%, than in the GI specimens, 6.2 to 7.0%.  
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Figure 5-3. The relationship between mapped reads and RT-PCR Ct.  
Panel A shows the proportion of unmapped reads following quality trimming and human reference 
alignment which mapped to the norovirus reference sequence and how this related with RT-PCR 
Ct. Linear regression R
2 = 
0.84 (p<0.0001). Panel B shows the number of unmapped reads 
mapping to the norovirus reference sequence. Linear regression R
2
 = 0.77 (p=0.0003). Panel C 
shows the average depth of sequencing coverage following alignment of reads to the top hit 
reference genome. Linear regression R
2 
= 0.83 (p <0.0001). Panel D shows the percentage of 
reference genome covered by sequenced reads following alignment. Linear regression R
2 
= 0.68 
(p=0.0018).   
5.9.2 Assembly 
Using a reference-based assembly with the top BLAST result as the template 
generated greater than 90% of reference genome coverage in all cases. The 
sequencing depth varied throughout the length of the genome but in general was 
greatest over the NTP and VP1 regions. In the genotype I specimens the depth of 
coverage was low out with these regions whereas in the genotype II specimens 
there was a further peak in coverage in the 3C coding region.   
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Figure 5-4. Reference based alignment of sequenced reads with a representation of the norovirus 
genome. 
5.9.3 Strain Analysis   
Using the Norovirus Automated Genotyping Tool, all specimens from outbreak 1 
returned a result of GI.P3. All specimens from outbreak 2 returned a result of 
GII.4 Sydney 2012. 
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5.9.4 Phylogenetic Analysis 
 
Figure 5-5. The phylogenetic relationship between clinical isolates and reference genomes, based 
on the VP1 segment.  
The areas within the boxes are shown in more detail in panels B and C. This neighbour joining tree 
was inferred with the Tamura-nei model in MEGA6. 1000 bootstrap replicates were carried out and 
relevant values shown on the tree as percentages. The analysis involved 315 nucleotide 
sequences. There were a total of 2166 positions in the final dataset. 
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Phylogenetic analysis based on the VP1 coding region of the norovirus genome 
reveals that the sequences obtained from the clinical specimens in each 
outbreak were most closely related to each other.  
The specimens from outbreak 2 are all on the same branch amongst genotype 
GII.4 sequences, suggesting a close relationship with each other. The specimens 
from outbreak 1 fall in a clade with genotype GI.3 sequences. In this outbreak 
one specimen, 500920, falls on a different branch from the remaining four 
specimens. This could suggest there are some differences in this virus. 
5.9.5 Recombination Analysis 
An alignment of the consensus and known full genome sequences was entered 
into RDP. The virus detected in outbreak 2 was result of a recombination event 
between KF72497 (US) and KJ685402 (Bangladesh). The breakpoint was 
identified between positions 4486 and 5146. This would be in keeping with the 
beginning of ORF2 which is in the region of position 5022. No recombination 
events occurred during the course of the outbreaks, although this would be the 
expected result given the short duration of each. 
5.9.6 Intrahost Variability and SNP Analysis 
The epidemiology of norovirus varies with that of the respiratory viruses 
described in previous chapters. As discussed earlier in this chapter, norovirus is 
commonly associated with outbreaks in closed settings such as healthcare 
facilities. SNPs can be identified and followed through the transmission chain to 
ascertain the direction of spread (Hughes, Allen et al. 2012).  
Variable nucleotides detected in the alignment where the sequencing coverage 
was greater than a depth of 10 reads were analysed. The probability of these 
being significant was based on a p value < 0.05.  
SNPs with a frequency below 1% were removed and the remaining sites plotted 
to highlight any areas with a high degree of variability.  
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Figure 5-6. Nucleotide variants, showing the proportion of reads different from the consensus.  
The figure shows an amalgamation of all samples with the different coloured symbols representing 
each sample. 
    
This shows that SNPs are found throughout the length of the virus genome, with 
the exclusion of the extreme ends of the alignment however this is a result of 
low coverage at these points. There is a suggestion of clusters of low frequency, 
less than 2%, SNPs at the beginning and end of the VP1 region.  
In the specimens from outbreak 2, 500968, 500970 and 500973 demonstrated a 
low level variant at nucleotide position 6537 which is found in the coding region 
for VP1.  Following translation this G to T switch would result in an amino acid 
change at position 485 from valine to phenylalanine.  
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Figure 5-7. A pairwise comparison of the consensus sequences generated from each clinical 
sample. 
The analysis was restricted to sites with coverage in all samples. Panel A shows outbreak 1 with a 
total of 7279 bases analysed. Panel B shows outbreak 2 where a total of 6820 bases were 
analysed. The blue cells show the percentage identity between sequences. The cells in red show 
the number of nucleotide differences between sequences.     
The specimens from each outbreak were collected over a short period of time, 
up to 72 hours. Specimens 500860 and 500868 were collected from the same 
individual as were 500968 and 500973. A small number of SNPs were 
demonstrated between these specimens. A large number of SNPs were seen in 
specimen 500920, up to 77. Despite these genetic differences, the virus isolated 
here was identified as the same genogroup and most closely related to the same 
reference strain as the others from this outbreak. A smaller number of SNPs were 
identified in samples 500922 and 500971, between 11 and 14. These may 
represent further introduction events but could be related to the lower depth of 
coverage generated from these specimens.  
5.10 Discussion 
The research presented in previous chapters demonstrated that NGS could 
successfully detect and type viral respiratory pathogens from clinical specimens 
and the resulting genetic sequence information generated as part of the process 
could be used for in-depth pathogen analyses, similar to those used for 
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epidemiological purposes. The aim of this chapter was therefore to demonstrate 
if these methods would be as effective when applied to different specimen 
types. To this end, NGS was carried out on a panel of norovirus RT-PCR positive 
faecal specimens with the initial aim of detecting norovirus, in line with the 
current diagnostic RT-PCR. As norovirus commonly occurs as outbreaks in 
healthcare facilities and these specimens regularly demonstrate low Ct values, 
therefore high viral load, it was hoped the depth and breadth of sequence 
information generated would allow analysis of mutations and variants within the 
viral population. These studies have been proposed as a mechanism to track viral 
spread during such outbreaks and may further our understanding of the outbreak 
process.   
From this small panel of 11 specimens from two outbreaks, the presence of 
norovirus was confirmed in each using both a de novo assembly and reference 
based assembly method. The proportion of viral reads from these clinical 
specimens was greater than those in previous chapters, where the majority of 
mapped reads were of human origin. This may be due to a lower level of host 
contamination within this type of specimen or more likely relates to high viral 
load as demonstrated by the low Cts in this panel as further to the previous 
work, there is a relationship between Ct and proportion of viral reads 
sequenced. This relationship was more pronounced with this panel of specimens 
where a linear regression model returned an R2 value of 0.84 compared with up 
to 0.40 in chapter 3. The percentage of reference genome covered by NGS reads 
was consistently above 90%. A difference in nucleotide mismatch levels was 
observed between the GI.3 and GII.4 samples. This is most likely explained by 
the fact that GII.4 is the most widely circulating virus strain and there are a 
greater number of reference sequences available. From the work in previous 
chapters, a lower limit of virus detection using NGS was proposed to be in the 
region of a Ct equal to 32. Using these norovirus positive specimens a lower limit 
of detection could not be identified. This again is likely a result of the high viral 
load in these specimens. Consequently this would imply that an NGS approach in 
the detection and typing of norovirus would be successful in the majority of 
cases.  
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Viral contigs were detected in all specimens. Following assembly to the top 
reference as determined by a BLAST search, great than 90% reference coverage 
was obtained in all cases. This shows a greater level of sensitivity and breadth of 
coverage in comparison with the respiratory specimens. Again this likely relates 
to the high viral load in these specimens. The number of specimens used in this 
research was considerably smaller than in previous chapters. The depth of 
coverage varied throughout the genome but returned particularly good coverage 
of the VP1 coding region. This may reflect the fact that this is the most 
abundant protein within the assembled viral particle as it constitutes the main 
component of the viral capsid.  
This sequence information allowed robust identification and subsequent 
genotyping of the virus as good coverage of the genome region used in molecular 
typing, VP1/ORF2 was obtained. Over 25 genotypes from genogroup I, II and IV 
are associated with clinical disease but the current diagnostic assay is only 
capable of determining genogroup I and II. While these tests are highly sensitive 
they provide a low resolution understanding of outbreaks and the spread of 
disease. Genotyping can be carried out however this requires additional 
laboratory work, namely Sanger sequencing. As mentioned in the previous 
chapter in relation to the Enteroviridae, a genogroup specific RT-PCR is required 
to detect norovirus as it would neither be cost effective or feasible to carry out 
multiple genotype tests on each clinical specimen.  
Determining genotype is not beneficial to the patient in real time as it will not 
change the course of management. This information is however useful from an 
epidemiological point of view. A new dominant norovirus strain circulating in a 
population emerges every two to four years and this emergence of a novel strain 
can be associated with a rise in the number of cases. Monitoring strain 
circulation in real time would provide early warning of a change in dominant 
strain and could assist in resource planning for potential outbreaks. Such 
measures may include additional ward space, isolation bays and cohorting of 
potentially infected individuals. As diagnostic techniques vary between 
laboratories, knowledge of a novel strain could ensure diagnostic services ensure 
their methods will be able to identify strains which are different to those 
currently circulating. This is applicable at a national and international level as 
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given the worldwide prevalence of norovirus, alerting neighbouring countries of 
emerging strains would be appropriate. 
Vaccines and anti-viral therapies are in development however currently there 
are no specific options for norovirus. The mainstay of treatment for patients who 
require admission is supportive until symptoms subside. Should a vaccine 
become available in the future the sequence information generated could be 
used in monitoring efficacy. As is the case with influenza, multiple strains are 
known to circulate although a limited number can be included in vaccines. It is 
therefore essential to determine which strains are circulating and aim to predict 
what should be included in a vaccination programme.     
Following detection and assembly, the sequence information generated in this 
process was used to assign the genogroup and genotype. In all cases the 
genogroup confirmed that found by RT-PCR i.e. the five specimens from 
outbreak 1 were GI and the six specimens from outbreak 2 were GII. In nine of 
11 cases the genotype could also be assigned based on the top BLAST hit, which 
was then confirmed using a web based genotyping tool. In two specimens, 
500970 and 500973, the top nucleotide BLAST hit did not specify genotype, only 
genogroup. It is worth noting however that the genotyping tool returned a result 
of GII.4.  
In outbreak 1 the same viral strain was identified in all cases. Phylogenetic 
analysis of the VP1 segment revealed all isolates were most closely related to 
each other however specimen 500920 fell on a separate branch from the other 
specimens. A pairwise comparison of the resulting full genome consensus 
sequences identified that specimen 500920 had a large number of nucleotide 
differences, minimum 67, from all other cases. The number of nucleotide 
differences between all other specimens was substantially smaller with a 
maximum of 14. This would suggest that an unrelated virus was identified from 
this specimen. The implication here is that a second introduction event occurred 
during this outbreak. 
In outbreak 2 the same viral strain was again identified in all cases, the current 
dominant Sydney 2012 strain. Similarly to outbreak 1, specimen 500971 stood 
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out as having more nucleotide differences than other specimen. In this case it 
may relate to the comparably lower depth of sequencing generated rather than 
a novel introduction.  
The suggestion of multiple viral introductions would imply the need for a 
broader approach and more consideration of possible introduction routes. It is 
not possible to draw a conclusion on the co-circulation of multiple virus strains 
in a community or healthcare setting. The strains detected in this study did not 
undergo recombination however the isolates from outbreak 2 were the result of 
a recombination even between two geographically distinct viruses. It is proposed 
that the co-circulation of multiple strains would certainly contribute to this 
process but there is a lack of understanding into what drives such events to 
happen. The use of NGS in diagnostics and the routine generation of whole 
genome sequences from all clinical isolates is certainly something that would 
contribute to this. 
The evolution of the virus within the host could not be analysed in this research 
as this would require multiple specimens from each individual over the course of 
the outbreak. We did however demonstrate that the methods required to carry 
this out could be employed with the NGS data generated in this study. Clinical 
details were not available for the cohort understudy here but the evolution 
within host is likely to be more significant in those who are known to shed virus 
for a long time and may have impaired viral clearance. Studies of outbreaks 
involving immunocompromised individuals have demonstrated that chronic 
infection can occur with detectable virus shedding for weeks or even months 
(Kundu, Lockwood et al. 2013). The lack of complete viral clearance along with a 
degree of immune pressure may have been responsible for the viral evolution 
that occurs within this group. Such information would not benefit individual 
patients rather it would further out understanding of viral evolution and 
diversity over time. This specialised data analysis could be carried out 
retrospectively for the subset of patients where it may be clinically significant. 
The foundation of outbreak limitation is case isolation and appropriate hygiene 
measures of staff and visitors to prevent disease spread in a healthcare setting. 
Such knowledge would have implications relating to the infection control 
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measures in place to limit viral spread. Multiple introduction events may be 
related to staff, visitors or patients in other areas of the healthcare facility. 
Patient isolation, hand hygiene and personal protective equipment (PPE) are the 
main infection control measures put in place to prevent spread from patient to 
patient. These are unlikely to impact on further virus introductions from outside 
the healthcare facility. If multiple strains are isolated then the focus should be 
on limitation of movement between wards and consideration of admitting new 
patients to separate area until known not to be infected. 
Testing a panel of samples with known concentrations would be needed to 
determine a detection cut off as this could not be addressed above. The ability 
to detect mixed infections would also need to be established. From this small 
panel we demonstrated that SNPs and variable nucleotides can be detected, 
however a well characterised outbreak with repeated sampling throughout the 
duration would need to be studied to determine their clinical utility.  
The research presented here demonstrates some of the potentially achievable 
benefits of using a NGS approach in diagnostics. The additional generation of 
genetic sequence information would allow molecular epidemiological studies in 
real time including monitoring for the emergence of novel strains. Understanding 
the spread and evolution of norovirus within a local population could warn of 
such novel strains, allowing forward planning of resources. Increasing our 
understanding of the pathogen may in time aid in the development of targeted 
therapies and preventative measures which to date are lacking. 
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6 Discussion 
6.1  Introduction 
The research carried out in this thesis aimed to determine the feasibility 
alongside the potential benefits and challenges of using next generation 
sequencing technology in a viral diagnostic service. Given that respiratory 
diagnostics contribute substantially to the overall workload of most viral 
diagnostic laboratories; this was thought to be an ideal setting to test the 
potential of NGS.  
As described in chapter 1, many viral respiratory pathogens cause human disease 
and the current diagnostic test used in Glasgow (which is similar to those in use 
in other laboratories in the United Kingdom) requires five multiplex RT-PCR 
assays to screen for an extensive but by no means exhaustive list of pathogens. 
These assays are highly sensitive and specific and enable laboratories to process 
large numbers of samples in a rapid turnaround time. Consequently the PCR-
based approach to respiratory pathogen diagnosis is now considered the gold 
standard.  
Respiratory viruses are in constant evolution and in recent decades a number of 
novel respiratory viruses have emerged (e.g. influenza, MERS, SARS and human 
metapneumovirus) and re-emerged (e.g EV-D68). As a result diagnostic PCRs 
must be constantly reassessed and in some cases altered to ensure these new 
targets are detected sensitively. The use of NGS to detect viruses from clinical 
specimens would not require such a targeted approach, rather a metagenomic 
approach where all genetic material is amplified and examined.  
Alongside detection of viral pathogens, many diagnostic laboratories also play an 
important role in infection control and public health/epidemiology relating to 
respiratory infections. For example, laboratories will often be asked to 
investigate closed setting outbreaks of respiratory infection to determine what 
type of virus is involved (especially if the clinical outcome is unexpectedly 
severe) and to investigate the cause and spread of the outbreak (e.g. patient to 
patient spread or multiple introductions). In addition, many laboratories now 
monitor influenza subtypes during the winter season to detect the emergence of 
novel subtypes that may not be covered by the current vaccine. Currently, the 
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technology used to carry such investigations would be Sanger sequencing which 
would be carried out after the diagnostic PCR and is usually a retrospective 
request (i.e. requested after the outbreak has been detected or after a new 
clinical syndrome has thought to have emerged). Although some laboratories will 
do this on site, laboratories without access to this technology would have to 
refer samples away. NGS offers the potential of providing such epidemiological 
data at the same time as the diagnostic data thus having a major impact on 
infection control and public health responses. 
The work described in this thesis aimed to evaluate the use of a metagenomic 
NGS pipeline for the diagnosis, subtyping and epidemiological study of 
respiratory pathogens. In each case the NGS method was compared to the 
existing gold standard (e.g. RT-PCR for diagnosis and Sanger sequencing for 
epidemiological analysis). The main benefit to the laboratory of introducing such 
a technique would be streamlining multiple processes into a single workflow, 
therefore in chapter 5 we aimed to determine if the NGS method could also be 
used for the detection of another non respiratory clinical syndrome, namely 
gastroenteritis caused by norovirus.  
6.2 Summary of Research 
In chapter 3, NGS was applied to a panel of respiratory specimens from 
individuals with symptoms of a respiratory infection to assess its usefulness when 
used in a diagnostic setting. The panel was tested by RT-PCR in parallel to allow 
a direct comparison of the two methodologies.  
We confirmed the ability to detect multiple different viral pathogens, such as 
RSV, rhinoviruses and coronaviruses, from clinical specimens using NGS in 
combination with SISPA PCR without a priori sequence knowledge or enrichment 
for specific targets. The sensitivity demonstrated by NGS was less than that of 
the diagnostic RT-PCR panel in this study with 38 of 49 viral detections being 
identified by both methods. This could be explained to a certain extent by the 
lower limit of detection of the NGS method which for viral pathogens from 
respiratory specimens (as shown in chapter 3) was estimated to equate to a Ct of 
32. This is approximately two logs less sensitive than RT-PCR which has the 
ability to reliably detect pathogens with Cts in the region of 38. Similar results 
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were obtained in chapter 4 when using NGS to test a panel of respiratory 
samples that had been typed as EV68 by RT-PCR. If NGS is to be used in place of 
RT-PCR then the sensitivity discrepancy will need to be addressed. The possible 
routes to increase NGS sensitivity will be discussed in more detail below.  
Chapters 3 and 4 both outlined that there was a relationship between the viral 
load in a clinical specimen (as determined by RT-PCR Ct) and the proportion of 
viral reads sequenced. Both chapters also described a relationship between the 
viral load and the breadth of genome coverage. Similar findings have been 
described in other studies comparing NGS to RT-PCR (Prachayangprecha, 
Schapendonk et al. 2014). These results are encouraging as they suggest that 
NGS could provide semi-quantitative results, in a similar fashion to RT-PCR. 
Quantitation is a useful adjunct to respiratory pathogen diagnosis. It can be used 
to make a judgment call on the relevance of the infection (i.e. a weak positive 
may represent the remnant of a previous infection). Quantitation can also be 
used to monitor the progress of an infection and in the case of influenza the 
patient’s response to therapy. It can also inform infection control aspect by 
determining a patient’s infectious status. Quantitation is particularly informative 
in subsets of individuals such as those with a compromised immune system or 
those who are ventilated. These individuals frequently shed virus for extended 
periods of time and in such patients, emergence of treatment resistant influenza 
strains have been described (van der Vries, Stittelaar et al. 2013). 
Respiratory viral co-infections are a well documented phenomenon, although the 
clinical significance of these events has not been established (Lim, de Klerk et 
al. 2016). Some studies suggest co-infections are more severe than single 
pathogen infections whereas others have failed to confirm this (Lim, de Klerk et 
al. 2016). Nonetheless it is essential for any novel diagnostic technique to be 
able to detect these events to a comparable level as is achieved with PCR. Only 
a single co-infection was detected by RT-PCR from the specimens understudy in 
chapter 3. This mixture was not identified by NGS but as the second pathogen 
was a DNA virus with Ct below the presumed detection cut-off it was not 
possible to draw any conclusions from the work in this chapter. However, the 
specimens under study in chapter 4 were all collected from children, who are 
known to have a greater incidence of respiratory virus co-infection (Nickbakhsh, 
Thorburn et al. 2016). This provided a further opportunity to assess the ability of 
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the NGS method to detect coinfection. Although the panel of samples was small, 
nine specimens contained an additional eleven viruses. Unfortunately, only three 
of these additional pathogens were detected by the NGS method, all RSV. Of the 
remaining eight additional pathogens that were missed by the NGS method, five 
had Cts greater than 32. A mentioned above, this is beyond the likely lower limit 
of detection of the NGS method and as a result is therefore not an unexpected 
finding.  
Of interest, three of the additional samples missed by the NGS method were DNA 
pathogens. Taken together with the missed adenovirus positive in Chapter 3, this 
result suggests that the detection of DNA targets may be precluded by the initial 
reverse transcription process step of the NGS pipeline. The ability to detect DNA 
pathogens is an essential component of any respiratory virus diagnostic test. 
Firstly it is required to detect adenovirus a well documented cause of upper and 
lower respiratory tract illness. Secondly, DNA detection is required to detect 
bacterial pathogens such as Mycoplasma pneumoniae and Bordetella pertussis 
which are commonly tested for as part of many laboratories routine respiratory 
screen.  Steps which could be taken to improve the performance of the NGS 
method in the detection of coinfections/DNA targets are discussed in more detail 
below.  
In chapter 4 the NGS method detected 4 cases of what seem to be mixed 
enterovirus infections (i.e. samples that contained EV-D68 and another 
enterovirus subtype) that were not detected by the combination of RT-PCR and 
Sanger sequencing. In three of these cases an additional rhinovirus subtype could 
be assigned. In the remaining case sequenced reads which mapped to the 5’-UTR 
of multiple hRV-B references were identified but as this region of the genome is 
relatively conserved between species it was not possible to ascertain if these 
arose from the presence of an additional virus. This was an interesting finding 
which highlights an advantage of NGS versus current methods. This benefit 
would also be useful if applied to other sample types. One example is the 
surveillance of enterovirus infections using sewage samples. Current Sanger 
based methods would only reliably detect predominant types whereas the NGS 
method described here would be able to detect mixtures of subtypes thus giving 
a more accurate reflection of viral epidemiology.  
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As well as being highly sensitive, RT-PCR is highly specific. Although, based on 
the work described here, the NGS seemed to be specific a small number of 
sequence reads were detected in 12 RT-PCR negative specimens. Of these 12, 11 
were hRV and 1 RSV. These could represent contamination during the preparation 
or sequencing process. The use of double indexing during sequencing aims to 
minimise reads being assigned to the wrong specimen however this can still 
occur at areas of high clustering (Kircher, Sawyer et al. 2012). These were most 
likely to represent false positive reads as the end point detection limit of the 
NGS was less than that of the RT-PCR.  
Most RT-PCR panels detect the viral pathogen but do not offer simultaneous 
subtyping. As discussed in chapter 1, numerous subtypes exist within each 
respiratory virus group. For example there are three species of human 
rhinovirus, A, B and C comprised of over 100 known serotypes and two RSV 
subtypes, A and B, each containing over 10 genotypes. At present laboratories 
must use Sanger sequencing to type such viruses.  
However, having rapid access to such information could be useful. For example, 
it could be used to identify and investigate outbreaks of respiratory illness far 
earlier than currently possible with the combination of RT-PCR and Sanger 
sequencing. The real time description of viral subtypes would also enable the 
detection of emerging viruses quicker than currently achievable. Such data 
would also aid in the investigation of the clinical relevance of some infections 
more effectively than currently. For example there is some evidence to suggest 
that hRV-C may be associated with more severe illness and a greater risk of post 
infection complications such a wheeze when compared to other rhinoviruses 
(Cox, Bizzintino et al. 2013). Similar variations may also exist with other virus 
subtypes.  
The results described in chapters 3 and 4 suggest that an NGS approach would be 
possible for the diagnosis of respiratory viral infections and could provide the 
additional benefit of combining subtyping and real-time epidemiological analyses 
thus providing a high resolution understanding of the viral pathogens present 
within a population. For example, In Chapter 3, as mentioned above the 
subtypes or serotypes could be determined for hRV, RSV-A and B and hMPV-B. 
There was a suggestion that the generated sequences could be used for further 
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epidemiological analysis though the study was not set up to assess this aspect. 
Therefore when the occasion arose to study EV-D68 positive specimens, this was 
used as an opportunity to test this characteristic.  
In chapter 4 we show that the sequence information generated by the NGS 
method as part of virus detection can be utilised in subsequent epidemiological 
analysis. The data generated by the established methods of type specific RT-PCR 
followed by nested PCR and Sanger sequencing was compared with that 
generated by NGS. We were able to show that identification of EV-D68 was 
comparable between both methods; the Sanger method targeted the VP1 coding 
region of the virus and was identified in 17 of 22 specimens. By NGS, the same 
region was sequenced in 17 of 22 specimens and an alternative coding region 
which can be used in viral typing, VP3, was identified in an additional case 
therefore the methods provided comparable results. Additionally near full 
genome sequences were generated from eight specimens.  
Direct comparison of the sequences generated by both methods was available in 
14 cases. Nucleotide differences were detected between methods in a small 
number of cases however this did not alter the phylogenetic analysis, which 
confirmed that EV-D68 isolated from individuals in the West of Scotland fell 
within multiple clades.  
The generation of full genome sequences in a proportion of cases, 8 of 22, 
allowed recombination analysis. This would not be possible using Sanger 
sequencing unless multiple reactions were carried out to cover the entire 
genome. No recombination events were detected from the isolates tested. 
Chapters 3 and 4 assessed the use of the NGS method on respiratory samples 
with the aim of determining whether such an approach could replace RT-PCR in 
that setting. However, the implementation of such a change in methodology 
would have a significant impact on the diagnostic service and workforce 
therefore it is important to consider if this same approach could be applied 
successfully to other areas of viral diagnostics. In chapter 5 we compared the 
NGS method to RT-PCR using a small panel of norovirus RT-PCR positive faecal 
specimens obtained from two healthcare associated outbreaks. In this proof of 
concept study, the presence of norovirus was confirmed in all samples, 
suggesting the NGS method had the potential to be used as a diagnostic assay in 
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this setting. As with chapters 3 and 4, the sequence reads correlated with RT-
PCR Ct, highlighting the NGS method was semi-quantitative. Unfortunately the 
panel didn’t contain other viral causes of gastroenteritis and no mixed infections 
were present. As a result we could not assess its ability to detect non norovirus 
targets of mixed infections. 
In addition to virus detection, near full norovirus genome sequences were 
obtained in all cases. As was demonstrated in previous chapters, the breadth of 
genome sequencing was related to the initial viral load within a clinical 
specimen. In the case of these norovirus positive specimens, the average Ct was 
16 (range 9.06 – 24.54) which is considerably lower than those demonstrated in 
the respiratory specimens. This would be expected given the high viral load 
associated with norovirus infection.  
The generation of full genome coverage allowed genogroup, genotype and strain 
determination in all cases something which is not achievable with RT-PCR alone. 
This confirmed that in each outbreak the same strain was identified from all 
specimens.  
Phylogenetic analysis of the ORF2 revealed that in each outbreak the clinical 
isolates were most closely related to each other, as would be expected, however 
in outbreak 1 this highlighted one specimen that fell on a different branch. A 
comparison of the nucleotide sequences generated showed that this sequence 
had a large number of nucleotide differences in comparison to the others from 
the same outbreak. This may indicate a second introduction event rather than a 
ward acquired case. Such information would not be readily available using RT-
PCR, and although Sanger sequencing is carried out for epidemiological purposes 
this is not done in real time, therefore would provide retrospective understand 
of outbreak events.  
The full genome sequences generated from clinical specimens could be analysed 
for recombination events. This revealed that no recombination occurred during 
the course of each outbreak although, again, this would be expected given the 
short duration and single circulating strain. The viruses isolated in outbreak 2 
were the result of a previous recombination event with a break point between 
ORF1 and ORF2. Again, this analysis would not be possible with the current 
diagnostic or sequencing methods. 
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A theoretical benefit of using an NGS approach is the ability to study outbreak 
dynamics. One way of doing this would to look at single nucleotide 
polymorphisms (SNPs). The study of SNPs and variants has been used in 
determining the direction of virus spread in an outbreak setting (Hughes, Allen 
et al. 2012). The transmission of polymorphisms and low level variants are also a 
contributor to the diversity of norovirus strains in circulation. With the number 
of specimens and the time involved in this study it was not going to be possible 
to look at virus evolution over the course of the outbreak but this was carried as 
a proof of concept, to demonstrate that such things could be looked at using the 
type of data generated.   
6.3 Impact to the laboratory 
We have demonstrated that NGS is capable of detecting viral pathogens and in 
the process generates virus sequence information which can be utilised in 
subsequent typing and epidemiological studies. There are issues with sensitivity 
which have already been discussed and would need to be addressed prior 
instituting this in a diagnostic service. There are many other aspects to consider 
when implementing a new diagnostic test or method.  
The cost of NGS is considerably greater than that of RT-PCR, around £70 per 
specimen in comparison to the multiplex assay used at WoSSVC which costs in 
the region of £20. This of course does not take in to account the cost of 
subsequent sequencing reactions which are carried out in a proportion of cases. 
The ease of use must also be consider as applying complicated procedures to the 
throughput of specimens encountered by a regional diagnostic laboratory would 
not be feasible. The methods used here aimed to minimise the number of 
processes required with a view to reducing both cost and hands on time. 
Automation where possible would be the ideal option to both reduce the 
potential for error and decrease turnaround time.  
There must also be standards and quality controls such as those out by Clinical 
Laboratory Improvement Amendments (CLIA) which include demonstrable 
reproducibility alongside positive and negative controls(Burd 2010). In the case 
of sequencing, there are measurable markers which are used in quality control. 
Using Illumina platforms as an example, the density of clusters generated during 
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the process must fall within a range; too low may indicate an issue with library 
preparation and too high can cause errors in base calling. A blank specimen i.e. 
water can be included to control for contamination, however the number of 
controls used should be considered in cost calculations as this will reduce the 
number of clinical specimens processed, increasing the overall cost per 
specimen. The addition of PhiX DNA is commonly used as a positive control for 
the sequencing reaction. This is added to the pooled libraries prior to 
sequencing, therefore does not affect the number of specimens which can be 
analysed. As a result, PhiX sequences can be detected within clinical specimens 
potentially resulting in erroneous results (Mukherjee, Huntemann et al. 2015). 
The greatest obstacle to overcome with regards to introducing NGS to a 
diagnostic facility will not be specimen processing, rather data processing. As 
this panel of specimens was run in parallel with RT-PCR the potential false 
positive results were highlighted. Using NGS exclusively would require that a cut-
off level of reads which may indicate a false positive result be determined. This 
number will vary depending on the sequencing platform used. The data from this 
study would suggest this is in the region of 10 reads however a greater number 
of specimens, including negative controls would be required.  
There is no agreed consensus as to which are the most appropriate bioinformatic 
tools for the analysis of NGS data. The most effective tools will vary depending 
on the specimens, sequencing methods and the genomes under study (Bao, Jiang 
et al. 2011). The use of such tools requires a level of expertise and support from 
bioinformaticians. It is most likely that specific programs would be purpose built 
for laboratory and clinical staff that would not require in-depth knowledge of 
the bioinformatics process however a degree of support from someone with such 
expertise would be required.  
6.4 Future work 
Although the work outlined in this thesis outlines that NGS has the potential to 
be a diagnostic method in virology,…there are many pieces of future work that 
need to be carried out in order to improve and test the system still further 
before the NGS pipeline described could be considered “routine ready”. 
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The sensitivity of viral detection in this research was less than that of the 
standard diagnostic RT-PCR. As discussed above the lower limit of viral detection 
using NGS here were the equivalent of an RT-PCR Ct in the region of 32. To be 
implemented as a diagnostic test this would need to be improved by ~1 log in 
order to be in line with current methods. Various amendments to the pipeline 
could be used. For example, concentrating the nucleic acid extraction process 
could improve sensitivity. The current method used a specimen volume of 200 µl 
and eluted to 110 µl  Increasing the input volume and reducing the output 
elution volume may be of benefit, for example 1 ml eluted in 60 µl. 
The relationship between PCR Ct and viral reads sequenced would suggest that 
increasing the depth of sequencing could in turn increase the likelihood of virus 
detection. Many approaches could be undertaken to increase viral sequencing 
depth such as hybridisation and poly-A enrichment but these are essentially using 
targets in a similar fashion to PCR. Rather than enriching for the genomes of 
interest, an alternative approach would be to reduce the proportion of genomes 
that are not of interest. One method would be to reduce the quantity of human 
genetic material within a sample which can be achieved by exploiting the 
genetic differences between the host and the pathogen. Methods are available 
which target the methylated CpG sites within human DNA as these are rare in 
microbial genomes. Protein bound antibodies attached to magnetic particles 
bind to these sites, allowing them to be drawn out of a specimen by a magnet, 
resulting in an increased concentration of microbial genetic material in the 
remaining specimen (Figure 6-1.Microbiome enrichment by removing methylated CpG 
sites.). Ribosomal RNA can also be targeted in a similar fashion. 
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Figure 6-1.Microbiome enrichment by removing methylated CpG sites. 
A) Addition of antibodies targeting methylated CpG sites, bound to magnetic beads. B) Antibodies 
bind to target if present in specimen. C) Application of a magnet, draws the antibodies and target 
out of solution. D) Remaining specimen, depleted of DNA containing methylated CpG sites.  
 
However, it should be noted that the use of additional processing steps will in 
turn increase not just the cost and turnaround time but also the opportunity for 
errors. As the aim of this research was to explore the use of NGS in a diagnostic 
setting, these are all essential components to consider. 
Another approach to increase sequencing depth would be to explore alternative 
platforms. In this research a benchtop sequencer, namely the MiSeq (Illumina) 
was used. Many platforms are available, some of which have greater throughput 
and output compared with this model, although the initial outlay for some of 
these may be prohibitive to a diagnostic service. It is important to note that 
even since the initial optimisation of this protocol there have been many 
upgrades to the reagents, hardware and software used here that have increased 
the volume of sequence data generation at no extra cost to the user.  
The results presented in this research suggest that the sensitivity of detection 
may vary between viral pathogens. For example, in chapter 3, an instance of 
HCoV OC43 with a Ct of 24.05 was not detected however hRV were detected to a 
Ct of 33.66. This has also been suggested by others. To investigate this it would 
be useful to test dilution panels of each relevant pathogen by NGS and compare 
the results to the gold standard, RT-PCR. Only after this can we determine 
whether the detection limit is comparable across pathogens. Such a panel would 
also be useful in confirming that there is definitely a link between Ct and 
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sequence reads. This will only answer the sensitivity issues with known 
pathogens and any emergent pathogens would need to be assessed as they arise.  
In chapter 3 a small number of specimens were found to have viral reads that 
were not confirmed by RT-PCR. This suggests there may an issue with false 
positivity using the NGS pipeline however such a problem was not encountered 
with specimens in chapters 4 and 5. To investigate further extended panels of 
known negative specimens should be tested to determine the extent of the 
issue. In the longer term, should this assay become a routine test, the use of 
negative controls, as per current testing, should be considered essential.  The 
ability of the NGS pipeline to detect co infections is another aspect that needs 
to be improved. There are at least two issues relating to this. First the data from 
chapter 3 and 4 suggests that the NGS assay may not be able to detect DNA 
pathogens.  
The protocol employed in this research required the use of reverse transcription 
and amplification as the quantity of DNA recovered directly from clinical 
specimens was not great enough to proceed to sequencing. The SISPA approach 
was chosen with the rationale that this would minimise any amplification bias as 
the aim was to use a non-targeted generic approach that could be used in any 
sample. As a result, in many cases full genome sequences could be 
reconstructed.  
However, although successful at detecting and sequencing RNA targets the 
pipeline was poor at detecting DNA pathogens. This is probably a result of the 
initial reverse transcription step. It was initially hoped that RNA transcripts 
would be detected and thus allow the identification of pathogens with DNA 
genomes. This process was successful for the identification of bacterial 
genomes; however the same success was not seen for viral pathogens. While the 
majority of viruses affecting the respiratory tract are RNA viruses there are many 
important DNA pathogens that need to be detected. Furthermore if the method 
is to be applied to other viral disease syndromes then DNA detection is a must.  
It is difficult to determine how an improvement in DNA detection could be 
achieved. Perhaps the methods employed in specimen preparation could be 
optimised for the identification of DNA alongside RNA. It could be that specimens 
are divided in two aliquots with DNA isolation from one and RNA isolation and 
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reverse transcription from the other. Specimens could then be merged for the 
remainder of the process.  However this would have a significant impact on cost, 
throughput and turnaround time. As a result other solutions will need to be 
sought. 
If this aspect can be improved then it is possible that this method could be used 
as a pan microbial test i.e. detection of viral, bacterial and fungal genomes from 
the same clinical specimen. Currently, the identification of these pathogens is 
carried out by separate laboratories requiring that multiple clinical specimens 
are sent to multiple locations. This is not always achieved therefore it is likely 
that diagnoses are being missed.  Indeed in this research bacterial sequenced 
reads were detected in the majority of specimens however it was beyond the 
scope of this project to determine if these could be used for diagnostic 
purposes.   
The other issue relating to missed co-infections may mostly be related to the 
detection limit of the NGS assay as most were weak positives with Cts >32.  The 
latter aspect could be answered via testing the dilution panels outlined above. 
Further experiments using viral mixtures at differing concentrations would also 
be beneficial to rule out target competition as a cause of missed detection.   
The turnaround time demonstrated in this research was in the region of seven 
days from the beginning of specimen preparation to initial results. This is 
obviously much greater than that of RT-PCR where results can be available in a 
matter of hours from the specimen arriving in the laboratory. Here, all 
preparation steps were carried out manually. This is both time consuming and 
leaves the process open to human error. To overcome this future work should 
examine whether we can automate these steps. The use of automation in the 
preparation of specimens would allow the setup process to be carried out 24 
hours a day with minimal hands on steps. This will both reduce the overall 
turnaround time but also the potential for human error. It is also likely that in 
coming years improvements to the methodology described which will have an 
impact on turnaround time and ease of use. Using an alternative sequencing 
platform such the Ion Torrent or MinIon will also likely improve turnaround time.  
Improvements into bioinformatic analysis are needed – although identification 
was automated and therefore straightforward, any further analysis required 
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more complex user input. Having a more automated process would be ideal, 
especially if this were to be considered for a routine service. As mentioned 
previously, custom built interpretation software would be necessary. An example 
of this would be DisCVR (Maabar 2016).  
To test the true potential of NGS in the diagnosis of IID, it would ideal to 
examine outbreaks involving multiple pathogens and mixed infections over a 
long period of time. It would also be interesting to apply the technique to 
outbreaks involving those with compromised immune systems to determine virus 
evolution within hosts. Other syndromes which may benefit from an NGS 
approach would be those of CNS infections as the diagnostic samples obtained in 
these cases come from what should be an acellular sterile site therefore host 
DNA contamination should present less of an issue. The diagnostic specimens can 
be difficult to obtain, are often a small volume and may be required for multiple 
tests so the application of a single assay would be of a great benefit.  
If successful then the next stage would be to focus on the detection of bacteria. 
The approach to infection management is changing to focus on delivering an 
infection service, combining clinical, microbiology and virology services. This is 
reflected in the fact that many virology services are carrying out molecular 
assays to detect bacteria which are difficult to identify by culture, such as 
Mycoplasma pneumoniae and Legionella sp..  
The ideal scenario would be to implement NGS methods into routine practice to 
see how it goes.   
6.5  Thesis Conclusion 
The thesis expounded in this research is that an in house developed 
metagenomic Next Generation Sequencing pipeline has the potential to be used 
for both the diagnosis and epidemiological analysis of viral infection. I have used 
the aforementioned method to diagnose, quantitate and study the epidemiology 
of respiratory pathogens directly from a small panel of clinical samples. The 
method has also successfully been applied to the detection, quantitation and 
epidemiological analysis of norovirus directly from extracted stool samples. 
Although improvements are necessary, the pipeline has shown potential to be 
used as a future diagnostic test for both viral and non viral infectious diseases. 
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7 Appendix 1. Commands used in data analysis  
Quality trimming 
#!/bin/bash 
############################# Name files ########################### 
for file1 in *L001_R1_001.fastq 
do 
 file2=${file1%L001_R1_001.fastq}L001_R2_001.fastq 
echo $file1 $file2 
##################### adapter and quality trimming ##################### 
 echo "Trimming ends with trim_galore"; 
 echo "Trimming Nextera adapters"; 
 echo "trim_galore --paired --length 30 --adapter CTGTCTCTTATACACATCT 
$file1 $fiel2;" 
 trim_galore --paired --length 30 --adapter CTGTCTCTTATACACATCT $file1 
$file2; 
 echo "Trimming standard Illumina adapters" 
 trim_galore --paired --length 30 ${file1%.fastq}_val_1.fq 
${file2%.fastq}_val_2.fq; 
 
 echo "Trimming FR20RV primer" 
 trim_galore --paired --length 30 --adapter GCCGGAGCTCTGCAGATATC 
${file1%.fastq}_val_1_val_1.fq ${file2%.fastq}_val_2_val_2.fq; 
###################### Rename files ################################ 
 mv ${file1%.fastq}_val_1_val_1_val_1.fq ${file1%.fastq}_validated_1.fq; 
 mv ${file2%.fastq}_val_2_val_2_val_2.fq ${file2%.fastq}_validated_2.fq; 
###################### Trimming ends with Prinseq #################### 
 echo "Trimming ends with prinseq"; 
 prinseq -fastq ${file1%.fastq}_validated_1.fq -fastq2 
${file2%.fastq}_validated_2.fq -lc_method dust -lc_threshold 20 -trim_left 20 -
derep 12345; 
# -lc_method = trimming low entropy reads from dataset, threshold can be set 
using -lc_threshold 
# -trim_left = removing first 20 bases from 5' end of sequence (this retains paired 
end information) 
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# -derep = removing dulpicate reads (exact duplicates, 5' and 3' duplicates) 
  
 mv ${file1%.fastq}_validated_1_prinseq_good_singletons* 
${file1%.fastq}_validated_1_singletons.fq; 
 mv ${file2%.fastq}_validated_2_prinseq_good_singletons* 
${file2%.fastq}_validated_2_singletons.fq; 
 mv ${file1%.fastq}_validated_1_prinseq_good* 
${file1%.fastq}_validated_1_good.fq; 
 mv ${file2%.fastq}_validated_2_prinseq_good* 
${file2%.fastq}_validated_2_good.fq; 
 trim_galore --paired --length 30 ${file1%.fastq}_validated_1_good.fq 
${file2%.fastq}_validated_2_good.fq; 
 mv ${file1%.fastq}_validated_1_good_val_1.fq ${file1%.fastq}_clean.fq; 
 mv ${file2%.fastq}_validated_2_good_val_2.fq ${file2%.fastq}_clean.fq; 
file3=${file1%L001_R1_001.fastq}L001_R1_001_clean.fq; 
file4=${file2%L001_R2_001.fastq}L001_R2_001_clean.fq; 
echo $file3 $file4 
################## Map to human references ########################## 
echo "Mapping trimmed reads to human reference files"  
 weeMapper -1 $file3 -2 $file4 -a 
###################### Remove report files ########################### 
rm *report.txt; 
rm *val_1.fq; 
rm *val_2.fq; 
rm *bad*; 
################### Rename output files ############################# 
mv ${file1%L001_R1_001.fastq}*unmapped_1.fq 
${file1%L001_R1_001.fastq}unmapped_clean_1.fq; 
mv ${file2%L001_R2_001.fastq}*unmapped_2.fq 
${file1%L001_R1_001.fastq}unmapped_clean_2.fq; 
##################### Aligned to viral databases ####################### 
echo "aligning to viral genome and cDNA databases" 
bowtie2 -x ~/Reference/viral_genomes -1 
${file1%L001_R1_001.fastq}unmapped_clean_1.fq -2 
${file1%L001_R1_001.fastq}unmapped_clean_2.fq --very-sensitive -S 
${file1%L001_R1_001.fastq}viral_genomes.sam 
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samtools view -bS ${file1%L001_R1_001.fastq}viral_genomes.sam > 
${file1%L001_R1_001.fastq}viral_genomes.bam 
echo "Get unmapped reads from viral genomes" 
bam2fastq --no-aligned --force --strict -o 
${file1%L001_R1_001.fastq}viral_genomes#.fq 
${file1%L001_R1_001.fastq}viral_genomes.bam 
bam2fastq --no-unaligned --force --strict -o 
${file1%L001_R1_001.fastq}viral_genomes_unmapped#.fq 
${file1%L001_R1_001.fastq}viral_genomes.bam 
echo "Aligned to viral cDNA" 
bowtie2 -x ~/Reference/viral_cDNA -1 
${file1%L001_R1_001.fastq}viral_genomes_unmapped_1.fq -2 
${file1%L001_R1_001.fastq}viral_genomes_unmapped_2.fq --very-sensitive -S 
${file1%L001_R1_001.fastq}viral_cDNA.sam 
echo "Get mapped reads from viral cDNA" 
samtools view -bS ${file1%L001_R1_001.fastq}viral_cDNA.sam > 
${file1%L001_R1_001.fastq}viral_cDNA.bam 
bam2fastq --no-aligned --force --strict -o 
${file1%L001_R1_001.fastq}viral_cDNA#.fq 
${file1%L001_R1_001.fastq}viral_cDNA.bam 
echo "get unmapped reads from viral cDNA" 
samtools view -bS ${ file1%L001_R1_001.fastq }viral_cDNA.sam > 
${file1%L001_R1_001.fastq}viral_cDNA.bam 
bam2fastq --no-unaligned --force --strict -o 
${file1%L001_R1_001.fastq}viral_cDNA_unmapped#.fq 
${file1%L001_R1_001.fastq}viral_cDNA.bam 
done 
Commands used in Data analysis: Metamos pipeline 
# calculate average inert size of mapped read pairs – required for contigs 
assembly 
Getinsertsize.py file.sam 
# run pipeline 
initPipeline -q -1 file_human_unmapped_1.fq -2 file_human_unmapped_2.fq -d 
file_metamos_directory –i insert size 
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runPipeline -d file_metamos_directory -c  blast -m bowtie2 -a 
sparseassembler,idba-ud,velvet -p 2 
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Appendix 2. Respiratory Specimens: Summary of Results 
Sample PCR Ct Total Reads 
% mapped to 
human 
reference 
Taxonomy Accession 
% reads 
mapping 
% Genome 
Covered 
Nucleotide 
Mismatch 
1B1 HRV 18.73 546282 20.17 HRV-A49 JN798589 75.48 100 2.5 
1B2 HRV 26.78 638257 93.07 HRV-B92 FJ445169 2.53 56.4 7.5 
1B5 PIV-3 27.57 696929 50.67 PIV-3 KJ672618 5.62 5.0 0.5 
1B7 HRV 28.94 537522 62.21 N/A     
1B8 Influenza A 22.34 818055 96.78 Influenza A H3N2 KJ942712 0.03 30.6 – 60.3 various 
1C2 HRV 26.75 1107488 81.67 Enterovirus D-68 AB601885 1.46 14.9 1.4 
1C3 HRV 28.15 1278307 65.56 HRV-A97 FJ445172 0.31 20.9 8.7 
1C7 HRV 24.93 538412 69.88 HRV-A1 JN837694 4.76 87.4 1.2 
1C9 hMPV 35.51 837310 47.23 N/A     
1D1 HRV 20.68 1010455 59.82 HRV-A1 JN837694 32.03 100 1.9 
1D3 HCoV NL63 27.17 801021 96.66 HCoV NL63 KF530112 0.38 11.7 0.5 
1D4 HRV 19.81 1089553 23.19 HRV-A1 JN837694 74.67 99.6 2.2 
1E1 HRV 20.1 758165 61.76 HRV-C15 GU219984 33.93 100 2.0 
1E3 RSV 20.84 700028 93.78 RSVA KJ627329 3.71 91.0 0.7 
1E5 RSV 30.01 714509 96.87 N/A     
1E7 HCoV NL63 24.36 426736 92.10 HCoV NL63 JQ765569 0.97 23.3 0.5 
1E8 HRV 25.09 887501 96.50 HRV-C15 GU219984 0.06 29.7 2.5 
1F1 RSV 25.08 322516 85.54 RSVA KF826849 3.79 54.6 0.5 
1F7 HRV 28.03 236596 70.59 N/A     
1F8 HCoV NL63 25.22 644660 93.24 HCoV NL63 JQ765567 0.03 3.7 0.4 
1G1 HRV 28.49 265505 78.73 HRV-A90 FJ445167 0.02 2.6 10.8 
1G1 Adeno 35.1 265505 78.73 N/A     
1G2 PIV-3 28.09 309778 78.95 PIV-3 KJ672606 0.04 2.8 0.6 
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1G6 hMPV 26.84 81749 37.68 hMPV-B KJ627397 1.41 18.5 2.0 
1H1 HCoV OC43 17.21 608153 94.92 HCoV OC43 KF530099 3.48 99.9 1.6 
1H3 HRV 20.44 413108 83.13 HRV-A2 X02316 6.65 96.0 8.1 
1H7 HRV 19.39 657627 56.80 HRV-B4 JN798573 39.08 99.7 1.4 
1I2 HRV 19.80 710612 60.67 HRV-C17 JN815240 33.29 99.1 3.8 
1I4 HRV 26.01 641357 98.15 HRV-B3 JF285331 0.64 97.2 2.4 
1I5 HRV 33.66 728425 92.82 HRV-A1 JN837694 0.01 39.0 5.6 
1I6 HRV 29.11 1063930 57.27 HRV-C (UTR) JX129433 2.92 N/A 2.3 
1I8 HRV 27.85 1132106 99.02 HRV-B27 JF285309 0.01 6.7 3.7 
2A2 HCoV 229E 32.35 745105 98.00 N/A     
2A3 HCoV 229E 18.14 1110727 88.23 HCoV 229E JX503060 9.63 99.8 0.6 
2A4 HCoV 229E 20.00 311141 98.39 HCoV 229E JX503060 0.16 55.3 0.6 
2A6 HRV 23.12 1056405 83.90 HRV-C11 EU840952 0.29 27.2 8.9 
2A9 hMPV 25.68 626886 84.12 hMPV-B KF530171 6.35 48.4 3.1 
2B4 RSV 19.32 612887 55.78 RSVB JX576741 40.52 99.3 2.0 
2B6 RSV 33.96 854593 77.09 N/A     
2B7 HRV 17.24 596971 95.94 HRV-A60 JN798590 1.82 95.3 3.7 
2B9 HRV 33.31 569654 76.13 N/A     
2C1 HRV 20.24 816200 91.89 HRV-A21 JN837693 5.32 97.9 2.5 
2C3 HCoV 229E 25.83 470840 93.93 HCoV 229E JX503060 0.48 20.0 0.7 
2C4 HCoV 229E 33.84 759226 98.06 N/A     
2D2 HCoV 229E 19.74 743683 94.07 HCoV 229E JX503060 2.50 73.9 0.6 
2D3 HCoV OC43 24.05 765913 89.42 N/A     
2D4 PIV-2 36.07 1034235 96.30 N/A     
2D5 HCoV OC43 14.63 992040 93.04 HCoV OC43 JN129835 2.70 97.6 0.7 
2D6 HRV 23.07 1016390 82.29 HRV-A8 FJ445113 6.23 97.0 8.1 
Table A-1. An overview of the total, human and viral sequenced reads per sample with a positive RT-PCR result. 
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Appendix 3. Clinical Details Associated with EV-D68 RT-PCR 
Positive Specimens 
Sample 
ID Age Gender 
Sample 
Date 
Sample 
Type Inpatient First Results 
EV 
D68 
Ct 
427086 49w M 10/10/2014 THS Y Rhino/Entero 31.16 
427334 1 M 14/10/2014 NPA Y Rhino/Entero 22.69 
427759 1 M 17/10/2014 NPA Y Rhino/Entero 24.02 
428005 1 M 21/10/2014 NPA Y 
Rhino/Entero, 
HPIV-4, Adeno 20.94 
428008 18w M 21/10/2014 NPA Y Rhino/Entero 28.79 
428129 30w F 22/10/2014 BAL ICU Rhino/Entero 25.39 
428134 30w F 22/10/2014 NS ICU Rhino/Entero 24.2 
428287 39w M 23/10/2014 THS Y Rhino/Entero 27.63 
428871 1 F 29/10/2014 NPA N 
Rhino/Entero, 
Adeno 21.92 
429031 11 F 29/10/2014 TNS N Rhino/Entero 35.24 
429110 6 M 02/11/2014 Swab Y 
Rhino/Entero, 
HHV-6 32.76 
429159 41w F 02/11/2014 NPA Y 
Rhino/Entero, 
RSV 32.82 
429319 41w F 03/11/2014 NPA Y 
Rhino/Entero, 
RSV, HPIV 4 25.5 
429323 22w M 03/11/2014 NPA Y Rhino/Entero 16.25 
429395 3 F 04/11/2014 THS Y Rhino/Entero 29.75 
429660 1 F 07/11/2014 NPA Y Rhino/Entero 28.11 
429915 1 M 07/11/2014 NS Y Rhino/Entero 28.07 
430038 1 M 07/11/2014 NPA Y 
Rhino/Entero, 
HPIV-4 24.96 
430139 1 M 11/11/2014 NPA Y 
Rhino/Entero, 
RSV 30.58 
430146 1 M 11/11/2014 NPA Y 
Rhino/Entero, 
hMPV 21.26 
430741 1 F 18/11/2014 NPA Y 
Rhino/Entero, 
HPIV-4 20.24 
431467 4 M 23/11/2014 THS Y Rhino/Entero 26.53 
Table A-2. Clinical information associated with study samples.  
An overview of the clinical details associated with each EV-D68 positive sample along with the 
results of the initial diagnostic RT-PCR screen NPA = nasopharyngeal aspirate, NS = nose swab, 
THS = throat swab, BAL = bronchio-alveolar lavage and Swab = swab with site unspecified). 
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Appendix 4. EV-D68 Full Genome Sequences Used in Analyses. 
Accession Complete genomes as of 16/6/15 
AY426531.1  Human enterovirus 68 strain Fermon 
JX070222.1  Human enterovirus 68 isolate NZ-2010-541 
JX101846.1  Human enterovirus 68 strain NYC403 from USA 
AB601883.2  Human enterovirus 68 genomic RNA 
AB601882.2  Human enterovirus 68 genomic RNA 
EF107098.1  Human enterovirus 68 isolate 37-99 from France 
KP114665.1  Enterovirus D68 isolate EV68_Alberta17789_2014  
KP114664.1  Enterovirus D68 isolate EV68_Alberta2985_2014  
KP114662.1  Enterovirus D68 isolate EV68_Alberta17390_2014  
KF726085.1  Enterovirus D68 isolate BCH895A 
KP745770.1  Enterovirus D68 isolate NY77  
KP745769.1  Enterovirus D68 isolate NY74  
KP745768.1  Enterovirus D68 isolate NY73  
KP745767.1  Enterovirus D68 isolate NY329 
KP745766.1  Enterovirus D68 isolate NY328 
KP745765.1  Enterovirus D68 isolate NY326  
KP745764.1  Enterovirus D68 isolate NY316 
KP745763.1  Enterovirus D68 isolate NY314  
KP745762.1  Enterovirus D68 isolate NY309  
KP745761.1  Enterovirus D68 isolate NY305  
KP745760.1  Enterovirus D68 isolate NY278 
KP745759.1  Enterovirus D68 isolate NY275  
KP745758.1  Enterovirus D68 isolate NY263  
KP745757.1  Enterovirus D68 isolate NY210 
KP745756.1  Enterovirus D68 isolate NY160  
KP745755.1  Enterovirus D68 isolate NY153 
KP745754.1  Enterovirus D68 isolate NY130  
KP745753.1  Enterovirus D68 isolate NY126  
KP745752.1  Enterovirus D68 isolate NY124  
KP745751.1  Enterovirus D68 isolate NY120 
KP126911.1  Enterovirus D68 strain US/CO/14-93  
KP100794.1  Enterovirus D68 strain US/CO/13-60  
KM881710.2  Enterovirus D68 strain EV-D68_STL_2014_12  
KP240936.1  Enterovirus D68 isolate Beijing-R0132 
KM851231.1  Enterovirus D68 strain US/KY/14-18953 
KM851228.1  Enterovirus D68 strain US/MO/14-18950 
KM851227.1  Enterovirus D68 strain US/MO/14-18949 
KM851226.1  Enterovirus D68 strain US/MO/14-18948 
KM851225.1  Enterovirus D68 strain US/MO/14-18947 
KP100796.1  Enterovirus D68 strain US/CA/14-6100  
KP100795.1  Enterovirus D68 strain US/CA/14-6103SIB  
KP100793.1  Enterovirus D68 strain US/CO/14-94  
KP100792.1  Enterovirus D68 strain US/CA/14-6092  
KM892501.1  Enterovirus D68 isolate CA/AFP/11-1767 
KM892500.1  Enterovirus D68 isolate CA/RESP/10-786 
KM892499.1  Enterovirus D68 isolate CA/AFP/v12T00346 
Table A-3. Full genome Enterovirus D68 genome sequences available from PubMed on 16/6/2016.  
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Appendix 5. EV-D68 Specimens: Summary of Results.  
Sample 
Ct 
Value 
Top Database Hit 
(Accession) 
Trimmed 
reads 
Database 
alignment 
(Reads) 
Coverage 
(%) 
Single reference 
alignment (Reads) 
Reads 
mapping (%) 
Coverage 
(%) 
Nucleotide 
Mismatch (%) 
427086 31.16 KP745768 820028 143 26.04 374 0.05 53.51 1.3 
427334 22.69 KP745769 154136 40833 95.12 107950 70.04 95.12 1.3 
427759 24.02 KP745768 99208 8470 93.51 26678 26.89 94.11 1.5 
428005 20.94 KP745768 365842 78674 99.70 205255 56.10 99.97 1.2 
428008 28.79 KP745769 28980 733 48.82 1643 5.67 68.99 1.7 
428129 25.39 KP126911 49208 61 9.94 1188 2.41 22.40 0.7 
428194 24.2 KP100793 60660 421 49.72 6862 11.31 84.90 0.6 
428287 27.63 KM851231 960540 254 26.27 336 0.03 36.94 2 
428871 21.92 KP745769 78434 6505 99.11 17813 22.71 99.93 1.3 
429031 35.24 KP745768 133912 49 50.94 129 0.10 68.12 2 
429110 32.76 KP745769 257764 21 19.99 51 0.02 37.90 1.5 
429159 32.82 KP745768 138358 3 2.73 5 0.00 4.18 4.8 
429319 25.5 KP745768 67598 238 41.89 624 0.92 47.35 1.5 
429323 16.25 KP745769 396444 109241 100 306593 77.34 100 1.5 
429395 29.75 KP745769 692546 17 20.85 35 0.01 23.30 5.3 
429660 28.11 KP745768 152066 3409 93.81 10544 6.93 94.62 1.4 
429915 28.07 KP745768 593212 332 44.71 730 0.12 58.60 1.1 
430038 24.96 KP745768 116842 6320 87.52 17976 15.38 90.97 1.3 
430139 30.58 KP745768 403344 73 43.94 202 0.05 64.55 1.8 
430146 21.26 KP745769 226678 52224 99.52 141956 62.62 100 1.5 
430741 20.24 KP745769 335942 23898 99.99 69601 20.72 100 1.5 
431467 26.53 KP745768 877546 8603 78.68 22945 2.61 86.80 1.5 
Table A-4. A summary of RT-PCR and NGS results. 
159 
 
Appendix 6. Krona Output Charts from EV-D68 RT-PCR Positive 
Specimens. 
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